<!DOCTYPE html>

<html lang="en">


<!doctype html>
<html lang="en" class="no-js">
  <head>
    
      <meta charset="utf-8">
      <meta name="viewport" content="width=device-width,initial-scale=1">
      
      
      
      
        <link rel="prev" href="..">
      
      
        <link rel="next" href="../Oncology/">
      
      
      <link rel="icon" href="../assets/images/favicon.png">
      <meta name="generator" content="mkdocs-1.5.3, mkdocs-material-9.5.12">
    
    
<title>Literature Survey (VPE)</title>

    
      <link rel="stylesheet" href="../assets/stylesheets/main.7e359304.min.css">
      
        
        <link rel="stylesheet" href="../assets/stylesheets/palette.06af60db.min.css">
      
      


    
    
  <!-- Add scripts that need to run before here -->
  <!-- Add jquery script -->
  <script src="https://code.jquery.com/jquery-3.7.1.js"></script>
  <!-- Add data table libraries -->
  <script src="https://cdn.datatables.net/2.0.1/js/dataTables.js"></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/2.0.1/css/dataTables.dataTables.css">
  <!-- Load plotly.js into the DOM -->
	<script src='https://cdn.plot.ly/plotly-2.29.1.min.js'></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/buttons/3.0.1/css/buttons.dataTables.css">
  <!-- fixedColumns -->
  <script src="https://cdn.datatables.net/fixedcolumns/5.0.0/js/dataTables.fixedColumns.js"></script>
  <script src="https://cdn.datatables.net/fixedcolumns/5.0.0/js/fixedColumns.dataTables.js"></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/fixedcolumns/5.0.0/css/fixedColumns.dataTables.css">
  <!-- Already specified in mkdocs.yml -->
  <!-- <link rel="stylesheet" href="../docs/custom.css"> -->
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/dataTables.buttons.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.dataTables.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/jszip/3.10.1/jszip.min.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/pdfmake/0.2.7/pdfmake.min.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/pdfmake/0.2.7/vfs_fonts.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.html5.min.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.print.min.js"></script>
  <!-- Google fonts -->
  <link rel="stylesheet" href="https://fonts.googleapis.com/icon?family=Material+Icons">
  <!-- Intro.js -->
  <script src="https://cdn.jsdelivr.net/npm/intro.js@7.2.0/intro.min.js"></script>
  <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/intro.js@7.2.0/minified/introjs.min.css">


  <!-- 
      
     -->
  <!-- Add scripts that need to run afterwards here -->

    
      
        
        
        <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
        <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:300,300i,400,400i,700,700i%7CRoboto+Mono:400,400i,700,700i&display=fallback">
        <style>:root{--md-text-font:"Roboto";--md-code-font:"Roboto Mono"}</style>
      
    
    
      <link rel="stylesheet" href="../assets/_mkdocstrings.css">
    
      <link rel="stylesheet" href="../custom.css">
    
    <script>__md_scope=new URL("..",location),__md_hash=e=>[...e].reduce((e,_)=>(e<<5)-e+_.charCodeAt(0),0),__md_get=(e,_=localStorage,t=__md_scope)=>JSON.parse(_.getItem(t.pathname+"."+e)),__md_set=(e,_,t=localStorage,a=__md_scope)=>{try{t.setItem(a.pathname+"."+e,JSON.stringify(_))}catch(e){}}</script>
    
      

    
    
    
  </head>
  
  
    
    
      
    
    
    
    
    <body dir="ltr" data-md-color-scheme="default" data-md-color-primary="white" data-md-color-accent="black">
  
    
    <input class="md-toggle" data-md-toggle="drawer" type="checkbox" id="__drawer" autocomplete="off">
    <input class="md-toggle" data-md-toggle="search" type="checkbox" id="__search" autocomplete="off">
    <label class="md-overlay" for="__drawer"></label>
    <div data-md-component="skip">
      
    </div>
    <div data-md-component="announce">
      
    </div>
    
    
      

<header class="md-header" data-md-component="header">
  <nav class="md-header__inner md-grid" aria-label="Header">
    <a href=".." title="Literature Survey for Swathi" class="md-header__button md-logo" aria-label="Literature Survey for Swathi" data-md-component="logo">
      
  <img src="../assets/VPE.png" alt="logo">

    </a>
    <label class="md-header__button md-icon" for="__drawer">
      
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M3 6h18v2H3V6m0 5h18v2H3v-2m0 5h18v2H3v-2Z"/></svg>
    </label>
    <div class="md-header__title" data-md-component="header-title">
      <div class="md-header__ellipsis">
        <div class="md-header__topic">
          <span class="md-ellipsis">
            Literature Survey for Swathi
          </span>
        </div>
        <div class="md-header__topic" data-md-component="header-topic">
          <span class="md-ellipsis">
            
              Immunology
            
          </span>
        </div>
      </div>
    </div>
    
      
        <form class="md-header__option" data-md-component="palette">
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="default" data-md-color-primary="white" data-md-color-accent="black"  aria-label="Switch to dark mode"  type="radio" name="__palette" id="__palette_0">
    
      <label class="md-header__button md-icon" title="Switch to dark mode" for="__palette_1" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 6H7c-3.31 0-6 2.69-6 6s2.69 6 6 6h10c3.31 0 6-2.69 6-6s-2.69-6-6-6zm0 10H7c-2.21 0-4-1.79-4-4s1.79-4 4-4h10c2.21 0 4 1.79 4 4s-1.79 4-4 4zM7 9c-1.66 0-3 1.34-3 3s1.34 3 3 3 3-1.34 3-3-1.34-3-3-3z"/></svg>
      </label>
    
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="slate" data-md-color-primary="white" data-md-color-accent="black"  aria-label="Switch to light mode"  type="radio" name="__palette" id="__palette_1">
    
      <label class="md-header__button md-icon" title="Switch to light mode" for="__palette_0" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 7H7a5 5 0 0 0-5 5 5 5 0 0 0 5 5h10a5 5 0 0 0 5-5 5 5 0 0 0-5-5m0 8a3 3 0 0 1-3-3 3 3 0 0 1 3-3 3 3 0 0 1 3 3 3 3 0 0 1-3 3Z"/></svg>
      </label>
    
  
</form>
      
    
    
      <script>var media,input,key,value,palette=__md_get("__palette");if(palette&&palette.color){"(prefers-color-scheme)"===palette.color.media&&(media=matchMedia("(prefers-color-scheme: light)"),input=document.querySelector(media.matches?"[data-md-color-media='(prefers-color-scheme: light)']":"[data-md-color-media='(prefers-color-scheme: dark)']"),palette.color.media=input.getAttribute("data-md-color-media"),palette.color.scheme=input.getAttribute("data-md-color-scheme"),palette.color.primary=input.getAttribute("data-md-color-primary"),palette.color.accent=input.getAttribute("data-md-color-accent"));for([key,value]of Object.entries(palette.color))document.body.setAttribute("data-md-color-"+key,value)}</script>
    
    
    
      <label class="md-header__button md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5Z"/></svg>
      </label>
      <div class="md-search" data-md-component="search" role="dialog">
  <label class="md-search__overlay" for="__search"></label>
  <div class="md-search__inner" role="search">
    <form class="md-search__form" name="search">
      <input type="text" class="md-search__input" name="query" aria-label="Search" placeholder="Search" autocapitalize="off" autocorrect="off" autocomplete="off" spellcheck="false" data-md-component="search-query" required>
      <label class="md-search__icon md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5Z"/></svg>
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11h12Z"/></svg>
      </label>
      <nav class="md-search__options" aria-label="Search">
        
        <button type="reset" class="md-search__icon md-icon" title="Clear" aria-label="Clear" tabindex="-1">
          
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M19 6.41 17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12 19 6.41Z"/></svg>
        </button>
      </nav>
      
    </form>
    <div class="md-search__output">
      <div class="md-search__scrollwrap" data-md-scrollfix>
        <div class="md-search-result" data-md-component="search-result">
          <div class="md-search-result__meta">
            Initializing search
          </div>
          <ol class="md-search-result__list" role="presentation"></ol>
        </div>
      </div>
    </div>
  </div>
</div>
    
    
      <div class="md-header__source">
        <a href="https://github.com/VirtualPatientEngine/literatureSurvey" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 496 512"><!--! Font Awesome Free 6.5.1 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2023 Fonticons, Inc.--><path d="M165.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6zm-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3zm44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9zM244.8 8C106.1 8 0 113.3 0 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C428.2 457.8 496 362.9 496 252 496 113.3 383.5 8 244.8 8zM97.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1zm-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7zm32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1zm-11.4-14.7c-1.6 1-1.6 3.6 0 5.9 1.6 2.3 4.3 3.3 5.6 2.3 1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2z"/></svg>
  </div>
  <div class="md-source__repository">
    VPE/LiteratureSurvey
  </div>
</a>
      </div>
    
  </nav>
  
</header>
    
    <div class="md-container" data-md-component="container">
      
      
        
          
            
<nav class="md-tabs" aria-label="Tabs" data-md-component="tabs">
  <div class="md-grid">
    <ul class="md-tabs__list">
      
        
  
  
  
    <li class="md-tabs__item">
      <a href=".." class="md-tabs__link">
        
  
    
  
  Home

      </a>
    </li>
  

      
        
  
  
    
  
  
    <li class="md-tabs__item md-tabs__item--active">
      <a href="./" class="md-tabs__link">
        
  
    
  
  Immunology

      </a>
    </li>
  

      
        
  
  
  
    <li class="md-tabs__item">
      <a href="../Oncology/" class="md-tabs__link">
        
  
    
  
  Oncology

      </a>
    </li>
  

      
    </ul>
  </div>
</nav>
          
        
      
      <main class="md-main" data-md-component="main">
        <div class="md-main__inner md-grid">
          
            
              
                
              
              <div class="md-sidebar md-sidebar--primary" data-md-component="sidebar" data-md-type="navigation" hidden>
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    


  


<nav class="md-nav md-nav--primary md-nav--lifted" aria-label="Navigation" data-md-level="0">
  <label class="md-nav__title" for="__drawer">
    <a href=".." title="Literature Survey for Swathi" class="md-nav__button md-logo" aria-label="Literature Survey for Swathi" data-md-component="logo">
      
  <img src="../assets/VPE.png" alt="logo">

    </a>
    Literature Survey for Swathi
  </label>
  
    <div class="md-nav__source">
      <a href="https://github.com/VirtualPatientEngine/literatureSurvey" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 496 512"><!--! Font Awesome Free 6.5.1 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2023 Fonticons, Inc.--><path d="M165.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6zm-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3zm44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9zM244.8 8C106.1 8 0 113.3 0 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C428.2 457.8 496 362.9 496 252 496 113.3 383.5 8 244.8 8zM97.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1zm-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7zm32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1zm-11.4-14.7c-1.6 1-1.6 3.6 0 5.9 1.6 2.3 4.3 3.3 5.6 2.3 1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2z"/></svg>
  </div>
  <div class="md-source__repository">
    VPE/LiteratureSurvey
  </div>
</a>
    </div>
  
  <ul class="md-nav__list" data-md-scrollfix>
    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href=".." class="md-nav__link">
        
  
  <span class="md-ellipsis">
    Home
  </span>
  

      </a>
    </li>
  

    
      
      
  
  
    
  
  
  
    <li class="md-nav__item md-nav__item--active">
      
      <input class="md-nav__toggle md-toggle" type="checkbox" id="__toc">
      
      
      
      <a href="./" class="md-nav__link md-nav__link--active">
        
  
  <span class="md-ellipsis">
    Immunology
  </span>
  

      </a>
      
    </li>
  

    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href="../Oncology/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    Oncology
  </span>
  

      </a>
    </li>
  

    
  </ul>
</nav>
                  </div>
                </div>
              </div>
            
            
              
                
              
              <div class="md-sidebar md-sidebar--secondary" data-md-component="sidebar" data-md-type="toc" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    

<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
  
  
</nav>
                  </div>
                </div>
              </div>
            
          
          
            <div class="md-content" data-md-component="content">
              <article class="md-content__inner md-typeset">
                
                  

  
  


  <h1>Immunology</h1>

<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
</head>

<body>
  <p>
  <i class="footer">This page was last updated on 2025-11-17 09:19:40 UTC</i>
  </p>

  <div class="note info" onclick="startIntro()">
    <p>
      <button type="button" class="buttons">
        <div style="display: flex; align-items: center;">
        Click here for a quick intro of the page! <i class="material-icons">help</i>
        </div>
      </button>
    </p>
  </div>

  <!--
  <div data-intro='Table of contents'>
    <p>
    <h3>Table of Contents</h3>
      <a href="#plot1">1. Citations over time on Immunology</a><br>
      <a href="#manually_curated_articles">2. Manually curated articles on Immunology</a><br>
      <a href="#recommended_articles">3. Recommended articles on Immunology</a><br>
    <p>
  </div>

  <div data-intro='Plot displaying number of citations over time 
                  on the given topic based on recommended articles'>
    <p>
    <h3 id="plot1">1. Citations over time on Immunology</h3>
      <div id='myDiv1'>
      </div>
    </p>
  </div>
  -->

  <div data-intro='Manually curated articles on the given topic'>
    <p>
    <h3 id="manually_curated_articles">Manually curated articles on <i>Immunology</i></h3>
    <table id="table1" class="display" style="width:100%">
    <thead>
      <tr>
          <th data-intro='Click to view the abstract (if available)'>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/ Conference</th>
          <th>Citation count</th>
          <th data-intro='Highest h-index among the authors'>Highest h-index</th>
          <th data-intro='Recommended articles extracted by considering
                          only the given article'>
              View recommendations
              </th>
      </tr>
    </thead>
    <tbody>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8f2918cad295af222dcbefbcbfa7b2c18903efa6" target='_blank'>
                Bispecific T cell engager therapy for refractory rheumatoid arthritis
                </a>
              </td>
          <td>
            Laura Bucci, M. Hagen, T. Rothe, M. G. Raimondo, F. Fagni, Carlo Tur, Andreas Wirsching, J. Wacker, Artur Wilhelm, Jean-Philippe Auger, Milena Pachowsky, Markus Eckstein, S. Alivernini, A. Zoli, G. Krönke, S. Uderhardt, A. Bozec, Maria-Antonietta D’Agostino, G. Schett, Ricardo Grieshaber-Bouyer
          </td>
          <td>2024-04-26</td>
          <td>Nature Medicine, Nature Network Boston</td>
          <td>82</td>
          <td>47</td>

            <td><a href='../recommendations/8f2918cad295af222dcbefbcbfa7b2c18903efa6' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="Background Mesenchymal stromal cell derived extracellular vesicles (MSC-EVs) are a promising therapeutic for neuroinflammation. MSC-EVs can interact with microglia, the resident immune cells of the brain, to exert their immunomodulatory effects. In response to inflammatory cues, such as cytokines, microglia undergo phenotypic changes indicative of their function e.g. morphology and secretion. However, these changes in response to MSC-EVs are not well understood. Additionally, no disease-relevant screening tools to assess MSC-EV bioactivity exist, which has further impeded clinical translation. Here, we developed a quantitative, high throughput morphological profiling approach to assess the response of microglia to neuroinflammation-relevant signals and whether this morphological response can be used to indicate the bioactivity of MSC-EVs. Results Using an immortalized human microglia cell-line, we observed increased size (perimeter, major axis length) and complexity (form factor) upon stimulation with interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α). Upon treatment with MSC-EVs, the overall morphological score (determined using principal component analysis) shifted towards the unstimulated morphology, indicating that MSC-EVs are bioactive and modulate microglia. The morphological effects of MSC-EVs in TNF-γ/IFN-α stimulated cells were concomitant with reduced secretion of 14 chemokines/cytokines (e.g. CXCL6, CXCL9) and increased secretion of 12 chemokines/cytokines (e.g. CXCL8, CXCL10). Proteomic analysis of cell lysates revealed significant increases in 192 proteins (e.g. HIBADH, MEAK7, LAMC1) and decreases in 257 proteins (e.g. PTEN, TOM1, MFF) with MSC-EV treatment. Of note, many of these proteins are involved in regulation of cell morphology and migration. Gene Set Variation Analysis revealed upregulation of pathways associated with immune response, such as regulation of cytokine production, immune cell infiltration (e.g. T cells, NK cells) and morphological changes (e.g. Semaphorin, RHO/Rac signaling). Additionally, changes in microglia mitochondrial morphology were measured suggesting that MSC-EV modulate mitochondrial metabolism. Conclusion This study comprehensively demonstrates the effects of MSC-EVs on human microglial morphology, cytokine secretion, cellular proteome, and mitochondrial content. Our high-throughput, rapid, low-cost morphological approach enables screening of MSC-EV batches and manufacturing conditions to enhance EV function and mitigate EV functional heterogeneity in a disease relevant manner. This approach is highly generalizable and can be further adapted and refined based on selection of the disease-relevant signal, target cell, and therapeutic product.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a1e655e5284ada5880ec741fd1452f6a9e088a59" target='_blank'>
                Microglia Morphological Response to Mesenchymal Stromal Cell Extracellular Vesicles Demonstrates EV Therapeutic Potential for Modulating Neuroinflammation
                </a>
              </td>
          <td>
            K. R. Daga, A. M. Larey, Maria G. Morfin, Kailin Chen, S. Bitarafan, Jana Carpenter, Hannah M. Hynds, Kelly M. Hines, Levi B. Wood, Ross A. Marklein
          </td>
          <td>2024-07-03</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>15</td>

            <td><a href='../recommendations/a1e655e5284ada5880ec741fd1452f6a9e088a59' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e665b02560db74abd44a14d0e0ad225c2a41b63b" target='_blank'>
                Myeloid progenitor dysregulation fuels immunosuppressive macrophages in tumors
                </a>
              </td>
          <td>
            Samarth Hegde, Bruno Giotti, Brian Y. Soong, Laszlo Halasz, J. Berichel, Assaf Magen, Benoit Kloeckner, Raphaël Mattiuz, Matthew D. Park, Adam Marks, Meriem Belabed, Pauline Hamon, Theodore Chin, Leanna Troncoso, Juliana J Lee, Dughan Ahimovic, Michael J. Bale, Grace Chung, D. D’souza, K. Angeliadis, T. Dawson, S. Kim-Schulze, R.M. Flores, Andrew J. Kaufman, Florent Ginhoux, S. Josefowicz, Sai Ma, A. Tsankov, T. Marron, Brian D. Brown, M. Merad
          </td>
          <td>2024-06-28</td>
          <td>bioRxiv</td>
          <td>4</td>
          <td>133</td>

            <td><a href='../recommendations/e665b02560db74abd44a14d0e0ad225c2a41b63b' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d3c93b16e6c2ea8684026f637118f57acb1b437f" target='_blank'>
                Rebalancing Viral and Immune Damage versus Tissue Repair Prevents Death from Lethal Influenza Infection
                </a>
              </td>
          <td>
            H. Ichise, Emily Speranza, Federica La Russa, T. Z. Veres, Colin J. Chu, Anita Gola, Ronald N. Germain
          </td>
          <td>2024-07-07</td>
          <td>bioRxiv</td>
          <td>1</td>
          <td>11</td>

            <td><a href='../recommendations/d3c93b16e6c2ea8684026f637118f57acb1b437f' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="Gastrointestinal (GI) B cells and plasma cells (PCs) are critical to mucosal homeostasis and the host response to HIV-1 infection. Here, high resolution mapping of human B cells and PCs sampled from the colon and ileum during both viremic and suppressed HIV-1 infection identified a reduction in germinal center (GC) B cells and follicular dendritic cells (FDCs) during HIV-1 viremia. IgA+ PCs are the major cellular output of intestinal GCs and were significantly reduced during viremic HIV-1 infection. PC-associated transcriptional perturbations, including type I interferon signaling, persisted in antiretroviral therapy (ART)-treated individuals, suggesting ongoing disruption of the intestinal immune milieu during ART. GI humoral immune perturbations were associated with changes in the intestinal microbiome composition and systemic inflammation. These findings highlight a key immune defect in the GI mucosa due to HIV-1 viremia. One Sentence Summary Intestinal germinal center B cell reduction in HIV-1 infection linked to reduced IgA+ plasma cells and systemic inflammation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2ab6d82fe97aac3e9bb88e1a47a346848d1ab7ff" target='_blank'>
                Gastrointestinal germinal center B cell depletion and reduction in IgA+ plasma cells in HIV-1 infection
                </a>
              </td>
          <td>
            F. Cossarini, Joan Shang, A. Krek, Z. Al-taie, Ruixue Hou, Pablo Canales-Herrerias, M. Tokuyama, M. Tankelevich, Adam Tillowiz, D. Jha, A. Livanos, L. Leyre, M. Uzzan, G. Martínez-Delgado, Matthew Tylor, Keshav Sharma, A. Bourgonje, Michael Cruz, G. Ioannou, T. Dawson, D. D’souza, S. Kim-Schulze, Ahmed Akm, Judith A. Aberg, Benjamin K. Chen, Sacha Gnjatic, A. Polydorides, Andrea Cerutti, C. Argmann, I. Vujkovic-Cvijin, M. Suarez-Farinas, F. Petralia, J. Faith, S. Mehandru
          </td>
          <td>2024-05-20</td>
          <td>bioRxiv</td>
          <td>3</td>
          <td>52</td>

            <td><a href='../recommendations/fc131532914bbcb165dc44342891066be53f33b0' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

    </tbody>
    <tfoot>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/ Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
          <th>View recommendations</th>
      </tr>
    </tfoot>
    </table>
    </p>
  </div>

  <div data-intro='Recommended articles extracted by contrasting
                  articles that are relevant against not relevant for Immunology'>
    <p>
    <h3 id="recommended_articles">Recommended articles on <i>Immunology</i></h3>
    <table id="table2" class="display" style="width:100%">
    <thead>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
      </tr>
    </thead>
    <tbody>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/db216fc3d5be7dbd3db4a74639b3258d970f9b5a" target='_blank'>
              Reinvigoration of translational activity in dysfunctional T cells initiates the early intratumoral response to PD-1 blockade
              </a>
            </td>
          <td>
            Paulien Kaptein, Nadine Slingerland, A. M. van der Leun, Eline Runderkamp, Roos A. Wagensveld, S. Michael Chin, Janniek R. Mors, M. Machuca-Ostos, Timm M. Reissig, K. Moynihan, I. Djuretic, Y. A. Yeung, T. Schumacher, D. Thommen
          </td>
          <td>2025-09-27</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0d1250d29d7374ebca7719549a2dd260ee1ecf40" target='_blank'>
              Divergent Macrophage-Regulated T cell States Determine Response to Bacillus Calmette-Guérin (BCG) in High-Risk Bladder Cancer
              </a>
            </td>
          <td>
            Ryan J. Brown, Mairah T. Khan, Hongshen Niu, Joseph R. Podojil, B. Choy, Weiguo Cui, Joshua J. Meeks
          </td>
          <td>2025-09-21</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>31</td>
        </tr>

        <tr id="Metastatic lung carcinoma poses considerable treatment difficulties. It exhibits cellular characteristics that differ from those of early-stage cancer. Immunotherapy demonstrates enhanced hope for patients with advanced and metastatic lung cancer. Tumor-associated macrophages (TAMs) may be a contributing factor that diminishes the effectiveness of immunotherapy. Secreted phosphoprotein 1 (SPP1)+ TAMs are considered to possess immunosuppressive characteristics, as their interaction with CD8+ T lymphocytes results in the exhaustion of these cells. We analyzed single-cell RNA sequencing datasets of lung cancer metastases in order to examine the development of brain metastatic tumors. Furthermore, the cell–cell interactions between SPP1+ TAM cells and CD8+ T cells within primary and brain metastatic cancers were systematically compared. Additionally, we utilized a flow cytometer and immunofluorescence to demonstrate how SPP1 affects the function of CD8+ T cells. In vitro, we generated SPP1-overexpressing macrophages and performed qPCR, Western blot, and co-culture assays with or without anti-SPP1 or anti-A2AR treatment to evaluate immunosuppressive effects. The results demonstrated that the proportions of immune cells in metastatic brain tissues are lower, while the infiltration of macrophages is higher. SPP1+ TAMs contribute to immune suppression in lung cancer by limiting the activation of CD8+ T cells and cytokine production. Anti-SPP1 treatment positively impacts CD8+ T cell function, counteracting SPP1-induced dysfunction and facilitating the production of cytokines. SPP1 overexpression in macrophages enhanced their immunosuppressive phenotype by upregulating CD73 and cytokines such as IL-10 and TGF-β, leading to impaired CD8⁺ T cell function via A2AR signaling; notably, neutralization of SPP1 or A2AR successfully restored CD8⁺ T cell activity. Our findings characterize the immunological environment of both primary and metastatic lung cancer, highlighting SPP1-mediated immune suppression as a potential therapeutic target to restore T cell responses. Preclinical data demonstrate that Anti-SPP1 antibodies can reverse T cell exhaustion and enhance immune responses in lung cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/659292b315a12f27348d32dba8f9ec9a4a03cedd" target='_blank'>
              Single-cell transcriptomic analyses provide insights into SPP1+ TAM-mediated immune suppression and CD8+ T cell dysfunction in lung cancer
              </a>
            </td>
          <td>
            Rahma Taher Almgrami, Tengyue Zhang, Qitai Zhao, Mingming You, Jinyan Liu, Yi Zhang
          </td>
          <td>2025-09-29</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="Background Chimeric antigen receptor (CAR) T cells targeting CD19 induce durable responses in B-cell acute lymphoblastic leukemia (B-ALL). However, the contribution of the tumor microenvironment to the therapeutic response after CAR T-cell treatment remains incompletely understood. Methods We performed single-cell RNA sequencing and spectral flow cytometry-based analyses of bone marrow-resident immune cells from B-ALL patients before and after CAR T-cell treatment. Results We observed profound changes in the microenvironment in response to CAR T-cell-mediated inflammation, including an increase in myeloid cells. Significant induction of the interferon response, hypoxia, and TGF-β signaling was accompanied by expansion of myeloid-derived suppressor cells (MDSCs) and endogenous exhausted CD8+ T cells. PD-1 expression in endogenous T cells post-treatment was associated with a lack of durable response in the cohort of patients analyzed. Further, we revealed that HIF-1α, VEGF, and TGFBR2 are key players in the intercellular communication between CAR T cells and the immune niche, potentially driving widespread T-cell dysfunction. Infusion of anti-CD19 CAR T cells led to increased accumulation of human MDSCs, exacerbation of a hypoxic environment and T-cell exhaustion in hematopoietic stem/progenitor cell-humanized mice bearing a human tumor. Conclusions In conclusion, CAR T-cell-mediated myeloid activation is associated with pathways of immune dysregulation that may antagonize the effects of therapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e17ba18b5c3d494ffd54cbb6fc378f9f236571c2" target='_blank'>
              Acquisition of an immunosuppressive microenvironment after anti-CD19 CAR T-cell therapy is associated with T-cell dysfunction and resistance
              </a>
            </td>
          <td>
            Marianna Ponzo, Lorenzo Drufuca, C. Buracchi, Marco M. Sindoni, Silvia Nucera, C. Bugarin, Ramona Bason, G. Rossetti, R. Bonnal, Cristian Meli, B. Rambaldi, F. Lussana, Silvia Ferrari, Alex Moretti, G. Dastoli, Giulia Risca, C. Pellegrino, M. Manz, Stefania Galimberti, A. Rambaldi, G. Gaipa, A. Biondi, Massimiliano Pagani, Chiara F Magnani
          </td>
          <td>2025-10-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>38</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/150e482713115efc1b44d4529edb3279c0d13350" target='_blank'>
              Childhood brain tumours instruct cranial haematopoiesis and immunotolerance
              </a>
            </td>
          <td>
            Elizabeth Cooper, David A. Posner, C. Lee, Linda Hu, Sigourney Bonner, Jessica T. Taylor, Oscar Baldwin, Rocio Jimenez-Guerrero, Katherine E. Masih, Katherine Wickham Rahrmann, Jason Eigenbrood, Gina Ngo, Luca Porcu, Valar Nila Roamio Franklin, Clive S. D’Santos, Richard Mair, T. Santarius, Claudia Craven, I. Jalloh, Júlia Moreno Vicente, Timotheus Y. F. Halim, Li Wang, Arnold R. Kreigstien, F. Swartling, Javed Khan, M. Clatworthy, Richard J. Gilbertson
          </td>
          <td>2025-09-26</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>59</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/755725f1743ee5ddbe628ca1f1641cb9240f2088" target='_blank'>
              T-Cell Synaptosomes Orchestrate Long-Term Anti-Tumor Immunity via Proliferative and Metabolic Reprogramming
              </a>
            </td>
          <td>
            Sun-Kyoung Kang, , Sunghee Lee, Hyeonhee Lee, Won-Chang Soh, J. Park, Hee-Tae Kang, Jihwan Park, Sunjae Lee, Yujeong Shim, Joonha Kwon, Hye-Ran Kim, Chang-Duk Jun
          </td>
          <td>2025-11-08</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="Chemokines and their receptors play a pivotal role in shaping the tumor microenvironment (TME) and modulating immune responses by orchestrating immune cell recruitment, spatial positioning, and facilitating cell-cell interactions. However, the exact mechanisms underlying chemokine signaling across different cell populations within the TME remain poorly understood. In this study, we utilized multiple-omics approaches to explore the relationship between CCR1+ macrophages, CD8+ exhausted T (Tex) cells, and immune checkpoint blockade (ICB) therapy response, as well as the role of chemokine signaling in the formation of CCR1+ macrophage and CD8+ Tex cell niches. We found that CCR1+ macrophages were closely associated with ICB outcomes in melanoma. Additionally, combination therapy with a CCR1 antagonist and anti-PD-1 monoclonal antibody significantly reduced tumor burden in melanoma mouse models, which was attributed to the substantial depletion of CD8+ Tex cells. Further, CCR1+ macrophages were found to co-localize with CD8+ Tex cells in human melanoma tissue, and the CCR1+ macrophage-CD8+ Tex cell niche was correlated with ICB treatment response in mice. Importantly, the CCR1-CCL3 axis was identified as a critical mediator in the formation of this niche. Overall, our study underscores the spatial relationship between CCR1+ macrophages and CD8+ Tex cells in ICB therapy, providing a promising strategy to overcome ICB resistance in melanoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a30817fcd20d9c5c0a1a97d6e2d28c75431189be" target='_blank'>
              Blocking CCR1+ macrophages overcomes resistance to immune checkpoint inhibitors in melanoma
              </a>
            </td>
          <td>
            Xinyu Su, Rong Huang, Donglin Kang, Jiayu Wang, Lin Li, Zhengyun Zou
          </td>
          <td>2025-11-03</td>
          <td>Cell Communication and Signaling : CCS</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9a206f96029ea77d3f12043c80bdc9e380da94fc" target='_blank'>
              Tertiary lymphoid structures support the development of allergen-specific progenitor CD4+ T cells
              </a>
            </td>
          <td>
            Derek J. Bangs, Brian Hondowicz, Kathleen Abadie, Remi Savard, Madeleine Weiss, Triantafyllia Karakousi, Peter J. Skene, Amanda W. Lund, Ananda W. Goldrath, Maximilian Heeg, Marion Pepper
          </td>
          <td>2025-10-05</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>70</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/063232094274864c9ecb7e230d62b1cabacbd418" target='_blank'>
              ETV4 restrains the formation of CD74+ cytotoxic exhausted CD8+ T cells
              </a>
            </td>
          <td>
            Dongwook Lee, Yewon Kim, Hyeonmin Gil, Jiyun Lee, Yoon Ha Choi, Minjung Kang, Yunjung Hur, Youngkwon Song, J. S. Park, K. Kim, Jong Kyoung Kim, Yoontae Lee
          </td>
          <td>2025-10-04</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Background Immune checkpoint inhibitor (ICI) therapies present a pillar of modern cancer therapy but can cause neurological immune-related adverse events (n-irAEs), of which up to 35% are severe or even fatal. However, the detailed immunological mechanisms and risk factors underlying n-irAEs remain largely unknown. Here, we leveraged single-cell genomics to dissect immune cell type, state, and clonal heterogeneity associated with n-irAEs. Methods We performed coupled single-cell RNA sequencing and T cell receptor (TCR) profiling on peripheral blood cells of 17 patients with cancer receiving ICI therapy, including 8 patients with acute neurotoxicity. This approach enabled integrated analyses of immune cell states and T cell clonality linked to ICI-induced n-irAEs. Results We profiled 186 435 immune cells and conducted pseudotime analyses, revealing that patients with n-irAEs, compared with controls, present with clonally expanded CD4+ cytotoxic T lymphocytes (CD4+ CTLs) with an n-irAE-specific effector gene expression profile. These T cells predominantly belong to a select set of expanded clonal families and express genes linked to antigen-induced activation, cell lysis, and neuroinflammation. Moreover, they highly express CXCR3 (FC=2.03 compared with control CD4+ CTLs, with a false discovery rate=7.7×10⁻⁴), encoding the chemokine receptor of CXCL10, previously nominated as a biomarker for severe ICI therapy-induced n-irAEs with concomitant multiple organ system toxicity. Conclusions Overall, our study highlights the expansion and activation of CD4+ CTLs in ICI-induced neurotoxicity, proposing these cells as potential targets for developing new biomarkers and therapeutic strategies to improve patient outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8a4f4e0b8916eaa4261cd264db53571afd725a2f" target='_blank'>
              Clonally expanded effector CD4+ cytotoxic T lymphocytes are associated with severe neurological adverse events after immune checkpoint inhibitor therapy
              </a>
            </td>
          <td>
            Ambre Giguelay, Patrick Maschmeyer, L. Müller-Jensen, Christian Schinke, Smilla K. Maierhof, Natasha Nambiar, Manpreet Meyer, Petra Huehnchen, Wolfgang Boehmerle, Matthias Endres, Samuel Knauss, L. S. Ludwig
          </td>
          <td>2025-10-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1ff24f2e8ab0ac14f953e55e0ecee156943f456a" target='_blank'>
              Longitudinal profiling of tumor-reactive T cells during TIL therapy in metastatic melanoma
              </a>
            </td>
          <td>
            M. Sandholzer, Clara Serger, Alessia G. Liner, Sarp Uzun, David König, H. Thut, R. Ritschard, Jonas D. Fürst, Andreas Zingg, N. Rodrigues Mantuano, B. Kasenda, K. Glatz, E. Kappos, Matthias Matter, A. Holbro, F. Stenner, J. Passweg, Nina Khanna, L. Jeker, Mascha Binder, A. Zippelius, Heinz Läubli
          </td>
          <td>2025-09-25</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="Colorectal cancer (CRC) is a highly immunosuppressive malignancy characterized by limited therapeutic options and a poor prognosis. Within the CRC tumor immune microenvironment (TIME), tumor-associated macrophages (TAMs) represent the predominant immune cell population. This study aimed to characterize the specific macrophage subsets contributing to CRC progression and resistance to immunotherapy. Single-cell RNA sequencing (scRNA-seq) was used to identify the key macrophage marker genes. The clinical significance of death-associated protein kinase 1 (DAPK1), was evaluated in clinical CRC cohorts using immunohistochemistry, immunofluorescence, Kaplan-Meier plots and Cox Proportional Hazards Models. Cytometry by time-of-flight, RNA-seq, flow cytometry and an in vitro co-culture system were performed to explore the functional role of macrophage-derived DAPK1 in the TIME. Subcutaneous tumor models and splenic-liver metastasis models were constructed to assess the potential of DAPK1 inhibition to enhance immune checkpoint blockade (ICB) efficacy. scRNA-seq analysis revealed predominant DAPK1 expression in intratumoral macrophages of CRC TIME. Elevated macrophage-specific DAPK1 level was significantly associated with worse prognosis. DAPK1+TAMs exhibited immunosuppressive properties and inhibit CD8+T cells cytotoxicity. Pharmacological inhibition of DAPK1 enhanced the efficacy of anti-PD-1 therapy in murine models. DAPK1+TAMs infiltration was an independent risk factor for overall survival in patients with CRC. These DAPK1+TAMs exhibit an immunosuppressive phenotype and promote the establishment of the TIME with immune evasion. Targeting DAPK1 may represent a potential strategy for synergizing immunotherapy in CRC treatment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d25841457c8b6bc5218514a8ce08f04c9f270986" target='_blank'>
              DAPK1-positve macrophages facilitate immunosuppressive microenvironment and determine immunotherapy efficacy in colorectal cancer
              </a>
            </td>
          <td>
            Jiang Chang, Yuxu Niu, Shizhao Zhou, Ziqi Zhang, Weiying Zhu, Junchang Zhu, Haoran Xiu, Ke Shang, Q. Feng, Ye Wei
          </td>
          <td>2025-11-04</td>
          <td>Journal of Translational Medicine</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7fa20c09bfd50db94368631ee0108a21b0b7fd57" target='_blank'>
              Immune cell de novo steroidogenesis regulates inflammation resolution and recovery in acute lung injury
              </a>
            </td>
          <td>
            Hosni Hussein, S. Shaji, Clara Veiga-Villauriz, Soura Chakraborty, J. Pramanik, Fatma Abo Zakaib Ali, Jing Yuan, Esam Khanfar, N. Makuyana, Youssif M. Ali, Qiuchen Zhao, Daniel Hebenstreit, Bidesh Mahata
          </td>
          <td>2025-09-23</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a872ad111f545dec2c3ad6375d1f4e56d1e106cf" target='_blank'>
              Therapeutic Blockade of Type 2 Cytokines and PD1 Unleashes Anti-Tumor Immunity Through Coordinated Reprogramming of Innate and Adaptive Immune Surveillance
              </a>
            </td>
          <td>
            Thomas Fabre, Eleanore Hendrickson, Katherine McGourty, Paola M. Marcovecchio, James McMahon, Sara Patti, KaiLi Cage, Stephen Searles, Christella Widjaja, Christopher Stairiker, Kathryn Bound, Roxanne Martino, Edward Pyszczynski, Ying Zhang, Graham Thomas, Samuel A. Stoner, Keith A. Ching, Fang Jin, Christopher P. Dillon, Thomas A. Wynn, Richard L. Gieseck, Alexander M. S. Barron
          </td>
          <td>2025-09-29</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="Background LKB1 (STK11)-deficient tumors exhibit an immunosuppressive microenvironment that limits the efficacy of immunotherapies such as anti-programmed cell death protein 1 (PD-1) antibodies. However, the underlying mechanisms driving immune evasion remain unclear. Dendritic cells (DCs), especially conventional DC 1 (cDC1), play a crucial role in antigen presentation and CD8+ T-cell activation, yet their dysfunction in LKB1-deficient tumors has not been well characterized. Methods Tumor-intrinsic LKB1 deficiency was modeled by subcutaneous inoculation of CRISPR/Cas9-engineered Stk11-knockout tumor cell lines into syngeneic mice. DC infiltration and function were assessed through a series of flow cytometry-based in vivo and in vitro assays, including analyses of infiltration, migration, antigen uptake, maturation, and CD8+ T-cell priming. Naïve CD8+ T-cell activation by cDC1s was evaluated via adoptive transfer of CD45.1+ OT-I T cells. Secretome proteomics and functional rescue experiments identified anterior gradient 2 (AGR2) as a key immunosuppressive mediator, and arginase 1 (ARG1) was validated as its functional interactor through liquid chromatography-tandem mass spectrometry (LC-MS/MS), co-immunoprecipitation, and imaging flow cytometry. Upstream regulation of AGR2 was investigated by AMPKα/FOXA1 silencing and chromatin immunoprecipitation (ChIP) quantitative PCR, revealing a tumor-intrinsic AMPKα–FOXA1–AGR2 axis driving DC dysfunction. Results LKB1-deficient tumors exhibited significantly reduced cDC1 infiltration, and cDC1s were functionally impaired in antigen uptake, migration, and naïve CD8+ T-cell priming. AGR2, a secreted protein transcriptionally upregulated via the tumor-intrinsic AMPKα–FOXA1 pathway, was identified as a key mediator of DC dysfunction. Mechanistically, AGR2 interacted with ARG1, stabilizing its expression and promoting ARG1 accumulation in DCs. Restoring DC infiltration and activity through FLT3L-driven expansion and tumor-antigen–specific DC supplementation significantly enhanced the efficacy of anti-PD-1 treatment in LKB1-deficient lung adenocarcinoma models. Conclusion Our study identifies profound DC dysfunction—characterized by impaired antigen uptake, migration, and naïve CD8+ T-cell priming—as a key mechanism of immune evasion in LKB1-deficient tumors. This dysfunction is driven by tumor-secreted AGR2, which stabilizes ARG1 in DCs and suppresses CD8+ T-cell activation. Targeting the AMPKα–FOXA1–AGR2–ARG1 axis or restoring DC competence offers a promising strategy to enhance immunotherapy efficacy in LKB1-deficient subtype.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3e07849093d53dea4843df9f47992371aef80f74" target='_blank'>
              Tumor-secreted AGR2 induces dendritic cell dysfunction and impairs immunotherapy efficacy in LKB1-deficient cancer
              </a>
            </td>
          <td>
            Yuxin Yao, Yuejun Luo, Zhanyu Wang, Enzhi Yin, Chengming Liu, Sufei Zheng, Xinfeng Wang, Xiaoya Tang, Nan Sun, Jie He
          </td>
          <td>2025-10-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="Introduction A comprehensive characterization of immune cells within the tumor microenvironment (TME) of cervical squamous cell carcinoma (CSCC) is essential to advance understanding of tumor biology and guide immunotherapy development. Methods Using single-cell RNA sequencing, we analyzed 14,441 immune cells isolated from tumor tissues and paratumor tissues of three CSCC patients. By integrating data on tumor suppressors, oncogenic factors, cytokines, and chemokines, we performed differential gene expression analyses across immune populations. Results This analysis identified nine major immune cell subsets, including CD8+ T cells, regulatory T cells (Tregs), natural killer/T cells (NK/T cells), B cells, plasmacytoid dendritic cells (pDCs), and macrophages. Notably, elevated CCR7 expression in exhausted CD8+ T cells was associated with improved prognosis, suggesting it as a preliminary candidate for an immunoregulatory target that warrants further investigation. Additionally, CCL5 levels were elevated in Tregs, indicating a possible involvement in their recruitment to the tumor site that requires further validation. Furthermore, differential gene expression analysis identified candidate genes for further mechanistic investigation. Discussion This systematic comparison of the TME between tumor and paratumor tissues reveals dynamic changes in the immune landscape, providing insights and suggesting potential targets for further study to enhance understanding and treatment of CSCC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/37a843f84193a8f20739341bcfd74ef25632d521" target='_blank'>
              Profiling of immune cell subsets and functional characteristics of cervical cancer based on single cell RNA sequencing
              </a>
            </td>
          <td>
            Yue Yuan, Dejun Sun, Mingyue Yang, Ying Xia, Chunli Yuan, Xiaosong Wang
          </td>
          <td>2025-09-25</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1b829e516ebd849b779eb9a27bfa0536b868f851" target='_blank'>
              Regulatory T cells inhibit CD8+ TRM-like cells during the early stages of tumor immune escape
              </a>
            </td>
          <td>
            Jason B. Williams, Shishir M. Pant, Alexander L. Kley, B. Rajmalani, Clarence Yapp, Jiang Zhang, Kyle Deans, E. Rotrosen, Angelika Sales, Peter K. Soger, Thomas S. Kupper
          </td>
          <td>2025-10-22</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8bf2e04bf6e2797aba3ea1f4f0aeb768b1def37b" target='_blank'>
              Memory Regulatory T Cells Reprogram into Protective Tfh-like Effectors in Recurrent Malaria
              </a>
            </td>
          <td>
            Nana Appiah Essel Charles-Chess, A. Ruberto, Carson Bowers, N. Obeng-Adjei, M. R. Hansen, Disha Bangalore Renuka Prasad, B. Traore, K. Klonowski, Peter D. Crompton, S. P. Kurup
          </td>
          <td>2025-10-15</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>47</td>
        </tr>

        <tr id="T follicular regulatory cells (Tfr) play a pivotal role in maintaining immune self-tolerance and prevention of autoantibody induction. However, the stages of Tfr formation have still not been clarified. Here, we found that 30 to 50% of circulating Tfr in human blood have a naïve-like phenotype (preTfr, CD45RA+CD45RO−Foxp3+CXCR5+). PreTfr are expandable in vitro while retaining suppressive capacity. They are transcriptionally similar to naïve Tregs (nTregs) ex vivo, but after stimulation, they gain increased expression of Tfr-related suppressive molecules such as IL-1RA, suggesting that they are primed for full differentiation into mature Tfr. Further, we demonstrate that preTfr but not nTreg are significantly reduced in the blood of patients with COVID-19 and patients with sepsis and that this loss is correlated with increased anti–interferon-γ antibodies and activated atypical B cells. Together, these data suggest that Tfr are disrupted at the earliest stage of their formation during severe disease and may be an important therapeutic target in future vaccine developments.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/56c2e2e7fe87e9ba317c343bbbacab121050c33c" target='_blank'>
              Human precursor T follicular regulatory cells are primed for differentiation into mature Tfr and disrupted during severe infections
              </a>
            </td>
          <td>
            J. Tulyeu, J. Søndergaard, David G Priest, Takeshi Ebihara, Hisatake Matsumoto, Mara A. Llamas-Covarrubias, Masaki Imai, Shinichi Esaki, Shinichi Iwasaki, A. Morita, S. Yamazaki, Shimon Sakaguchi, James B. Wing
          </td>
          <td>2025-09-26</td>
          <td>Science Advances</td>
          <td>0</td>
          <td>33</td>
        </tr>

        <tr id="The immunosuppressive tumor microenvironment (TME) drives radioresistance, but the role of γδ T cells in regulating radiosensitivity remains incompletely understood. In this study, we found that γδ T cell infiltration in the TME substantially increased after radiotherapy and contributed to radioresistance. Depletion of γδ T cells enhanced radiosensitivity. Single-cell RNA sequencing revealed that γδ T cells in the post-radiotherapy TME were characterized by the expression of Zbtb16, Il23r, and Il17a, and served as the primary source of IL-17A. These γδ T cells promoted radioresistance by recruiting myeloid-derived suppressor cells and suppressing T cell activation. Mechanistically, radiotherapy-induced tumor cell-derived microparticles containing dsDNA activated the cGAS-STING/NF-κB signaling pathway in macrophages, upregulating the expression of the chemokine CCL20, which was critical for γδ T cell recruitment. Targeting γδ T cells and IL-17A enhanced radiosensitivity and improved the efficacy of radiotherapy combined with anti-PD-1 immunotherapy, providing potential therapeutic strategies to overcome radioresistance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1b1efdac109d7acd0476c2a995db227fa1bebc94" target='_blank'>
              IL-17-producing γδ T cells in the tumor microenvironment promote radioresistance in mice.
              </a>
            </td>
          <td>
            Yue Deng, Xixi Liu, Xiao Yang, Wenwen Wei, Jiacheng Wang, Zheng Yang, Yajie Sun, Yan Hu, Haibo Zhang, Yijun Wang, Zhanjie Zhang, Lu Wen, Fang Huang, Kunyu Yang, Chao Wan
          </td>
          <td>2025-10-07</td>
          <td>The Journal of clinical investigation</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b846de35114daacf2b8cb62d0ddc0dc54e1e9471" target='_blank'>
              Immunometabolic determinants of long-term response in leukemia patients receiving CD19 CAR T cell therapy
              </a>
            </td>
          <td>
            Lior Goldberg, Eric R Haas, Jiaqi Wu, Bryan Garcia, Ryan Urak, Vibhuti Vyas, Ruby Espinosa, Tamara Munoz, Shirley Bierkatz, K. Pathak, Nathaniel P. Hansen, P. Pirrotte, Jyotsana Singhal, J. Figarola, Ricardo Zerda Noriega, Zhuo Li, Dasol Wi, Erin Tanaka, Ramon I. Klein Geltink, Min-Hsuan Chen, Xiwei Wu, J. Wagner, Jinny A Paul, Mary C. Clark, Dat Ngo, Ibrahim Aldoss, Stephen J. Forman, Xiuli Wang
          </td>
          <td>2025-10-24</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>40</td>
        </tr>

        <tr id="Investigation of the cellular and molecular mechanisms of disease progression from precursor plasma cell disorders to active disease increases our understanding of multiple myeloma (MM) pathogenesis and supports the development of novel therapeutic strategies. In this analysis, single-cell RNA sequencing, surface protein profiling, and B lymphocyte antigen receptor profiling of unsorted, whole bone marrow (BM) mononuclear cell samples was used to study molecular changes in tumor cells and the tumor microenvironment (TME). A cell atlas of the BM microenvironment was generated from 123 subjects including healthy volunteers and patients with monoclonal gammopathy of unknown significance (MGUS), smoldering MM (SMM), and MM. These analyses revealed commonalities in molecular pathways, including MYC signaling, E2F targets and interferon alpha response, that were altered during disease progression. Evidence of early dysregulation of the immune system in MGUS and SMM, which increases and impacts many cell types as the disease progresses, was found. In parallel with disease progression, population shifts in CD8 + T cells, macrophages, and classical dendritic cells were observed, and the resulting differences in CD8 + T cells and macrophages were associated with poor overall survival outcomes. Potential ligand-receptor interactions that may play a role during the transition from precursor stages to MM were identified, along with potential biomarkers of disease progression, some of which may represent novel therapeutic targets. MIF, IL15, CD320, HGF and FAM3C were detected as potential regulators of the TME by plasma cells, while SERPINA1 and BAFF (TNFSF13B) were found to have the highest potential to contribute to the downstream changes observed between precursor stage and MM cells. These findings demonstrate that myeloma tumorigenesis is associated with dysregulation of molecular pathways driven by gradually occurring immunophenotypic changes in the tumor and TME. Trial registration: This project has been registered at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database) with protocol number NOPRODMMY0001 and EudraCT Number 2018-004443-23 on 12 December 2018.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/98a4e027d57002b46ccf88e1aa10930bce31da48" target='_blank'>
              Immunophenotypic changes in the tumor and tumor microenvironment during progression to multiple myeloma
              </a>
            </td>
          <td>
            Isabelle Bergiers, M. C. Köse, Sheri Skerget, Milan Malfait, N. Fourneau, Jenna-Claire Ellis, Greet Vanhoof, Tina Smets, Bie Verbist, Dries De Maeyer, Jeroen Van Houdt, Koen Van der Borght, Raluca Verona, Bradley Heidrich, William Kurth, Michel Delforge, Nathalie Meuleman, Jan Van Droogenbroeck, P. Vlummens, Christoph J Heuck, Yves Beguin, Nizar J. Bahlis, T. Casneuf, J. Caers
          </td>
          <td>2025-10-01</td>
          <td>PLOS Genetics</td>
          <td>0</td>
          <td>36</td>
        </tr>

        <tr id="Introduction Sepsis is responsible for 1 in 5 deaths globally and the majority of those who survive have lasting health issues. A hallmark of sepsis is a deregulated inflammatory response to infection, with leukocytes playing a critical role. Methods This study utilised a targeted single-cell multi-omics approach to characterise peripheral blood mononuclear cell (PBMC) populations and their transcriptomic profiles in an Irish cohort of people with (i) sepsis and (ii) bacteraemia without sepsis (defined as clinically significant positive blood culture without sepsis as assessed by the Clinical Microbiology service). Results Variable leukocyte distributions were identified, with decreased cytotoxic lymphocytes, including CD8+ T cells, natural killer cells, CD56+ T cells, γδ T cells, mucosal-associated invariant T cells, and increased T helper (Th) cell subsets within sepsis samples. Additionally, PBMCs from sepsis samples displayed an impaired expression profile in effector T cells, resulting in widespread suppression of PBMC cytotoxic activity. Discussion These results identify potential mechanisms underlying the functional impairment witnessed in sepsis. Such mechanisms may inform future diagnostic and treatment strategies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5f9838d386bc3ba0f9823edf96e48770618f50b6" target='_blank'>
              Multi-omic analysis of PBMCs in sepsis reveals widespread cytotoxic dysfunction and an increased population of CD69 expressing naïve CD4+ T cells
              </a>
            </td>
          <td>
            Joshua Flynn, A. Baird, Eamon Breen, Michael Carty, Ciara S McNevin, Lisa McDermott, Elaine M. Kenny, J. D. Coakley, Thomas Ryan, Derek G. Doherty, O. Sheils
          </td>
          <td>2025-10-24</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>42</td>
        </tr>

        <tr id="Background Patients with colon cancer liver metastases (CCLM) frequently exhibit poor responses to immunotherapy, a phenomenon attributed in part to an immune desert tumor microenvironment. This study aimed to comprehensively characterize the immune landscape in primary colon cancers and their matched liver metastases via single-cell transcriptome analysis, with the goal of identifying potential immunotherapeutic targets. Methods Tumor specimens from patients with CCLM were subjected to single-cell RNA sequencing. Immune subpopulations were profiled with emphasis on exhausted T cells (Tex)—including both CD8+ and CD4+ ANK3+ subsets—as well as on a distinct stress response T-cell subset (TSTR) defined by high HSPA1A/HSPA1B expression. In parallel, we performed assessments of the phenotype and prognostic impact of SPP1high myeloid cells, along with in vitro assays to examine their role in modulating T-cell number and function. Results Liver metastatic lesions exhibited a significantly elevated infiltration of Tex compared with primary tumors. Notably, Tex cells exhibited upregulated expression of exhaustion-related marker genes such as ANK3, ZBTB20, ETV6, and CAMK4, which were markedly downregulated in TSTR cells. TSTR was identified as an intermediate developmental state between effector and exhausted T cells in patients with CCLM, suggesting that TSTR cells represent a distinct state from exhausted T cells. Furthermore, myeloid cells expressing high levels of secreted phosphoprotein 1 (SPP1), along with apolipoprotein C-I and apolipoprotein E, were associated with poor prognosis in patients with CCLM. In vitro studies revealed that Macro_SPP1high cells diminished T-cell populations and triggered a stress response state in both CD4+ and CD8+ T cells via the SPP1/CD44/PI3K/AKT signaling pathway in a CD44-dependent manner. Importantly, combination treatment with anti-SPP1 and anti-programmed cell death protein-1 antibodies significantly inhibited liver metastasis growth, enhanced dendritic cell maturation, decreased M2-polarized macrophages, and restored T-cell infiltration and function. Conclusions These findings reveal a previously unrecognized relationship between Macro_SPP1high cells and HSPA1Ahigh/HSPA1Bhigh T cells in driving CCLM progression, suggesting a potential synergistic therapeutic approach that could boost immune checkpoint treatment efficacy in patients with CCLM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/70332185d211e11f66dfe54e607751159e5a3aea" target='_blank'>
              SPP1high macrophage-induced T-cell stress promotes colon cancer liver metastasis through SPP1/CD44/PI3K/AKT signaling
              </a>
            </td>
          <td>
            Dongbing Ding, Weibo Li, Jiannan Ren, Yiquan Li, Guangchun Jiang, Rongpu Liang, He Huang, Jiarong You, Yuan Wang, Bo Wei
          </td>
          <td>2025-10-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/313fedd146b7503db4be885b70aaa8b04e759604" target='_blank'>
              A data-driven model of macrophage polarization states reveals an IFN macrophage signature in active Crohn’s disease
              </a>
            </td>
          <td>
            Sarina C. Lowe, Madelaine Leitman, Noah Yan, Alexander Hoffmann
          </td>
          <td>2025-09-25</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/947b164d575d504b4f5969e1b5f9b04297205045" target='_blank'>
              A distinct population of CD8+ T cells expressing CD39 and CD73 accumulates with age and supports cancer progression
              </a>
            </td>
          <td>
            M. Bodogai, Bongsoo Park, Fatima-Zohra Braikia, Fnu Naqing, Konda Kumaraswami, Chen Chen, Emeline Ragonnaud, Sharon Stack, Steffen Ormanns, Michael Günther, H. Ishikawa-Ankerhold, Supriyo De, L. Ferrucci, Ranjan Sen, Zhana Duren, Isabel Beerman, Arya Biragyn
          </td>
          <td>2025-09-25</td>
          <td>Nature Aging</td>
          <td>0</td>
          <td>23</td>
        </tr>

        <tr id="Immune checkpoint inhibitors (ICIs), targeting checkpoint receptors such as programmed cell death protein 1 (PD-1), are associated with increased risk of cardiovascular events, but the underlying mechanisms remain poorly understood. Here we show that PD-1+ T cells from murine atherosclerotic aortas mainly display a progenitor exhausted phenotype (PD-1intSlamf6+Tim3−), produce IFNγ in vivo, exhibit signs of recent proliferation and maintain polyfunctionality. PD-1 blockade induced marked changes in plaque immune phenotype, with increased PD-1high T cell accumulation, IFNγ production, formation of lymphocyte foci and neutrophil recruitment. Depletion of PD-1high T cells prior to PD-1 blockade did not impede T cell recruitment, suggesting a role for progenitor exhausted PD-1int T cells in ICI-driven T cell plaque accumulation. Human circulating PD-1+ T cells produced IFNγ and were associated with subclinical coronary atherosclerosis. Our studies highlight IFNγ-producing PD-1+ T cells as a potential key immune cell population mediating increased cardiovascular risk in patients with cancer receiving ICI. Mulholland et al. identify progenitor exhausted T cells, expressing intermediate levels of PD-1 (PD-1int), as a prominent source of pro-inflammatory cytokines in the murine atherosclerotic aorta and potential cellular targets driving checkpoint inhibition-elicited pro-atherosclerotic immune responses. They further demonstrate elevated levels of circulating PD-1-expressing T cells in individuals with subclinical cardiovascular disease.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5a29caf4329bc4f3e79ec49abf0bdad10c56e11d" target='_blank'>
              Progenitor exhausted PD-1+ T cells are cellular targets of immune checkpoint inhibition in atherosclerosis
              </a>
            </td>
          <td>
            Megan Mulholland, Anthi Chalou, Samuel H A Andersson, M. Depuydt, Yinda Yu, Shiying Lin, Klara Tallbäck, Astrid Ericsson, G. Jakobsson, J. de Mol, Dmytro Kryvokhyzha, A. Lichtman, A. Foks, A. Schiopu, Harry Björkbacka, B. Slütter, Anton Gisterå, D. Engelbertsen
          </td>
          <td>2025-10-01</td>
          <td>Nature Cardiovascular Research</td>
          <td>0</td>
          <td>65</td>
        </tr>

        <tr id="Massive immune cell infiltration and persistent inflammation in the central nervous system (CNS) are key hallmarks of multiple sclerosis. Here, we report a myeloid-derived suppressor cell (MDSC)–based therapeutic strategy, named CNS Immune Targeting Enabled by MDSCs (CITED), which uses surface-decorated MDSCs carrying rapamycin nanoparticles (NPs) for targeted multimodal immune reprogramming in CNS. We show that NP decoration enhances MDSC immunomodulatory function, facilitates their trafficking to inflamed CNS regions, and increases NP accumulation within CNS. In an experimental autoimmune encephalomyelitis model, CITED exhibited robust therapeutic efficacy, resulting in reduced disease progression, improved motor function, and diminished myelin damage. Mechanistic studies reveal that CITED exerts its therapeutic effects by targeted reprogramming of both innate and adaptive immune responses in CNS. Specifically, CITED inhibits immune cell infiltration, rebalances CD4 T cell phenotypes, and promotes the polarization of myeloid cells toward anti-inflammatory phenotypes. Collectively, CITED could provide a broadly effective approach for targeted immune restoration in multiple sclerosis and potentially other autoimmune diseases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c8f24c23e0ed496fd13e4cd70e0bb4daac42d668" target='_blank'>
              Nanoparticle-boosted myeloid-derived suppressor cell therapy for immune reprogramming in multiple sclerosis
              </a>
            </td>
          <td>
            Endong Zhang, H. Algarni, Luyu Zhang, Chih-Jia Chao, Shan He, Aditi Upadhye, Qing Bao, Dahee Jung, Shubhi Srivastava, Edidiong Michael Udofa, Philana Phan, Dejan S. Nikolic, Steve Seung-Young Lee, Jalees Rehman, Zongmin Zhao
          </td>
          <td>2025-10-15</td>
          <td>Science Advances</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Epigenetic scarring of terminally dysfunctional (TDysf) CD8+ T cells hinders long-term protection and response to immune checkpoint blockade during chronic infections and cancer. We developed a faithful in vitro model for CD8+ T cell terminal dysfunction as a platform to advance T cell immunotherapy. Using TCR-transgenic CD8+ T cells, we found that 1-week peptide stimulation, mimicking conditions in previous models, failed to induce a stable exhaustion program. In contrast, prolonged stimulation for 2–3 weeks induced T cell dysfunction but triggered activation-induced cell death, precluding long-term investigation of exhaustion programs. To better mimic in vivo exhaustion, we provided post-effector, chronic TGF-β1 signals, enabling survival of chronically stimulated CD8+ T cells for over 3 weeks. These conditions induced a state of terminal dysfunction, marked by a stable loss of effector, cytotoxicity, and memory programs, along with mitochondrial stress and impaired protein translation. Importantly, transcriptomic and epigenetic analyses verified the development of terminal exhaustion-specific signatures in TDysf cells. Adoptive transfer of TDysf cells revealed their inability to recall effector functions or proliferate after acute lymphocytic choriomeningitis virus rechallenge. This tractable model system enables investigation of molecular pathways driving T cell terminal dysfunction and discovery of therapeutic targets for cancer or chronic infections.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cc4dbe9ec01dc079f493706a4c9a1123f839c591" target='_blank'>
              Faithful modeling of terminal CD8+T cell dysfunction and epigenetic stabilization in vitro
              </a>
            </td>
          <td>
            Amira Yousif, Abbey A. Saadey, Ava Lowin, Asmaa M. Yousif, Ankita Saini, Madeline R. Allison, Kelley Ptak, Eugene M Oltz, Hazem E. Ghoneim
          </td>
          <td>2025-10-08</td>
          <td>JCI Insight</td>
          <td>0</td>
          <td>18</td>
        </tr>

        <tr id="Neutrophils are integral components of the bone marrow and stromal cell network. They express the immune checkpoint molecule PD-L1 and can induce T cell exhaustion, thereby promoting immunosuppression. In this study, we investigated whether tumor-derived Cldn7 deficiency could recruit polymorphonuclear neutrophils (PMNs), induce their metabolic reprogramming, and consequently drive their transition toward a pro-tumor phenotype, leading to the establishment of an immunosuppressive tumor microenvironment (TME). Using single-cell RNA sequencing, clinical sample validation, and both in vivo and in vitro experiments, we found that Cldn7 deficiency in colorectal cancer (CRC) results in a tumor microenvironment characterized by significantly increased infiltration of CD11b⁺ Ly6G⁺ neutrophils. This is accompanied by neutrophil metabolic reprogramming that facilitates their phenotypic shift toward a tumor-promoting state, which in turn suppresses the cytotoxic function of CD8⁺ T cells and contributes to the formation of an immunosuppressive TME, thereby accelerating CRC progression. Mechanistically, Cldn7 deficiency indirectly activates the NF-κB signaling pathway, leading to elevated secretion of chemokines such as CXCL1 that are responsible for PMN recruitment. Inhibition of the NF-κB/CXCL1 axis reduces PMN infiltration, decreases PD-L1 expression on neutrophils, suppresses neutrophil glycolysis and histone lactylation, reverses the exhausted phenotype of CD8⁺ T cells, thereby mitigating the immunosuppressive microenvironment. Furthermore, overexpression of Cldn7 enhances the efficacy of immune checkpoint blockade (ICB) therapy.Collectively, our findings indicate that Cldn7 deficiency not only contributes to immune evasion and malignant progression in CRC but also plays a critical role in immune modulation. Targeting PMN metabolic reprogramming and immunosuppressive function associated with Cldn7 loss may offer a promising strategy to improve the therapeutic efficacy of immunotherapy in CRC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/57fa7d965f4e46d2deb56381980d3616631c7424" target='_blank'>
              Claudin-7 deficiency induces metabolic reprogramming of neutrophils in the colorectal cancer microenvironment
              </a>
            </td>
          <td>
            Xiaoqing Liang, Dajin Yuan, Songyun Zhao, Jianbo Zhou, Kun Wang, Xiaoli Liu, Yin Liu, Huimin Li, Mengdi Hao, Wenbin Huang, Wenjie Li, Lei Ding
          </td>
          <td>2025-10-16</td>
          <td>Cell Death & Disease</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/739a87fd565af12d2e067e28eb04d43a769bbc0a" target='_blank'>
              Skin-derived G-CSF activates pathological granulopoiesis upon psoriasis
              </a>
            </td>
          <td>
            Tomson Kosasih, Tatsuya Morishima, Sohyeon Lee, Jungyeon Yoon, Kanako Wakahashi, Pilhan Kim, Aiko Sada, Hitoshi Takizawa
          </td>
          <td>2025-10-11</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c63743e84578638f8c9499455b868d94cba45959" target='_blank'>
              Splenic granulopoiesis and S100A9 drive resistance to checkpoint inhibitors conferred by liver metastases
              </a>
            </td>
          <td>
            R. Lee, S. Hooper, L. Pallett, Mariana Diniz, Tate McKinnon Snell, Zoe Ramsden, Nicolas Rabas, Stefan Boeing, Oliver Kennedy, Charlotte Buttercase, Gloryanne Aidoo-Micah, Gareth Price, Sarah C. Macfarlane, Sasha Bailey, Jessica Davies, Anandita Mathur, Ginevra Pistocchi, Alexandrine Carminati, Avinash Gupta, Patricio Serra, Brian Davidson, Joerg-Matthias Pollok, V. Papayannopoulos, I. Malanchi, Paul Lorigan, M. Maini, E. Sahai
          </td>
          <td>2025-10-01</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>67</td>
        </tr>

        <tr id="Background Bispecific T cell-engagers (BTEs) are engineered antibodies that redirect T cells to target antigen-expressing tumors. BTEs targeting tumor-specific antigens such as interleukin 13 receptor alpha 2 (IL13RA2) and epidermal growth factor receptor variant III (EGFRvIII) have been developed for glioblastoma (GBM). However, there is limited mechanistic understanding of the action of BTE since prior studies were mostly conducted in immunocompromised animal models. To close this gap, the function of BTEs was assessed in the immunosuppressive tumor microenvironment (TME) of orthotopic and genetically engineered mouse models (GEMM) with intact immune systems. Methods A BTE that bridges CD3 epsilon on murine T cells to IL13RA2-positive GBM cells was developed, and the therapeutic mechanism was investigated in immunocompetent mouse models of GBM. Multicolor flow cytometry, single-cell RNA sequencing (scRNA-seq), multiplex immunofluorescence, and multiparametric MRI across multiple preclinical models of GBM were used to evaluate the mechanism of action and response. Results BTE-mediated interactions between murine T cells and GBM cells triggered T cell activation and antigen-dependent killing of GBM cells. BTE treatment significantly extended the survival of mice bearing IL13RA2-expressing orthotopic glioma and de novo forming GBM in the GEMM. Quantified parametric MRI validated the survival data, showing a reduction in glioma volume and decreased glioma viability. Flow cytometric and scRNA-seq analyses of the TME revealed robust increases in activated and memory T cells and decreases in immunosuppressive myeloid cells within the brains of mice following BTE treatment. Conclusions Our data demonstrate that the survival benefits of BTEs in preclinical models of glioma are due to the ability to engage the host immune system in direct killing, induction of immunological memory, and modulation of the TME. These findings provide a deeper insight into the mechanism of BTE actions in GBM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c3d8175d96b7c6cd7d7b5ae734fb75666b210772" target='_blank'>
              Bi-specific T cell-engaging antibody triggers protective immune memory and glioma microenvironment remodeling in immune-competent preclinical models
              </a>
            </td>
          <td>
            M. Zannikou, J. Duffy, Daniel Procissi, H. Najem, R. Levine, A. Thakur, D. Hambardzumyan, Catalina Lee-Chang, Lara Leoni, C. Horbinski, D. Simberg, Bin Zhang, A. Heimberger, J. Miska, Irina V. Balyasnikova
          </td>
          <td>2025-10-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>38</td>
        </tr>

        <tr id="B lymphocytes exhibit a multifaceted and context-dependent role in tumor biology, acting as both promoters and suppressors of malignancy through dynamic interactions within the tumor microenvironment (TME). This review synthesizes current evidence on the dual functions of B cells in tumor immunity, highlighting their capacity to orchestrate antitumor responses via antigen presentation, antibody-dependent cytotoxicity, and tertiary lymphoid structure (TLS)-mediated T cell activation, while paradoxically driving immunosuppression through regulatory B cells (Bregs), pro-angiogenic signaling, and immune checkpoint modulation. Key mechanisms include TLS formation, which enhances cytotoxic T cell priming and correlates with improved immunotherapy outcomes, and Breg-mediated secretion of IL-10/TGF-β, which fosters T cell exhaustion and myeloid-derived suppressor cell recruitment. Tumor-type specificity is evident: TLS-rich malignancies like melanoma and Non-Small Cell Lung Cancer (NSCLC) show B cell-driven immune activation, whereas pancreatic and hepatocellular carcinomas demonstrate B cell functional plasticity influenced by metabolic and epigenetic reprogramming. Therapeutically, B cell-targeted strategies—including CD20 antibodies, CAR-T cells, and B cell epitope vaccines—demonstrate efficacy in hematologic and solid tumors, yet face challenges due to subset heterogeneity and sex-specific response disparities. Emerging approaches combine immune checkpoint inhibitors (ICBs) with TLS-inducing agents or exploit B cell-derived biomarkers for personalized therapy. Future directions emphasize deciphering B cell metabolic-niche crosstalk, optimizing combinatorial regimens, and leveraging spatial multiomics to resolve functional heterogeneity. By bridging mechanistic insights with clinical translation, this work underscores B cells as pivotal regulators of tumor immunity and advocates for precision strategies to harness their antitumor potential while mitigating pro-tumor plasticity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ebd579b54f9dae49f949806c09388f29afa2ecc8" target='_blank'>
              The dual immunomodulatory role of B cells in tumorigenesis: mechanisms, microenvironment crosstalk, and therapeutic implications
              </a>
            </td>
          <td>
            Zhuangwei Lv, Ruohao Yang, Kai Zhang, Ruihan Wang, Xiaoyu Shi, Jinhua Wu, Lulu Liu, J. Jiao
          </td>
          <td>2025-10-30</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Immune checkpoint inhibitors have traditionally been understood to exert their effects primarily within the tumor microenvironment, particularly targeting CD8 + T cells. However, recent studies have highlighted a pivotal role of tumor-draining lymph nodes in mediating responses to immune checkpoint inhibitor therapy. This study aimed to elucidate the specific mechanisms by which tumor-draining lymph nodes respond to immune checkpoint inhibitor therapy and regulate the tumor microenvironment in human colorectal cancer. We performed single-cell RNA sequencing and T cell receptor sequencing on tumor-draining lymph nodes and tumor tissues from patients with colorectal cancer. Through in-depth analysis of the single-cell data, we established the connection between TDLNs and tumor, and explored the impact of immune checkpoint inhibitor therapy on the immune microenvironment of tumor-draining lymph nodes. In addition, we conducted animal experiments to validate these findings. Our findings revealed that immune checkpoint inhibitor treatment induced the expansion of tumor-specific CD8 + effector memory T cells within tumor-draining lymph nodes, which may serve as a source for the progenitor-exhausted CD8 + T cells in the tumor microenvironment. Moreover, conventional dendritic cells type 1 and macrophages within tumor-draining lymph nodes facilitated this process. We also observed that immune checkpoint inhibitor therapy promoted the expansion of tumor-specific CD4 + follicular helper T cells in tumor-draining lymph nodes, which may explain the increase of CD4 + follicular helper T cells in the tumor microenvironment after immune checkpoint inhibitor therapy. These hypotheses were corroborated through experiments in mice. Our findings delineate the critical regulatory function of tumor-draining lymph nodes in modulating the tumor microenvironment during Immune checkpoint inhibitor therapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7b9de1a203560b665a61560f8094ade12f18f1b7" target='_blank'>
              Tumor-draining lymph nodes respond to immune checkpoint inhibition and orchestrate tumor immune remodeling
              </a>
            </td>
          <td>
            Jinzhu Zhang, Jian Ma, Yaru Niu, Jialiang Liu, Zhexue Wang, Jinyu Guo, Yongsheng Meng, Ruifang Sun, Zhen Zhang, Haiyi Liu, Juan Xu, L. Zan, Xu Guan, Xishan Wang
          </td>
          <td>2025-10-06</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Lung cancer remains the leading cause of cancer-related mortality worldwide, with its progression shaped not only by tumor-intrinsic factors but also by a complex and immunosuppressive tumor microenvironment (TME). Within this niche, diverse immune populations—including CD8+ cytotoxic T cells, CD4+ helper T cell subsets (Th1, Th17, Tregs), B cells, natural killer (NK) cells, tumor-associated macrophages (TAMs), and myeloid-derived suppressor cells (MDSCs)—collectively regulate immune surveillance and tumor escape. While effector lymphocytes mediate antitumor responses, their function is often attenuated by TAM- and MDSC-driven immunosuppression via cytokines (IL-10, TGF-β), metabolic disruption, and immune checkpoint expression. High densities of M2-polarized TAMs and MDSCs correlate with poor prognosis and resistance to therapy. Immune checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4 have improved outcomes in lung cancer, yet therapeutic efficacy remains limited by the immunosuppressive TME. This review outlines the functional roles of key immune cell subsets in lung cancer and highlights emerging strategies to reprogram the TME and enhance immunotherapeutic responsiveness.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ec07b573d2c713f5c6d11528b863b0a4240be315" target='_blank'>
              Reprogramming the immune microenvironment in lung cancer
              </a>
            </td>
          <td>
            Kai Chen, Linqi Luo, Yong Li, Ge Yang
          </td>
          <td>2025-09-29</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Abstract Background Numerous studies have demonstrated the promising efficacy of granulocyte colony‐stimulating factor (G‐CSF) in the treatment of couples with unexplained recurrent pregnancy loss (URPL) during early pregnancy. While neutrophils are recognised as the main effectors mediating immunoregulation, their G‐CSF‐mobilised phenotype and mechanisms regulating maternal–fetal immunity remain unclear. Methods Single‐cell RNA sequencing (scRNA‐seq) and single‐cell T‐cell receptor sequencing (scTCR‐seq) were conducted to uncover the immune reconstitution dynamics of peripheral blood under G‐CSF stimulation. Integrative analysis of transcriptomic‐proteomic profiles with functional validation revealed a unique immunomodulatory neutrophil population. Further, we used spatial transcriptomics, flow cytometry and immunohistochemistry to explore the spatial distribution characteristics of this population at the maternal–fetal interface, and validated its therapeutic efficacy in animal models. Results G‐CSF‐mobilised peripheral blood (G‐PB) displayed immune hyporesponsiveness. Unique neutrophils expressing high levels of CD177 and the S100A gene family expanded substantially in response to G‐CSF. These neutrophils exhibited a comparatively immature morphology and impaired T‐cell responses via contact‐dependent arginase 1 release, as well as upregulation of T‐cell immune checkpoints. A reduction of CD177+S100Ahi neutrophils was observed in both peripheral blood and decidua of URPL patients relative to healthy pregnant women. Functional validation in abortion‐prone murine models confirmed that exogenous supplementation of G‐CSF or adoptive transfer of CD177+S100Ahi neutrophils could successfully improve the pregnancy outcomes. Conclusion G‐CSF played a crucial regulatory role in improving pregnancy outcomes by selectively expanding CD177⁺S100Ahi neutrophils with polymorphonuclear myeloid‐derived suppressor cells (PMN‐MDSCs) properties, providing a solid theoretical foundation for the treatment of patients with URPL using G‐CSF. Key points G‐CSF induces peripheral blood immune hyporesponsiveness in patients with UPRL. First to characterize G‐CSF mobilised CD177+S100Ahi neutrophils displayed PMN‐MDSCs properties. Both CD177+S100Ahi‐LDNs and CD177+S100Ahi‐NDNs induce T cell hyporesponsiveness through coordinated activation of the ARG1/L‐Arg metabolic axis and synergistic upregulation of immune checkpoint molecules. CD177+S100Ahi neutrophils are diminished in the peripheral blood and decidua of patients with UPRL.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f6e8e769871352922cc92c745bad2ac8d159aa41" target='_blank'>
              Granulocyte colony‐stimulating factor induced T‐cell hyporesponsiveness via modulation of CD177+S100Ahi neutrophils in unexplained recurrent pregnancy loss
              </a>
            </td>
          <td>
            Ping-Fen Li, Xue Zhang, Peng-Sheng Zheng
          </td>
          <td>2025-10-01</td>
          <td>Clinical and Translational Medicine</td>
          <td>1</td>
          <td>3</td>
        </tr>

        <tr id="The co-inhibitory receptor TIGIT suppresses excessive immune responses in autoimmune conditions while also restraining antitumor immunity. In viral infections, TIGIT alone does not affect viral control but has been shown to limit tissue pathology. However, the underlying mechanisms are incompletely understood. Here we found TIGIT+ T cells to express not only an immunoregulatory gene signature but also a tissue repair gene signature. Specifically, after viral infection, TIGIT directly drives expression of the tissue growth factor amphiregulin (Areg), which is strongly reduced in the absence of TIGIT. We identified regulatory T (Treg) cells, but not CD8+ T cells, as the critical T cell subset mediating these tissue-protective effects. In Treg cells, TIGIT engagement after T cell antigen receptor stimulation induces the transcription factor Blimp-1, which then promotes Areg production and tissue repair. Thus, we uncovered a nonclassical function of the co-inhibitory receptor TIGIT, wherein it not only limits immune pathology by suppressing the immune response but also actively fosters tissue regeneration by inducing the tissue growth factor Areg in T cells. Joller and colleagues show that the co-inhibitory receptor TIGIT induces the expression of the tissue growth factor amphiregulin (Areg) in regulatory T cells and contributes to tissue repair in response to viral infection.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0b61dd16412c6f14fc56828dfe7806631ed84034" target='_blank'>
              The co-inhibitory receptor TIGIT promotes tissue-protective functions in T cells
              </a>
            </td>
          <td>
            C. Panetti, Rahel Daetwyler, A. Moncsek, Nikolaos Patikas, A. Agrafiotis, Adelynn Tang, F. Andreata, Valeria Fumagalli, Jean de Lima, Lifen Wen, Carolyn G King, Ajithkumar Vasanthakumar, Matteo Iannacone, Axel Kallies, A. Yermanos, M. Hemberg, Nicole Joller
          </td>
          <td>2025-10-15</td>
          <td>Nature Immunology</td>
          <td>1</td>
          <td>31</td>
        </tr>

        <tr id="Cholangiocarcinoma (CCA) is an aggressive malignancy with limited treatment options. Despite the approval of chemotherapy and immune checkpoint inhibitors (ICIs) in clinical practice, treatment outcomes remain poor, largely due to the poorly immunogenic tumor microenvironment associated with this type of carcinoma. Necroptosis, an inflammatory form of programmed cell death, has emerged as a promising therapeutic target for stimulating antitumor immunity. Our previous study linked necroptosis to increased CD8 + T cell infiltration and T cell-induced PD-L1 expression in CCA cells, suggesting its role in enhancing ICI efficacy. However, the underlying mechanisms by which necroptosis-activated T cells induce PD-L1 expression remain unclear. Here, we investigate how necroptosis in CCA cells influences T cell response, which subsequently promotes PD-L1 expression, thus providing insights for optimizing necroptosis-based therapies in combination with ICIs. Conditioned medium from gemcitabine-induced necroptotic CCA cells triggers PBMC-derived T cell activation by upregulating the surface activation marker CD69 and promoting cytokine release, primarily IL-6 and IL-1β. This cytokine release subsequently induces PD-L1 expression in CCA cells via IL-6, as confirmed by IL-6 neutralizing antibodies. Furthermore, T cell killing assays demonstrated that pembrolizumab, an anti-PD-1 inhibitor, enhances T cell cytotoxicity against PD-L1-upregulated CCA cells. Additionally, bioinformatics analysis identified an IL-6 signaling-related gene signature associated with ICI responsiveness, suggesting potential biomarkers for personalized treatment strategies. This study highlights that necroptosis shapes the tumor immune microenvironment by promoting T cell activation and IL-6-mediated PD-L1 upregulation in CCA cells. These findings support the integration of necroptosis-based therapies with ICIs as a sequential chemo-immunotherapy strategy. Additionally, the identified IL-6 signaling-related gene signature may serve as a biomarker for patient stratification and personalized treatment in CCA.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b332b9862a9454fda1fad0e5ce1b8b1d16ea6a48" target='_blank'>
              Necroptosis-driven T cell activation promotes IL-6-mediated PD-L1 upregulation in cholangiocarcinoma cells: IL-6 gene signature as a biomarker for chemo-immunotherapy response
              </a>
            </td>
          <td>
            Thanpisit Lomphithak, Nattaya Duangthim, Sasiprapa Sonkaew, Siriporn Jitkaew
          </td>
          <td>2025-09-23</td>
          <td>Biology Direct</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/394995c0fcb10ae0448160919d2f62f9453d3170" target='_blank'>
              Comprehensive single-cell analysis reveals mast cells’ roles in cancer immunity
              </a>
            </td>
          <td>
            Hao Qian, Wenbo Wang, Jiaomeng Pan, Ming Zhao, Li Gao, Jia Zeng, Hang Gong, Guangyan Zhangyuan, Zi Li, Mao Zhang, Xia Shen, Yuanchi Weng, Xiaxing Deng, Yingying Huang
          </td>
          <td>2025-10-10</td>
          <td>Oncogene</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="Colorectal cancer (CRC) remains one of the most lethal malignancies worldwide, with outcomes shaped not only by genetic alterations but also by the complexity of the tumor microenvironment (TME). The TME encompasses stromal and endothelial cells, extracellular matrix components, gut microbiota, and a diverse array of immune cells that dynamically interact to influence tumor initiation, progression, and therapeutic response. This review delineates the immunological landscape of CRC, highlighting the dual functions of innate immune cells—including tumor-associated macrophages, natural killer cells, dendritic cells, neutrophils, and mast cells—and adaptive immune players such as cytotoxic T lymphocytes, helper T-cell subsets, and B/plasma cells. These cellular interactions contribute to the heterogeneity between immunologically “hot” microsatellite instability-high (MSI-H) tumors, which are highly responsive to immunotherapy, and “cold” microsatellite-stable (MSS) tumors, which remain resistant. Key mechanisms of immune evasion, such as cancer immunoediting, checkpoint signaling, and exosome-mediated communication, are examined alongside prognostic tools like the Immunoscore that serve as biomarkers of immune infiltration. Emerging immunotherapeutic strategies, including checkpoint blockade, macrophage reprogramming, natural killer cell agonists, and microbiome modulation, are discussed with emphasis on both their promise and limitations in CRC management. By integrating current insights into immune–tumor interactions, the review underscores opportunities for developing personalized, TME-targeted interventions to improve CRC outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1877a469ae4ff5d08c11f55218aceb0c7af5a6c3" target='_blank'>
              Immunological landscape of colorectal cancer: tumor microenvironment, cellular players and immunotherapeutic opportunities
              </a>
            </td>
          <td>
            Adile Buse Andac-Aktas, Gizem Calibasi-Kocal
          </td>
          <td>2025-10-30</td>
          <td>Frontiers in Molecular Biosciences</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Abstract SLAMF8 is predominantly expressed in macrophages and plays an important role in autoimmune diseases and inflammation. Our previous studies have focused on SLAMF8, however, the potential of SLAMF8 as an immunotherapeutic target and its role in regulating the tumor immune microenvironment remain to be elucidated. This study demonstrated that macrophage-specific SLAMF8 is significantly associated with a poor prognosis for colorectal cancer (CRC). Additionally, M2 macrophage and tumor-associated macrophages (TAMs) models were used to verify that SLAMF8 induces an immunosuppressive phenotype in macrophages and regulates antitumor immunity by inhibiting the activation and function of CD8+ T cells. In vivo, we confirmed that SLAMF8 inhibition promoted remodeling of the immunosuppressive microenvironment and augmented immunotherapy sensitivity in CRC. Mechanistically, we demonstrated that SLAMF8 promotes the polarization of macrophages toward the M2 phenotype via the PI3K/AKT and JAK/STAT3 signaling pathways. In summary, this study confirmed that inhibiting SLAMF8 exerts an antitumor effect by reversing the immunosuppressive tumor microenvironment in CRC, providing new therapeutic targets and strategies for combined immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0eb7d8ffd5d61d0e44a547a2d1181cb708517e0e" target='_blank'>
              Inhibiting SLAMF8 modulates tumor-associated macrophages and restores CD8+ T cell-mediated antitumor immunity in colorectal cancer
              </a>
            </td>
          <td>
            Xingzhi Han, Xueying Bai, Ning Wang, Yuexin Sun, Jing Hu, Li Li, Zhihao Liu, Yaping Zhang, Zixin Liang, Liuqi Sang, Lu Han, Qun Zhang, Xiaoping Qian
          </td>
          <td>2025-11-10</td>
          <td>Oncoimmunology</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="For patients with metastatic uveal melanoma (UM), tebentafusp is currently the only systemic therapy approved by the EMA and FDA, but its use is limited to HLA-A*02:01-positive individuals. Immune checkpoint blockade (ICB) represents another option, though only a small subgroup of patients benefits, and no reliable predictive biomarkers are available to date. The aim of this study was therefore to identify parameters associated with favorable ICB response. Tumor samples and clinical data from 30 patients were analyzed. Group A (n = 16) showed clinical benefit, while Group B (n = 14) experienced disease progression. NanoString® analyses revealed 258 upregulated genes in Group A, including IDO1, CD28, and CCL8. The enriched pathways were predominantly linked to immune activation, leukocyte adhesion, and responses to external stimuli. Immunohistochemistry confirmed significantly higher CD28 expression on infiltrating immune cells in Group A, while a machine learning approach identified CCL8 as a predictive marker with ~78% accuracy. Overall survival differed significantly between the groups. These findings indicate that patients responding to ICB display tumors with enhanced immune activation. CD28 and CCL8 emerged as promising candidates and should be validated in prospective studies to determine their clinical utility.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/21fb1f7f11d72549844add3236526177a487e0d8" target='_blank'>
              Checkpoint Blockade Efficacy in Uveal Melanoma Is Linked to Tumor Immunity, CD28, and CCL8
              </a>
            </td>
          <td>
            Elias A. T. Koch, R. Liguori, Alejandro Afonso Castro, S. Schliep, A. Petzold, A. Wessely, Waltraud Fröhlich, F. Ferrazzi, Julio Vera, Markus Eckstein, C. Berking, M. Heppt
          </td>
          <td>2025-10-01</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/276902406914fa26315122d32de7c8926d35072f" target='_blank'>
              Interferon Restores Antigen Presentation and Sensitizes Medulloblastoma to T Cell Killing
              </a>
            </td>
          <td>
            Tanja Eisemann, M. Masihi, Theophilos Tzaridis, Veronika Pister, Isaac Youm, Kendall R. Chambers, Aditi Dutta, Alexander T Wenzel, Koei Chin, Scott L. Pomeroy, J. Mesirov, E. Fraenkel, Anindya Bagchi, Lukas Chavez, Robert J Wechsler-Reya
          </td>
          <td>2025-10-02</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Tertiary lymphoid structures (TLSs) in the tumor microenvironment (TME) act as local hubs for antigen presentation and lymphocyte activation, reinforcing antitumor immunity. They act as ectopic, lymph node-like niches that orchestrate local antitumor immunity through well-defined B-cell follicles, T-cell zones, follicular dendritic cells (FDCs), and high endothelial venules (HEVs). Although various cancer treatment methods can impact TLSs, thereby changing the state of the TME, the dynamic changes in TLSs caused by treatment and the mechanisms therein have not been comprehensively summarized to date. This review highlights the mechanisms of different cancer treatment effects on TLSs dynamic change, including the number and functionality of TLSs within tumors. We also summarize the value of TLSs in predicting prognosis and therapeutic effect, as well as the deficiencies in current research and future development directions.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4b10ea5ef7732254210365008058829408071ec8" target='_blank'>
              Dynamic remodeling of tertiary lymphoid structures in response to cancer therapy: a recent review
              </a>
            </td>
          <td>
            Chongyu Tan, Jinliang Huang, Ning Gao, Bingquan Wu, Matsika Juliet, Jiatong Xiao, Jiao Hu, Ping Liu, Jinbo Chen
          </td>
          <td>2025-09-29</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6a9f3325348d0e9acac4d1170eb3ed6e4599ca92" target='_blank'>
              Co-Stimulatory Blockade Prevents Intragraft Accrual of Class-Switched, Activated B Cells Despite Failing to Prevent T-Cell Mediated Rejection
              </a>
            </td>
          <td>
            J. T. Caldwell, Tiffany Shi, Ashley R. Burg, Ashley Koby, Krishna M. Roskin, Anna L. Peters, E. DePasquale, E. Woodle, D. Hildeman
          </td>
          <td>2025-10-24</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous and aggressive hematologic malignancy, with the activated B-cell-like (ABC) subtype displaying particularly poor prognosis due to inherent treatment resistance and elevated recurrence rates. Despite advances in targeted therapies and immunotherapies, a significant proportion of patients experience relapse or refractory disease, highlighting the urgent need for novel biomarkers and innovative therapeutic strategies to improve clinical outcomes. A multi-dimensional analysis of SH3BP5 expression was performed across DLBCL subtypes, integrating transcriptomic, proteomic, and clinical datasets to assess its correlation with immune infiltration, tumor metabolism, and patient prognosis. Single-cell RNA sequencing data were employed to examine the tumor microenvironment (TME) with higher resolution. Further analysis of the association between SH3BP5 and immune checkpoint gene expression was conducted to explore its potential role in immunotherapy response. Functional in vitro assays were carried out to assess the impact of SH3BP5 knockdown on DLBCL cell proliferation and apoptosis. The analysis revealed that SH3BP5 is preferentially overexpressed in the ABC subtype of DLBCL across multiple datasets and validated cohorts, and its high expression is significantly associated with poor overall survival. Single-cell transcriptomic profiling demonstrated that SH3BP5 is mainly expressed in malignant B cells and inversely correlated with immune cell infiltration, particularly CD8 + T cells. Mechanistically, pathway enrichment and metabolic assays indicated that SH3BP5 is linked to mitochondrial metabolic reprogramming, promoting oxidative phosphorylation (OXPHOS) and potentially contributing to reduced responsiveness to immune checkpoint inhibitors (ICIs). Functional studies showed that SH3BP5 knockdown significantly suppressed DLBCL cell proliferation, induced apoptosis, and reduced tumor cell viability in vitro. This study suggests that SH3BP5 may serve as a prognostic biomarker and a potential therapeutic target in DLBCL, particularly within the ABC subtype. By delineating its associations with immune evasion and metabolic reprogramming, these findings provide a mechanistic basis for further exploration of SH3BP5-targeted interventions to help overcome therapy resistance. Future studies in larger clinical cohorts and functional models are warranted to validate these results and assess the potential of integrating SH3BP5 expression profiling into precision medicine strategies for DLBCL. The study was registered in the Chinese Clinical Trial Registry (ChiCTR2200060430; http://www.chictr.org.cn/) on June 1, 2022.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d27222190fd1301e27cfd9869b08b07fc58aa185" target='_blank'>
              SH3BP5-driven metabolic-immune crosstalk in DLBCL: a prognostic biomarker and therapeutic target for reshaping immunosuppressive microenvironment
              </a>
            </td>
          <td>
            Tong Wu, Yi Yang, Yuan Zong, Jiawen Zhao, Xiaoyu Zhao, Lei Li, Yiming Gao, Ning Li, Liting Jiang, Yinyin Xie
          </td>
          <td>2025-09-24</td>
          <td>Journal of Translational Medicine</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="ABSTRACT The immune landscape of healthy prostate and its alterations during prostate cancer (PCa) progression remain poorly characterized. Using scRNA-sequencing and multiparametric flow-cytometry analysis, we comprehensively characterized immune cells in wild-type and PTEN(i)pe−/− mouse prostates, a model that closely recapitulates human PCa. PCa in PTEN(i)pe−/− is marked by the recruitment of tumor-associated neutrophils (TANs), which represent the dominant immune cell population and resolved into eight distinct states, Trem2+ tumor-associated-macrophages (TAMs), and exhausted CD8+ T cells. Trem2+ TAMs differ from the three main resident macrophage populations in the healthy prostate, exhibiting a strong metabolic and immunosuppressive signature, likely driven by the MIF/HIF1A-signaling axis. This study provides the first detailed characterization of immune cells in the healthy mouse prostate and reveals changes in the immune landscape associated with prostate cancer progression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ddbb0c0592aa197777e78a6d1020c20a4157e6fc" target='_blank'>
              Characterization of the immune landscape in healthy mouse prostate and during prostate cancer progression
              </a>
            </td>
          <td>
            Despoina Pervizou, Joanna De Chiara, L. Spinelli, Maia Nestor-Martin, Lionel Chasson, Kateryna Len-Tayon, Darya Yanushko, Frédéric Fiore, Marc Bajénoff, Bernard Malissen, Daniel Metzger, Gilles Laverny, S. Henri
          </td>
          <td>2025-09-26</td>
          <td>Oncoimmunology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Relapsed and refractory multiple myeloma (RRMM) remains a major clinical challenge, as most patients eventually relapse following standard treatments and are left with limited therapeutic options. Although b-cell maturation antigen (BCMA) CAR-T cell therapy has recently shown remarkable efficacy in select patients, broader implementation is hindered by its reliance on autologous cells, prolonged manufacturing timelines, high costs, and severe immune-related toxicities. These challenges have prompted an urgent demand for safer, more accessible, and rapidly applicable immunotherapeutic alternatives. CBMC (cord blood mononuclear cells) were cultured with irradiated BMMC (bone marrow mononuclear cells) from RRMM patients in the presence of defined cytokines, aiming to develop a new therapeutic immune cell product for RRMM. Their phenotypic and functional characteristics, including non-MHC-restricted and MHC-restricted cytotoxicity mechanisms, were analyzed using surface marker profiling, cytokine secretion assays, in vitro cytotoxicity assays, functional and blocking assays. Antitumor activity was evaluated in xenograft mouse models using MM.1 S and RPMI-8226 cells. We successfully generated CD8+ NKT-like cells through tumor priming, which exhibited potent cytotoxicity and elevated cytokine production against multiple myeloma cell lines and primary RRMM samples. Mechanistically, tumor-priming CD8+ NKT-like cells (TPNC) cytotoxicity was mediated by both non-MHC–restricted pathways involving LFA-1 and DNAM-1, and MHC-restricted, TCR-mediated recognition. TPNC efficiently formed immune synapses, rapidly polarized cytotoxic granules, and engaged in serial killing. In xenograft models, TPNC significantly suppressed tumor progression, prolonged survival, and persisted in circulation without observable toxicity. Based on these findings, we extended the tumor-priming strategy to acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), successfully generating TPNC with robust cytotoxic activity. In ALL samples, TPNC exhibited cytotoxicity comparable to anti-CD19 CAR-NK cells. TPNC represents a novel cytotoxic lymphocyte product generated through tumor-driven priming. Their dual recognition capacity, functional versatility, and favorable safety profile highlight their potential as a scalable and personalized immunotherapy platform for hematologic malignancies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/93312d628496ab87e87c047dff1fc445e08f269c" target='_blank'>
              Tumor-priming CD8+ natural killer T-like cells as an efficient novel cell therapy for relapsed/refractory multiple myeloma
              </a>
            </td>
          <td>
            Juheon Lee, E. Choi, Bohwa Han, Jeongmin Kim, Dana Jung, Kyeong-Hee Kim, Sung Yong Oh, Sung-Hyun Kim, Kyungsoo Ha, Ji-Hoon Kim, Ji Hyun Lee, Duck Cho, Junsang Doh, Seok-Ho Kim
          </td>
          <td>2025-09-29</td>
          <td>Experimental Hematology & Oncology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Background and objective Tumor antigen–escape variants undermine immunotherapy by subverting lymphocyte effector functions and reshaping tumor–immune dynamics. It is essential to delineate functional interplay within immune networks during tumor progression. We investigated whether homeostatic crosstalk between CD8+T cells and natural killer (NK) cells preempts tumor antigen–escape. Methods Adoptive CD8+T cell transfers were administered before (D–7, homeostatic pre-priming) or after (D+1) tumor establishment in Rag1−/− and Rag1−/−γc−/− mice. Antigen presentation, immune activation, proliferation, cytotoxicity, and memory were quantified by flow cytometry, live bioluminescence and confocal imaging. Monoculture, co-culture, and a 3D silica nanofiber carpet mimicking basement-membrane-like topography modeled intercellular interactions. Signaling arrays and motion metrics (Speed-Distance Index, deceleration) were conducted. Human ligand–receptor pairs engaged in CD8+T–NK crosstalk were probed in silico. Results and discussion Pre-tumor D–7 CD8+T cell transfer completely suppressed antigen–escape tumors with NK cells as major effectors showing elevated CD25, CD69, CD107a, and GzmB, marking activated and effector phenotype, and promoting central-memory CD62L⁺CD44⁺CD8⁺TCM precursors. By contrast, post-tumor D+1–transferred CD8+T cells allowed emergence of tumor variants resistant to antigen-specific cytolysis as assessed on day 25, despite those T cells retaining higher intrinsic cytotoxic capacity than the D–7 T cell cohort. Mechanistically, CD8+T and NK cells formed stable contacts through pseudopodial intercellular nanotubes enabling bidirectional membrane exchange and signaling via STAT, Akt, and mTOR pathways, augmenting NK effector function and promoting CD8+TCM differentiation. In silico analysis identified human ligand–receptor pairs engaged in CD8+T–NK adhesion, stimulatory and regulatory axes, including CD200–CD200R, PD-L1–PD-1, and CD18/CD11a–DNAM-1 (CD226). Together, data support a three-phase model of preemptive immunosurveillance initiated by early CD8⁺T–NK crosstalk. Conclusion Homeostatic conditioning and effector cooperativity between CD8+T and NK cells protect against tumor immune escape. The findings uncover a mechanistic axis of preemptive immunosurveillance that lays the foundation for next-generation preventive immunotherapies to control antigen–escape tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7da5a7fdb4ec2b2b9a760d690ae1d6009548f667" target='_blank'>
              CD8+ T–NK cell crosstalk establishes preemptive immunosurveillance to eliminate antigen–escape tumors
              </a>
            </td>
          <td>
            R. Uzhachenko, Salvador González Ochoa, T. Kanagasabai, H. Rajakaruna, Menaka C Thounaojam, M. T. D. de Aquino, Tanu Rana, L. Costa, A. Terekhov, William H. Hofmeister, Thomas J. Sayers, Claude Boyer, Alla Ivanova, J. S. Goodwin, A. Schmitt-Verhulst, A. Shanker
          </td>
          <td>2025-09-22</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>44</td>
        </tr>

        <tr id="Administration of IL-2 may promote the suppressive function and proliferation of Treg cells that cause immune tolerance in patients with cancer, which causes low-dose IL-2 to fail in achieving an optimal anti-tumor effect. Here, we designed an immunocytokine by fusing IL-2 and an anti-TIGIT monoclonal antibody, named αTIGIT-IL2, that targets Treg cells and promotes their fragility in the tumor milieu. These fragile-like Treg cells show impaired suppressive function and high IFN-γ production, triggering an immune-reactive tumor microenvironment. Such inflammation leads to the recruitment and functional reprogramming of intratumoral neutrophils, improving cross-talk between neutrophils and CD8+ T cells and enhancing the antitumor ability of CD8+ T cells. Combination therapy with αTIGIT-IL2 and PD-1 blocker could eliminate triple-negative breast cancer (TNBC) tumors resistant to immune checkpoint blockade (ICB) therapy. These findings provide the basis for developing a new generation of immunocytokines that target Treg cells and promote their fragility in the tumor milieu, resulting in robust antitumor immunity. Interleukin-2 (IL-2) and checkpoint inhibitors such as anti-TIGIT have been used individually as tumour therapies. Here the authors fuse IL-2 and anti-TIGIT in a combined therapeutic and show that this promotes Treg cell fragility in the tumour environment which in turn promotes neutrophil function to enhance CD8 T cell anti-tumour function in mouse models.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a8f381b44371297ad7f4ba1f04d5155ffd6052c5" target='_blank'>
              αTIGIT-IL2 achieves tumor regression by promoting tumor-infiltrating regulatory T cell fragility in mouse models
              </a>
            </td>
          <td>
            Tianci Wang, Yupu Xu, Zhengfeng Zhang, Yaqi Wu, Long Chen, Xiaodong Zheng, Hui Peng, Qiang Zou, Rui Sun, Hongdi Ma, Haoyu Sun, Zhigang Tian, Xiaohu Zheng
          </td>
          <td>2025-10-17</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a4abcaf5776ad97c1813abd2abb8852a605b524d" target='_blank'>
              Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T cell therapies
              </a>
            </td>
          <td>
            A. Carturan, Mathew G. Angelos, P. Guruprasad, R. Patel, R. Pajarillo, Andrew Lee, Yunlin Zhang, Yi-Hao Chiang, Wei Xie, Jesse L. Rodriguez, Jaryse Harris, Pooja Devi, Olabisi I. Afolayan-Oloye, Jason Xu, Jonathan Sussman, Omar Elghawy, Austin Yang, Adam Barsouk, J. Cho, Carolyn E. Shaw, Ekta Singh, O. Ugwuanyi, D. Espie, L. Paruzzo, Federico Stella, Shan Liu, Siena Nason, Antonio Imparato, Antonia Rotolo, Jean Lemoine, David M. Barrett, A. Posey, A. Rook, Vinodh Pillai, Adam Bagg, S. Pileri, Dongfang Liu, Kai Tan, S. Schuster, D. Teachey, P. Porazzi, M. Ruella
          </td>
          <td>2025-09-26</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>66</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4e312c1a3a9dbed5ee9046577d5060ddafb93654" target='_blank'>
              Identifying the therapeutic potential of Niclosamide in overcoming IFN-gamma dependent cancer immune evasion in the Tumor Microenvironment
              </a>
            </td>
          <td>
            Yue Zhang, Sophia Peng, Hamid Akhbariyoon, Suzi Kim, Ellie Lai, En Cai
          </td>
          <td>2025-10-28</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Objective: T cell exhaustion is a major mechanism of immune evasion in cancer, characterized by the sustained expression of multiple inhibitory receptors. This study aimed to evaluate the expression of immune checkpoints in peripheral and tumor-infiltrating CD8+ T cells from cervical cancer patients. Methods: We enrolled 104 participants: 37 treatment-naïve patients, 36 treated patients, and 31 age-matched healthy donors. Peripheral blood mononuclear cells (PBMCs) were isolated from all participants. Ten cervical biopsies were collected for tumor-infiltrating lymphocyte (TIL) isolation and paraffin fixation. Immune checkpoint expression was analyzed by multiparametric flow cytometry and immunohistochemistry. Results: In peripheral CD8+ T cells, we found a significant upregulation of exhaustion-associated markers PD-1, TIGIT, Tim-3, and LAG-3. In the tumor infiltrating lymphocytes, these same molecules, with the addition of NKG2A, were notably upregulated further. While BTLA and NKG2A showed no systemic changes, NKG2A increased in TILs and BTLA decreased in TILs. The co-expression of PD-1 with TIGIT, Tim-3, LAG-3, and NKG2A was notably enriched between 2- and 6-fold in TILs compared with patient PBMCs. The tumor microenvironment was highly immunosuppressive, characterized by enrichment with PD-1, PD-L1, and TIGIT; TIGIT was notably upregulated in locally advanced versus early-stage tumors. Conclusions: Our findings highlight the strongly immunosuppressive environment of cervical tumors in treatment-naïve patients and the presence of elevated inhibitory checkpoint expression in peripheral blood of both pre- and post-treatment patients. These results underscore the importance of investigating immune regulation within the tumor site itself and suggest that immune checkpoint co-expression may serve as a biomarker of T cell exhaustion and therapeutic resistance. Understanding how treatment alters these pathways could guide rational combination immunotherapies to restore CD8+ T cell function in cervical cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/dc558c84054fe2039b48c74e300596d32e9772ff" target='_blank'>
              T Cell Exhaustion in the Cervical Cancer Tumor Microenvironment: PD-1 Overexpression and Co-Expression with TIGIT, Tim-3, LAG-3, and NKG2A
              </a>
            </td>
          <td>
            Nadia Tatiana Garcia-Barrientos, Fabiola Solorzano-Ibarra, Ksenia Klimov-Kravtchenko, Jose Manuel Rojas-Diaz, Marcela Sofia Guitron-Aviña, Francisco Javier Ceja-Flores, J. Cruz-Ramos, P. Ortiz-Lazareno, Felipe de Jesús Bustos-Rodriguez, J. C. Vázquez-Limón, M. Bueno-Topete, M. C. Téllez-Bañuelos, J. Haramati, S. del Toro-Arreola
          </td>
          <td>2025-11-11</td>
          <td>Cancers</td>
          <td>0</td>
          <td>24</td>
        </tr>

        <tr id="Myeloid cells are a diverse group of immune cell types with systemic and organ-specific functions. Myeloid cells are frequently found in the tumor microenvironment and their infiltration correlates with survival and response to treatment. High myeloid infiltration is typically a poor prognostic factor, and the immune suppressive and prometastatic roles of myeloid cells are well established. However, there is an increasing appreciation of the antitumor functions performed by myeloid cells, which include direct tumor cell killing, phagocytosis, antigen presentation and T and natural killer cell recruitment. Moreover, advances in immune phenotyping have uncovered myeloid subsets with positive prognostic significance, including subsets correlating with higher response rates to immunotherapy. This review summarizes recent progress in mapping and dissecting the opposing effects of myeloid cells on cancer progression and immunotherapy response. The overall impact of myeloid cells is context-dependent, and combination therapies are needed to leverage the antitumor potential of these cells.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3823ee46218e3233f5b48e60b02f6fa9d09ba69f" target='_blank'>
              Positive and negative roles of myeloid cells in cancer immunotherapy
              </a>
            </td>
          <td>
            Jaroslav Zak, Judith A. Varner
          </td>
          <td>2025-10-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/18d334efdd4d167f301eb6b862ccafe18092402f" target='_blank'>
              Localized immunomodulation with cytokine-producing cells to mitigate host immune rejection responses in rodents and a non-human primate
              </a>
            </td>
          <td>
            Boram Kim, Dilrasbonu Vohidova, A. Nash, Yuen San Chan, Samantha Fleury, Shravani Deo, Danna Murungi, Peter D Rios, Ira Joshi, Hafsa Nasir, Daisy Lopez, Mor Sela Golan, Cassidy Hart, Jose Oberholzer, H. C. Hodges, O. Veiseh
          </td>
          <td>2025-10-15</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Non-small cell lung cancer (NSCLC) exhibits profound immune dysregulation, driven in part by the opposing roles of regulatory T cells (Tregs) and T helper 17 (Th17) cells. Tregs facilitate tumor progression through immune suppression, angiogenesis, and checkpoint engagement, while Th17 cells display dual effects depending on the tumor microenvironment, either promoting anti-tumor responses or enhancing malignancy. Importantly, plasticity between these subsets, orchestrated by cytokines such as TGF-β, IL-6, and IL-1β, allows dynamic interconversion that shapes immune outcomes. This review comprehensively summarizes the differentiation, molecular mechanisms, and functions of Tregs and Th17 cells in NSCLC. We highlight recent advances in targeting the Th17/Treg axis via immune checkpoint inhibitors, Treg depletion, and metabolic reprogramming. Understanding this immunological balance offers promising avenues for restoring anti-tumor immunity and improving therapeutic efficacy in NSCLC patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cc2fe215418a201aa8b5de519c7cfb5b11dfb23a" target='_blank'>
              Rewiring immune suppression in NSCLC: Roles and plasticity of Tregs and Th17 cells
              </a>
            </td>
          <td>
            Shasha Zhu, Ning Zhou, Qingling Li, Xiaoxing Liu
          </td>
          <td>2025-10-16</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/842af96f572eb3d970548668b36cfda84da5efb2" target='_blank'>
              Glucocorticoid Receptor Signaling in Myeloid Cells Orchestrates Inflammation Resolution and Muscle Repair
              </a>
            </td>
          <td>
            Sirine Souali-Crespo, Joe G. Rizk, Emilia Calvano, Rajesh Sahu, Emina Colovic, Imane Chabba, Valentine Gilbart, Erwan Grandgirard, Bastien Morlet, Qingshuang Cai, Daniel Metzger, D. Duteil
          </td>
          <td>2025-10-30</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/64a8bf2f0e1e9b9b72d805335f54c3671ab83124" target='_blank'>
              Targeting neoantigens conserved across organs and species overcomes tumor immune escape
              </a>
            </td>
          <td>
            G. Mestrallet, Ross W. Ward, Matthew Brown, Jesse Boumelha, Frederika Rentzeperis, Natalie Vaninov, Miriam Saffern, Ezekiel Olumuyide, Prerna Suri, Sreekumar Balan, L. Velazquez, Aparna Ananthanarayanan, Zhihong Chen, Aimee L Lucas, Miriam Merad, C. C. Bozkus, Nicolas Vabret, R. Samstein, Nina Bhardwaj
          </td>
          <td>2025-09-29</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="T cell responses are generally curtailed by suppressive mechanisms within the tumor microenvironment (TME) that prevent T cell infiltration and function. Consequently, T cell-based therapies for solid tumors have yielded limited and often non-durable clinical responses. Tumors develop a hostile TME, where tumor-associated macrophages (TAMs) that initially support T cells are converted into immune suppressive TAMs that facilitate tumor evasion from T cell control. In fact, immune suppressive TAMs represent a dominant fraction of immune cells within the TME and their presence is associated with poor prognosis and resistance to immunotherapy. Often in close contact with effector T cells, TAMs directly suppress CD8+ T cells through mechanisms involving metabolic mediators, co-signaling receptors, their ligands and/or cytokines. Here, we revisit molecular interactions behind TAM-mediated suppression of T cell responses and address the potential targeting of such molecules and pathways to re-boost anti-tumor T cell immunity. This perspective, focusing on molecular interactions between TAM and T cells, may aid the improvement of T cell-based therapies for solid tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8c01dfbcf193a83248342e1e2c8db14cdc37f598" target='_blank'>
              Tumor-associated macrophages: untapped molecular targets to improve T cell-based immunotherapy
              </a>
            </td>
          <td>
            R. M. Coelho, R. Debets, Dora Hammerl
          </td>
          <td>2025-10-16</td>
          <td>Molecular Cancer</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Myeloid cells play critical roles as Fc effector cells in antibody‐mediated immunity. Granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) is a pleiotropic cytokine that promotes the recruitment and activation of multiple myeloid populations and has been used in combination with vaccines/treatments against infectious diseases, inflammatory conditions and cancers. To evaluate GM‐CSF‐mediated kinetics of immune cell expansion and immune outcomes, we compared subcutaneous (subQ) and topical hypoosmolar (intravaginal/intrarectal) administration in vivo using rhesus macaques (RM), as they provide easy access to longitudinal mucosal tissue sampling and are a critical model species for vaccines/therapeutics development. While topical GM‐CSF did not result in a major change, neutrophils, eosinophils and monocytes were elevated within 1–3 days of subQ GM‐CSF administration, with peak eosinophil and neutrophil enrichment in blood at days 7 and 8, respectively. Corresponding elevations of neutrophils, eosinophils, total CD64+ and total CD32+ were observed at days 7 and 14 in rectal biopsies, indicating general Fc effector cell accumulation in these animals. Histological evaluations of vaginal biopsies showed myeloid cell infiltration at day 14 of subQ GM‐CSF treatment. Further, subQ GM‐CSF administration resulted in myeloid cell activation and trafficking, as evidenced by elevated levels of cytokines (CXCL13, MCP‐1, IL‐1RA). Importantly, neither subQ nor topical GM‐CSF administration induced overt systemic inflammation or adverse clinical impacts. Overall, our findings delineate the kinetics of systemic and mucosal myeloid cell expansion, activation and trafficking achieved by subQ GM‐CSF administration in RM. These findings will inform the use of GM‐CSF as an adjuvant in clinical applications where myeloid cell mobilization is advantageous.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/492d90767cafd39d09bc074bbefa23b57af9983b" target='_blank'>
              Myeloid cell recruitment and activation through systemic and mucosae‐directed cytokine therapy
              </a>
            </td>
          <td>
            C. Manickam, Rhianna Jones, Nihar R. Deb Adhikary, Kyle W. Kroll, Karen Terry, Hari Balachandran, Griffin Woolley, G. Tomaras, François J. Villinger, R. K. Reeves
          </td>
          <td>2025-10-07</td>
          <td>Immunology and Cell Biology</td>
          <td>0</td>
          <td>82</td>
        </tr>

        <tr id="Autoimmune kidney diseases (AIKDs) are a consequence of the dysregulation of immune response and the loss of tolerance to self-antigens, which led to glomerulonephritis and tissue damage. Autoantibody-producing B cells, as well as T cells, neutrophils and macrophages play a pivotal role in the pathogenesis and progression of various AIKDs. In recent years, B cell-depleting/modulating therapies and molecules that modulate T cell differentiation pathways and cytokine production have become a new hope for patients with immune-mediated kidney diseases. However, these biologicals often do not bring satisfactory therapeutic benefits, which is most likely related to incomplete B cell depletion of tissue-resident B cells. A new hope is immunotherapy with chimeric antigen receptor (CAR) effector cells. In CAR therapy, immune cells (mostly T cells) are genetically modified to express a CAR, which enables the recognition of the specific antigen on a target cell. This interaction leads to the formation of immune synapse and cytotoxicity. CAR-based strategies are a potent form of cell therapy that offers a better chance for deep and durable response than other recently approved immune therapies. Moreover, CAR-T cells can be programmed for higher precision and safety. This review explores the current landscape of CAR-T cell therapy in AIKDs.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f214144b87a7be044bf71857fed9fe114ce14c2a" target='_blank'>
              CAR-T Cell Therapy for Autoimmune Kidney Diseases: Where Do We Stand Now?
              </a>
            </td>
          <td>
            Beata Kaleta
          </td>
          <td>2025-10-01</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Abstract In the tumour microenvironment (TME) of renal cell carcinoma (RCC), tertiary lymphoid structures (TLS) play a crucial role in anti‐tumour immune responses. Resembling secondary lymphoid organs, TLS comprises B cells, T cell zones, high endothelial venules, and antigen‐presenting cells, facilitating local immune activation. While TLS has shown correlations with improved immune checkpoint inhibitors (ICIs) outcomes in other cancers, its role in RCC is still under investigation. Emerging evidence indicates that mature TLS enhances anti‐tumour activity by activating T and B cells, whereas immature TLS may contribute to immune suppression. The RCC TME is highly immunosuppressive, marked by regulatory T cells, myeloid‐derived suppressor cells, and elevated pro‐angiogenic and immunosuppressive cytokines. In this context, TLS, particularly mature TLS, can counteract immunosuppression, boost local immune responses, and improve ICIs efficacy. However, TLS in RCC is heterogeneous, with their formation and function affected by factors like CXCL13 expression. The presence, maturity, and functionality of TLS may serve as valuable predictors of ICIs response and patient prognosis. Further research is required to understand TLS regulation and leverage their potential to enhance personalised immunotherapy for RCC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e06e4f2c0f51b0e1b714cfca628cbbc454ea7b91" target='_blank'>
              Role of tertiary lymphoid structures in the tumour microenvironment and immunotherapy response of renal cell carcinoma
              </a>
            </td>
          <td>
            Lin Yang, Wentai Shangguan, Weijia Li, Wenxue Huang, Zhuohang Li, Boyuan Sun, Cunzhen Ma, Xunguo Yang, Bisheng Cheng, Peng Wu
          </td>
          <td>2025-10-01</td>
          <td>Clinical and Translational Medicine</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="ABSTRACT Adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) has demonstrated consistent clinical efficacy in treating advanced melanoma and other “hot” tumors. However, it has shown limited success in “cold” tumors like glioblastoma. We present the successful treatment of a rapidly progressing glioblastoma patient with TILs expanded using a defined cytokine combination of IL-2, IL-15, and IL-21. The patient received lymphodepletion with cyclophosphamide one day pre-TIL infusion, followed by a single dose of IL-2 post-transfer. Complete tumor regression was observed after two TIL infusions administered two weeks apart. The TIL products were enriched for CD8+ T-cells and demonstrated specific lysis of the autologous tumor cell line. Transcriptomic analysis of tumor biopsies post-TIL infusion revealed increased expression of genes associated with immunological synapse formation and T-cell effector function, correlating with the patient’s clinical outcome. T-cell receptor (TCR) next-generation sequencing of the infused TILs and post-treatment tumor biopsies confirmed the infiltration and expansion of TIL-derived clonotypes within the tumor microenvironment. CD8+ T-cell clonotypes exhibited robust tumor migration and expansion, while CD4+ T-cells showed limited tumor infiltration. In conclusion, TILs expanded with IL-2/IL-15/IL-21 represent a promising therapeutic approach for glioblastoma, overcoming traditional challenges posed by the tumor microenvironment and achieving significant clinical outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2803e1a4de6f344e11b914032849f558f3ea1e42" target='_blank'>
              Tumor-infiltrating lymphocytes-derived CD8+ clonotypes infiltrate the tumor tissue and mediate tumor regression in glioblastoma
              </a>
            </td>
          <td>
            L. C. Arruda, J. Karbach, D. Kiselicki, H. Altmannsberger, E. Sinelnikov, D. Gustavus, H. Hoffmeister, A. Atmaca, E. Jäger
          </td>
          <td>2025-10-07</td>
          <td>Oncoimmunology</td>
          <td>1</td>
          <td>28</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1dc5d3c63e2c8a598b2458f56705187d3452201c" target='_blank'>
              Neutrophils induce effective antibody responses to the pneumococcal conjugate vaccine by inhibiting regulatory T cells
              </a>
            </td>
          <td>
            Essi Y. I. Tchalla, Anagha Betadpur, Andrew Y. Khalil, Elena Lopez, Manmeet Bhalla, Musea Chang, Elizabeth A. Wohlfert, E. Ghanem
          </td>
          <td>2025-10-30</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Chronic inflammation can induce lymphocyte dysfunction, which is characterized by the expression of inhibitory immune checkpoints. For type 2 innate lymphoid cells (ILC2s), the acquisition of a state of hyporesponsiveness associated with PD-1 expression has been reported in severe allergic inflammation. However, the regulation of ILC2 reactivity in the context of cancer is less clear. The contribution of ILC2s to the antitumor immune response depends, indeed, on the type of tumor and the distinct cellular interplay within the microenvironment. Here, we show that ILC2s in malignant pleural effusions express the immune checkpoints PD-1 and CTLA-4. An in vitro model of the ILC2‒macrophage interaction demonstrated that this crosstalk is responsible for driving CTLA-4 expression and limiting ILC2 activation. Thus, by preventing ILC2 exhaustion, macrophages maintain ILC2 responsiveness to signals from the tissue. These results reveal that, unlike PD-1 expression, CTLA-4 expression on ILC2s is associated with the maintenance of a reactive state during chronic inflammation in the tumor microenvironment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d6d5467603d5e7f345ebab9e29b096e00e701725" target='_blank'>
              Macrophages regulate PD-1 and CTLA-4 expression on ILC2s and their responsiveness in the tumor microenvironment
              </a>
            </td>
          <td>
            Cecilia Ciancaglini, Silvia Santopolo, Stefania Martini, F. Scordamaglia, Giuseppe Pietropaolo, Mattia Laffranchi, G. Sciumè, Guido Ferlazzo, P. Vacca, Lorenzo Moretta, L. Quatrini
          </td>
          <td>2025-09-24</td>
          <td>Cellular and Molecular Immunology</td>
          <td>1</td>
          <td>45</td>
        </tr>

        <tr id="Cancer remains a leading cause of mortality worldwide, with rising incidence and death rates continuing to rise. While conventional treatments such as surgery, radiotherapy, and chemotherapy form the backbone of cancer care, they are often limited by adverse effects, recurrence risk, and incomplete tumor eradication. Tumor immunotherapy—particularly immune checkpoint inhibitors and chimeric antigen receptor (CAR) T cell therapy—has emerged as a transformative approach by activating and reprogramming anti-tumor immune responses. Despite these advances, significant challenges persist, including limited response rates to checkpoint inhibitors, the immunosuppressive nature of the tumor microenvironment (TME), and resistance mechanisms employed by tumor cells. Growing evidence suggests that immune cell senescence is a critical contributor to TME-driven immunosuppression. Senescent immune cells exhibit functional decline, elevated expression of inhibitory immune checkpoint molecules, and increased secretion of pro-inflammatory cytokines, collectively impairing anti-tumor immunity and reducing the efficacy of immunotherapy. This review highlights the role of immune cell senescence in shaping the immunosuppressive TME and driving resistance to immunotherapy. It further discusses emerging therapeutic strategies that combine immunotherapy with senescence-targeting interventions, aiming to provide novel insights into the development of more effective cancer treatment strategies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/56cdaa455cdfae646c5bce11b54ada6d03f2699c" target='_blank'>
              Senescent immune cells in the tumor microenvironment: emerging insights into cancer immunotherapy resistance
              </a>
            </td>
          <td>
            Duolun Gao, Peiyan Kan, Yanjie He, Siyu Sun, Lei Tang, Fan Yang
          </td>
          <td>2025-10-17</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Background/Objectives: Whilst adoptive cell therapy (ACT) using chimeric antigen receptor-engineered T (CAR-T) cells represents an efficient approach for the treatment of patients suffering from several hematological malignancies, solid tumors have been shown to be far more challenging to tackle, mainly due to the hostile tumor microenvironment that inhibits optimal T cell functionality. As proven by the broad clinical success of immune checkpoint inhibitors, blocking the interaction of programmed cell death ligand 1 (PD-L1) expressed on tumor cells and the checkpoint receptor programmed cell death 1 (PD-1) expressed on activated T cells allows an intrinsic T cell-mediated anti-tumor response to be unleashed. We developed a cellular product (MDG1015) consisting of New York esophageal squamous cell carcinoma-1 (NY-ESO-1)/L antigen family member 1a (LAGE-1a)-specific CD8+ T cell receptor-transduced (TCR-)T cells co-expressing the costimulatory switch protein (CSP) PD1-41BB, which turns an inhibitory signal mediated by the PD-1:PD-L1 axis into positive T cell costimulation. Methods: In vitro co-cultures of MDG1015 and PD-L1-positive or -negative target cells were used to analyze TCR-T cell functionality, such as TCR-T (poly-)cytokine release, the killing of target cells, and TCR-T proliferation. The safety of MDG1015 was evaluated via different panels of antigen-negative cell lines or primary cells expressing or lacking PD-L1. Results: Preclinical analyses demonstrated TCR-gated activation of the CSP, leading to enhanced functionality of MDG1015 against antigen-expressing, PD-L1-positive tumor cells without any impact on antigen-negative target cells. Conclusions: The favorable, preclinical functionality and safety profile qualifies MDG1015 as a promising cellular therapy for explorative clinical testing in hard-to-treat solid tumor indications.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0061d8fd9c6ec9b1979ffcc32d15a525ae895b20" target='_blank'>
              Preclinical Development of Costimulatory Switch Protein (CSP)-Armored NY-ESO-1/LAGE-1a-Specific TCR-T Cells for Therapy of Hard-to-Treat PD-L1-Positive Solid Tumors
              </a>
            </td>
          <td>
            M. Bürdek, Petra U. Prinz, Katrin Mutze, Miriam Bosch, S. Tippmer, A. Coluccio, C. Geiger, Snigdha Majumder, G. Longinotti, Dolores J. Schendel
          </td>
          <td>2025-09-26</td>
          <td>International Journal of Translational Medicine</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="Background Combining chemotherapy with anti-programmed cell death protein-1 (PD-1) improves clinical outcomes in oesophageal squamous cell carcinoma (ESCC), yet the underlying synergistic mechanism remains obscured. Moreover, 30–50% of patients still derive no therapeutic benefit from the combination strategy, highlighting the need to decipher and overcome resistance. Objective We sought to investigate the mechanisms by which chemotherapy augments the responses to immune checkpoint blockade and elucidate the factors contributing to persistent resistance in non-responding patients. Design We designed a systematic investigation involving longitudinal sampling of ESCC tissues both from patients treated with chemotherapy plus anti-PD-1 and anti-PD-1 monotherapy. The tumour microenvironment (TME) was then comprehensively characterised using single-cell transcriptomics, T cell receptor repertoire analysis, multiplex immunohistochemistry and murine models. Results We demonstrated that combination therapy exerted superior antitumour efficacy by mitigating immune checkpoint engagements (TIGIT-NECTIN2 and NECTIN1-CD96) between epithelial-stress tumour cells and CD8+ T cells, thereby preventing T cells from exhaustion and boosting vitality. In non-responders, we identified a subset of tumour cells with high SLC1A3 expression, which localised at the tumour boundary and interacted with COL1A1+ myofibroblastic cancer-associated fibroblasts, inducing an extracellular matrix-enriched TME that hindered the infiltration of CD8+ T cells. Inhibiting SLC1A3 significantly enhanced the efficacy of chemotherapy plus anti-PD-1, underscoring its potential as a therapeutic target. Conclusion This study elucidates the synergistic mechanisms and identifies key resistance pathways underlying chemo-immunotherapy combinations in patients with ESCC, providing a scientific basis for refining future combination therapeutic regimens.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6499f1de5fd4e40b0e29e55c9717b0471e592e12" target='_blank'>
              Alleviated T cell exhaustion and SLC1A3-mediated stroma-remodelling dictate chemoimmunotherapy efficacy in oesophageal squamous cell carcinoma
              </a>
            </td>
          <td>
            Shu-Jing Xiang, Yanxing Chen, Chaoye Wang, Min Wang, Ye-Mei He, Zhichao Liu, Jin-Ling Zhang, Lu-Ping Yang, Yun-Fu Wei, Qi-Nian Wu, Zi-Xian Wang, Shao-Yan Xi, Zhigang Li, Qi Zhao, Rui-Hua Xu, Feng Wang
          </td>
          <td>2025-09-22</td>
          <td>Gut</td>
          <td>0</td>
          <td>25</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/eb0d181b971ab9d5141b1475ee18608b8080d802" target='_blank'>
              Molecular Plasticity of T Cells Informs Their Possible Adaptation in 4T1 Tumors
              </a>
            </td>
          <td>
            Md. Iftehimul, Robert H. Newman, Scott H Harrison, Roshonda B. Jones, P. Muganda, Bryan L. Holloman, M. T. Hossain, C. J. Rorie, Misty D. Thomas, Joseph L. Graves, H. Kaufman, Dipongkor Saha
          </td>
          <td>2025-10-17</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Cold tumors, defined by insufficient immune cell infiltration and a highly immunosuppressive tumor microenvironment (TME), exhibit limited responsiveness to conventional immunotherapies. This review systematically summarizes the mechanisms of immune evasion and the therapeutic strategies for cold tumors as revealed by multi-omics technologies. By integrating genomic, transcriptomic, proteomic, metabolomic, and spatial multi-omics data, the review elucidates key immune evasion mechanisms, including activation of the WNT/β-catenin pathway, transforming growth factor-β (TGF-β)–mediated immunosuppression, metabolic reprogramming (e.g., lactate accumulation), and aberrant expression of immune checkpoint molecules. Furthermore, this review proposes multi-dimensional therapeutic strategies, such as targeting immunosuppressive pathways (e.g., programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors combined with TGF-β blockade), reshaping the TME through chemokine-based therapies, oncolytic viruses, and vascular normalization, and metabolic interventions (e.g., inhibition of lactate dehydrogenase A (LDHA) or glutaminase (GLS)). In addition, personalized neoantigen vaccines and engineered cell therapies (e.g., T cell receptor-engineered T (TCR-T) and natural killer (NK) cells) show promising potential. Emerging evidence also highlights the role of epigenetic regulation (e.g., histone deacetylase (HDAC) inhibitors) and N6-Methyladenosine (m6A) RNA modifications in reversing immune evasion. Despite the promising insights offered by multi-omics integration in guiding precision immunotherapy, challenges remain in clinical translation, including data heterogeneity, target-specific toxicity, and limitations in preclinical models. Future efforts should focus on coupling dynamic multi-omics technologies with intelligent therapeutic design to convert cold tumors into immunologically active (“hot”) microenvironments, ultimately facilitating breakthroughs in personalized immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5f521c611e55896b93cee504ac14c36afaf25953" target='_blank'>
              Igniting Cold Tumors: Multi-Omics-Driven Strategies to Overcome Immune Evasion and Restore Immune Surveillance
              </a>
            </td>
          <td>
            Xinyao Huang, Renjun Gu, Ziyu Li, Fangyu Wang
          </td>
          <td>2025-09-26</td>
          <td>Oncology Research</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Ankylosing spondylitis (AS) is a chronic immune‐mediated disease marked by sustained joint inflammation and aberrant bone remodelling. Although chronic antigen exposure usually enforces terminal exhaustion, emerging evidence indicates that a subset of CD8+ T cells in AS evades canonical exhaustion programmes while expressing programmed cell death protein 1 (PD‐1). These exhaustion‐resistant cells retain effector function and likely contribute to persistent tissue inflammation and structural damage. In this review, we dissect the cellular and molecular basis of exhaustion resistance in AS CD8+ T cells and focus on the convergence of intermittent T cell receptor (TCR) stimulation, metabolic adaptation that preserves mitochondrial fitness, and co‐stimulatory inputs from interleukin‐15 (IL‐15) and CD28. We propose an integrated three‐axis model governing CD8+ T cell fate and functional persistence in the AS context shaped by human leukocyte antigen‐B27 (HLA‐B27) and the gut–joint axis. Clarifying these mechanisms refines current views of T cell dysfunction in chronic inflammation and highlights therapeutic strategies aimed at reprogramming pathogenic immunity in AS.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/bcc208ede076a40cec13cb8b2e4d04e77729e53d" target='_blank'>
              Exhaustion‐Resistant CD8 + T Cells in Ankylosing Spondylitis: A Proposed Three‐Axis Model
              </a>
            </td>
          <td>
            Xuhong Zhang, Lu Jia, Xueni Lin, Lamei Zhou
          </td>
          <td>2025-10-02</td>
          <td>Immunology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="ABSTRACT Introduction Hepatocellular carcinoma (HCC) is a major cause of cancer-related death globally, characterized by an immunosuppressive tumor microenvironment (TME) that impairs immune surveillance. Immunotherapy has emerged as a transformative option; however, durable responses remain limited. The purpose of this review is to synthesize recent advances in HCC immunology, immunotherapy, and the TME. Areas Covered Literature was identified via PubMed and ClinicalTrials.gov (January 2001–May 2025), focusing on clinical and translational studies. We outline the immunological landscape of HCC, emphasizing the roles of T cells, natural killer cells, macrophages, dendritic cells, myeloid-derived suppressor cells, and regulatory T cells in shaping tumor immunity. TME components include cancer-associated fibroblasts, tumor-associated macrophages, suppressive cytokines, angiogenesis, hypoxia, metabolic reprogramming, and the gut-liver axis. Interactions with immunotherapy, mechanisms of resistance, and combination strategies were described. Emerging biomarkers – such as tertiary lymphoid structures, PD-L1, tumor mutational burden, gene signatures, and gut microbiota – are reviewed relative to patient stratification. Expert Opinion Immunotherapy has reshaped HCC management, but resistance, biomarker limitations, and heterogeneity remain major challenges. Advances will require TME reprogramming, multi-parametric biomarkers, and personalized strategies. Integration with targeted and locoregional approaches may achieve durable responses and move toward precision immuno-oncology, transforming HCC into a manageable or curable disease.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3f81fb97115d4549912d0ac1a8a271a719cc8ad4" target='_blank'>
              Immunology, immunotherapy, and the tumor microenvironment in hepatocellular carcinoma: a comprehensive review
              </a>
            </td>
          <td>
            Miho Akabane, Yuki Imaoka, Ghee Rye Lee, T. Pawlik
          </td>
          <td>2025-09-29</td>
          <td>Expert Review of Clinical Immunology</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Innate lymphoid cells (ILCs) are tissue-resident lymphocytes specialized in cytokine secretion that lack antigen-specific receptors. The contribution of ILCs to antiviral mucosal immunity in humans, particularly in the female genital tract (FGT), remains unexplored. Here we resolved human FGT ILC diversity by spectral flow cytometry and CITE-seq, spatial location within genital anatomical regions using ChipCytometry, and determined homeostatic function and antiviral responses. We uncovered spatial and functional specializations of genital ILC subsets under homeostasis, with compartmentalized age-related and pregnancy-related changes. CD161 expression differentially discriminated ILC subsets preloaded with cytokines at steady state. We identified a unique NKp44+CCR6+ ILC3 subset in the endometrium that actively degranulated at homeostasis and was located in lymphoid aggregates surrounded by B cells and T cells. By contrast, ILC1s were found scattered, enriched in the ectocervix and located close to the epithelium. Following in vitro HIV stimulation, genital ILCs displayed rapid subset-specific antiviral responses. These findings reveal distinct tissue and subset-specific features of FGT ILCs and their capacity to immediately respond to viral stimuli, providing a foundation for future studies to determine the potential role of ILCs in mucosal immune protection in the FGT. The authors spatially and functionally map innate lymphoid cells in the human female genital tract at homeostasis, uncovering tissue-specific and subset-specific distribution and functions, and rapid antiviral responses following HIV exposure.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2d03715a8f07fa91481c2c31ff5ec2c676c366a9" target='_blank'>
              Spatial and functional diversity of innate lymphoid cells in the human female genital tract may contribute to antiviral responses to HIV
              </a>
            </td>
          <td>
            Alexandra E. Werner, Laura Moreno de Lara, Aleah Holmes, Siddharth Parthasarathy, Genna E. Moldovan, Anna Borchers, Francisco J Carrillo-Salinas, Jared M. Fortier, Vidya Iyer, Alison Vogell, Rebecca Jameson, Jacquelyn E. Stephens, Marta Rodriguez-Garcia
          </td>
          <td>2025-09-22</td>
          <td>Nature Immunology</td>
          <td>1</td>
          <td>6</td>
        </tr>

        <tr id="Abstract Background Mounting evidence shows that myeloid‐derived suppressor cells (MDSCs) reprogramming can significantly enhance the outcomes of immunotherapy. However, the therapeutic potential of targeting MDSCs alone is limited by persistent immunosuppressive cytokines and cellular crosstalk. In our previous study, we found that novel cryo‐thermal therapy (CTT) can drive MDSCs maturation and induce CD4+ T helper type (Th)1‐dominant differentiation, improving long‐term survival in spontaneous high metastatic mouse models. Considering the established roles of Interleukin (IL)‐6 and IL‐17A in non‐small cell lung cancer (NSCLC) progression and immune evasion, we developed a combination strategy integrating cytokine neutralization with CTT (combination therapy) in LLC1 tumor‐bearing mice. Although the combination therapy successfully promoted MDSCs maturation and Th1 differentiation, the underlying mechanistic basis remained unclear. Methods The combination therapy was implemented in LLC1 tumor‐bearing mice. We then observed its impacts on MDSCs maturation and Th1 differentiation and explored the related mechanisms by examining various aspects including the expression of CD40, the reactive oxygen species (ROS)‐nuclear factor‐kappa B (NF‐κB) pathway, and the induction of tumor necrosis factor‐α (TNF‐α). Results It was observed that the combination therapy increased the expression of CD40 on MDSCs through the ROS‐NF‐κB pathway‐dependent TNF‐α induction. This TNF‐α‐mediated CD40 upregulation facilitated Th1 polarization via CD40L engagement on CD4+ T cells. Our results provided the first mechanistic evidence that autocrine TNF‐α production by reprogrammed MDSCs governs CD40 expression following combination therapy. Conclusion Our research elucidated the methods and mechanisms of MDSCs reprogramming and offered a promising therapeutic strategy for patients with NSCLC and other types of cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1b5c584eeb86580107a4b77d49be11b90194d483" target='_blank'>
              Reprogrammed MDSCs promote Th1‐dominant antitumour response via CD40 induced by autocrine TNF‐α after combining cryo‐thermal therapy with IL6 and IL17A neutralization
              </a>
            </td>
          <td>
            Yuankai Hao, Shicheng Wang, Junjun Wang, Zelun Zhang, Yichen Yao, Ke-fu Wang, Ping Liu, Lisa X. Xu
          </td>
          <td>2025-10-01</td>
          <td>Clinical and Translational Medicine</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Cancer-associated fibroblasts (CAFs) are known to shape the tumor microenvironment, yet the role of extracellular vesicles they produce, particularly migrasomes, in hepatocellular carcinoma (HCC) remains largely unexplored. In this study, we identified a subset of POSTN+ CAFs as the main source of migrasomes in HCC, predominantly located at the tumor–stroma interface. Transcriptomic data from TCGA and ICGC were used to compute a Migrasome_Score via GSVA, revealing strong associations with poor prognosis and immune checkpoint blockade resistance across cancers. Mechanistically, POSTN+ CAF-derived migrasomes enhanced endothelial angiogenic activity by delivering VEGFA and activating the VEGFR2–PI3K–AKT–eNOS pathway, promoting vascular remodeling within tumors. Migrasomes also induced malignant reprogramming of nearby hepatocytes by boosting oxidative phosphorylation and reactive oxygen species (ROS) production, leading to DNA damage and oncogenic transformation—effects reversed by ROS scavenging. Additionally, POSTN+ CAFs and their migrasomes physically hindered immune cell infiltration, forming a barrier that shielded tumor cells from immune surveillance. Together, these findings identify POSTN+ CAF-derived migrasomes as key drivers of HCC progression by promoting angiogenesis, malignant transformation, and immune exclusion. Their strong links to poor prognosis and immunotherapy resistance suggest that they may serve as promising therapeutic targets and prognostic biomarkers in HCC and beyond.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4e8f448cce9ddf3977da321301e1fc4919158389" target='_blank'>
              POSTN+ CAF-Derived Migrasomes Drive Hepatocellular Carcinoma Progression and Confer Resistance to Immunotherapy
              </a>
            </td>
          <td>
            Zhenhua Zhu, Kangnan Zhang, Wei Wu, Jingyi Zhou, Mingming Zhang, Jiong Chen, Jinlu Han, Na Wang, Biao Li, Wenhao Weng, Qinghui Zhang, Min Zhou, Ling Xu
          </td>
          <td>2025-09-28</td>
          <td>Research</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e63b1279f51d73cda78726f8cc10b215549aa1ac" target='_blank'>
              NK cells undergo transcriptional and functional reprogramming following Streptococcus pneumoniae infection
              </a>
            </td>
          <td>
            Júlia Torné, Claudia Chica, Tiphaine Camarasa, Bernd Jagla, Matilde Diaz Enes, Aymeric Zellner, S. Mella, V. Libri, M. Hamon
          </td>
          <td>2025-09-21</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>23</td>
        </tr>

        <tr id="CAR T cell therapy targeting BCMA has shown remarkable efficacy in multiple myeloma (MM), but relapses occur due to T cell exhaustion and the emergence of BCMA-negative subpopulations. Novel targets are needed to overcome antigen escape. B7-H3 (CD276) expression was assessed on primary MM patient samples. We engineered nanobody-based CAR T cells (nanoCARs) targeting B7-H3 and evaluated their cytotoxicity and cytokine production in vitro, including against patient-derived myeloma cells. Anti-tumor activity was tested in two different MM xenograft models. Dual CAR T cells (BCMA/B7-H3) and CARpooling (mix of BCMA and B7-H3 CAR T cells) were also tested for efficacy in antigen escape models. B7-H3 expression was detected on plasma cells in 60% of MM patients. B7-H3 nanoCAR T cells exhibited strong antigen-specific cytotoxicity and effector cytokine secretion, including against primary MM cells. In vivo, they reduced tumor burden and improved survival. Dual (BCMA/B7-H3) CAR T cells and CARpooling effectively eliminated heterogeneous tumor populations with mutually exclusive BCMA or B7-H3 expression. These findings show that BCMA/B7-H3 targeting may be a strategy to overcome antigen escape mechanisms. B7-H3 is a promising immunotherapy target in MM. B7-H3-specific and dual-targeting nanoCAR T cells could offer a strategy to prevent antigen escape and improve treatment durability.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8acf6cc8226c1556e3bfe11965ab8b6fdfd97e4d" target='_blank'>
              B7-H3 nanobody-based CAR T cells control multiple myeloma growth, while dual BCMA/B7-H3 CAR T cells overcome antigen escape
              </a>
            </td>
          <td>
            A. Van der Vreken, Fien Meeus, Chenggong Tu, Lauren van den Broecke, V. Raimondi, Rosanna Vescovini, Heleen Hanssens, Fenja Watté, Dorien Autaers, Marta Marco Aragon, Janne Billiau, K. De Veirman, K. Vanderkerken, Y. De Vlaeminck, Lorenzo Franceschini, Holly Lee, Paola Neri, E. De Bruyne, P. Storti, Nicola Giuliani, Karine Breckpot, E. Menu
          </td>
          <td>2025-11-14</td>
          <td>Journal of Hematology & Oncology</td>
          <td>0</td>
          <td>60</td>
        </tr>

        <tr id="Cancer stem cells (CSCs) are a minor subpopulation of tumor cells characterized by self-renewal capacity and stemness features and are responsible for tumor progression and therapy resistance. Several studies have shown that CSCs possess immunomodulatory properties that allow them to evade from immune responses. One of the mechanisms by which CSCs can escape from immune cells recognition and killing is represented by the overexpression of immune checkpoints (ICPs). The observation that cancer patients may still display or acquire resistance to immunotherapy despite targeting the PD-1/PD-L1 axis, highlights the importance of other ICPs as potential mediators of immune resistance. In this review, we summarize the immunomodulatory properties of CSCs and comprehensively discuss the crosstalk between these cells and selected ICPs (i.e., B7-H3, B7-H4, CD200 and CD155, VISTA, TIGIT, CD47, CD70, CEACAMs, and galectins) that are thought to be involved in CSC mediated immune evasion. Open questions regarding the immunological profile of CSCs, especially in relation to ICPs expression and their underlying regulatory mechanisms, are also addressed. Improved immunological profiling of CSCs will contribute to the identification of prognostic and predictive biomarkers for cancer patients and the development of effective therapeutic interventions that may lead to the eradication of malignant tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1811aab8b4ff863825064d5f429510095d9edbe9" target='_blank'>
              The role of immune checkpoints in modulating cancer stem cells anti-tumor immune responses: implications and perspectives in cancer therapy
              </a>
            </td>
          <td>
            Ola J. Hussein, Menatallah Rayan, Tasnim R. Matarid, Dana Elkhalifa, Hanan H. Abunada, Lubna Therachiyil, Ashraf Khalil, Shahab Uddin, Cristina Maccalli, H. Korashy
          </td>
          <td>2025-11-13</td>
          <td>Journal of Experimental & Clinical Cancer Research : CR</td>
          <td>0</td>
          <td>36</td>
        </tr>

        <tr id="Ovarian cancer represents a typically immune “cold” tumor, where obvious immunosuppression, spatial T-cell exclusion, and cellular dysfunction collectively limit immunotherapy effectiveness. Especially in high-grade serous ovarian carcinoma (HGSOC), the immune low-response state is driven by complex interactions among tumor-associated macrophages (TAMs), suppressive stromal networks, and the T-cell compartment (regulatory T cells, Tregs, and exhausted effector T cells). Emerging multi-omics technologies—particularly single-cell RNA sequencing and spatial transcriptomics—have showed the heterogeneity and spatial immune organization underlying this suppressed state. Here, we integrate these datasets to describe TAM phenotypes and spatial niches, T-cell exhaustion, Tregs accumulation, NK-cell dysfunction, and stromal barriers that enforce exclusion. We then derive phenotype-guided combination strategies to remodel the tumor microenvironment and improve responsiveness to immune checkpoint blockade. This synthesis provides a concise, multi-dimensional framework for precision immunotherapy and for overcoming resistance in immune-low ovarian cancers.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/880f6c405f773eb38fd078c68256074438417fa2" target='_blank'>
              Decoding immune low-response states in ovarian cancer: insights from single-cell and spatial transcriptomics for precision immunotherapy
              </a>
            </td>
          <td>
            Yalan Yan, Jiaan Lu, Huanyu Luo, Zizhang Wang, Ke Xu, Lexin Wang, Qin Wang
          </td>
          <td>2025-09-19</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Abstract Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that accumulate under pathological conditions such as cancer, where they contribute to immune evasion, tumor progression, and resistance to therapy. These cells exert potent immunosuppressive effects by inhibiting T cell activation, inducing regulatory T cells, modulating antigen-presenting cells, and shaping an immunosuppressive tumor microenvironment (TME). Their suppressive functions involve multiple mechanisms, including amino acid depletion, production of reactive oxygen and nitrogen species, expression of immune checkpoint ligands, and secretion of immunoregulatory cytokines such as IL-10 and TGF-β. Besides these immune-related roles, MDSCs also promote tumor growth through non-immunological mechanisms, including the stimulation of angiogenesis and undergoing metabolic reprogramming. These adaptations support their survival and function in the hostile TME. Given their multifaceted role in cancer, MDSCs represent a promising target for therapeutic intervention. Furthermore, their abundance and dynamic modulation during treatment confer them tremendous potential as biomarkers to monitor therapy efficacy and stratify patients. This review provides a comprehensive overview of MDSC biology, their mechanisms of action, and their emerging clinical relevance as biomarkers and therapeutic targets. We also explore current strategies aimed at targeting MDSCs, including their depletion, inhibition of recruitment, functional blockade, and promotion of their differentiation into mature myeloid cells. Integrating these approaches with existing cancer therapies holds great promise for enhancing antitumor immunity and overcoming resistance in both solid tumors and hematologic malignancies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d195f524c3054c9a1106fbc8581ac237b69c234e" target='_blank'>
              Emerging Role of MDSCS as Novel Biomarkers and Therapeutic Targets for Cancer Immunotherapy
              </a>
            </td>
          <td>
            S. Silva-Romeiro, Rocio del, Carmen Flores-Campos, M. L. Sánchez-León, V. Sánchez-Margalet, L. Cruz-Merino, María, Luisa Sánchez-León
          </td>
          <td>2025-11-01</td>
          <td>ImmunoTargets and Therapy</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="Peripheral nerve damage is intricately linked to the progression of various solid tumors. However, its effect on antitumor immunity and precise underlying mechanisms remain poorly understood. This study aimed to elucidate the effect of peripheral nerve damage and its subsequent immune-modulating effects influence on breast cancer progression. We analyzed nerve injury markers in the TCGA-BRCA database and clinical samples. In vivo experiments were conducted using orthotopic breast cancer models with chemical sympathetic denervation (6-OHDA) or nerve lysate/neurofilament light chain (NFL) treatment, where NFL was identified as a key effector molecule through mass spectrometry screening. The tumor microenvironment was evaluated by flow cytometry, multiplex immunohistochemistry, and single-cell RNA sequencing. In vitro co-culture systems were established to investigate the effects of NFL on macrophages and CD8+ T cells, with transcriptomic profiling revealing that NFL-activated macrophage supernatants induced CD8+ T cell senescence via NF-κB signal pathway activation. Peripheral nerve injury was associated with poor prognosis and immune evasion in breast cancer patients. In mouse models, chemical sympathectomy (6-OHDA) and nerve lysates injection both accelerated tumor growth, suggesting that nerve damage promotes immune escape. Single-cell RNA sequencing (scRNA-seq) further revealed that nerve injury increased tumor-associated macrophages (TAMs) proportion by promoting TAMs proliferation and attracting macrophages. The key effector molecule of nerve lysates neurofilament light chain (NFL) was identified with the TAMs proliferation effect, and intratumoral NFL administration recapitulated the pro-tumor effects of nerve damage and perfomed the same immune-modulating effects as 6-OHDA and nerve lysates. Importantly, NFL-induced TAM enrichment and remodeling promoted CD8+ T cell senescence, as evidenced by transcriptomic analysis showing NF-κB pathway activation and verified with NF-κB inhibitor (BAY 11-7082) in vitro, resulting in breast cancer immune escape. These findings underscore the critical role of peripheral nerve injury in reshaping the interplay between TAMs and antitumor immunity, via NFL-driven NF-κB activation and T cell dysfunction. Suggesting that neuroprotection could serve as a promising strategy to restore anticancer immunosurveillance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/df1adb4b76af6ae868daa4887750e56784c6b3ee" target='_blank'>
              Peripheral nerve injury-induced remodeling of the tumor-associated macrophages promotes immune evasion in breast cancer
              </a>
            </td>
          <td>
            Yongxue Jiang, Wenfeng Zeng, Yaxin Feng, Xiaoting Deng, Jiayi Wang, Haiyu Liu, Boying Gao, Dexi Bi, Zifei Liu, Chaoqun Yang, Minxia Chen, Tang Li, Houying Chen, Yuxi Zhang, Luyuan Liang, Jiannan Xu, Wen Deng, Zeyu Yao, Wei Wu, Liyan Lao, Jianing Chen, Penghan Huang
          </td>
          <td>2025-10-06</td>
          <td>Journal of Experimental & Clinical Cancer Research : CR</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="Lung cancer remains the leading cause of cancer-related death worldwide. Despite the success of immune checkpoint inhibitors (ICIs), particularly those targeting PD-1/PD-L1 pathways, a significant number of patients exhibit either primary resistance or acquire resistance over time. While genomic and epigenetic mechanisms contribute to this resistance, increasing evidence points to the pivotal role of immunometabolism—the interface of cellular metabolism and immune regulation. This review focuses on how altered metabolic states in both immune cells and cancer stem-like cells (CSCs) within the lung tumor microenvironment contribute to ICI resistance. We discuss key metabolic pathways involved in immune suppression, the metabolic plasticity of CSCs, and how these factors interact to shape a metabolically hostile tumor niche for immune effector cells. Finally, we explore emerging therapeutic strategies targeting immunometabolism to enhance immunotherapy efficacy in lung cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1ff0a30d0ef98d677493dbe8ab0f277a0639e63e" target='_blank'>
              Immunometabolic reprogramming in lung cancer: interplay between immune and stem-like cells in immune checkpoint inhibitor resistance
              </a>
            </td>
          <td>
            Ji-Yong Sung, Eui Tae Kim
          </td>
          <td>2025-10-29</td>
          <td>Journal of Translational Medicine</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Although chimeric antigen receptor (CAR)-redirected T lymphocytes have achieved unprecedented clinical responses in hematologic neoplasms, their role in solid tumors still needs to be improved. To overcome current limitations, we rationally designed a next-generation CAR-T cell construct incorporating autonomous costimulatory signaling pathways that operate independently of tumor antigen engagement, thus faithfully emulating physiological T cell activation paradigms. We screened seven costimulatory receptors from the TNF receptor superfamily and identified that CD30 is the most effective enhancer of CAR-T cell function. Subsequent structural analysis revealed that the intracellular domain (ICD) of CD30 is primarily responsible for its costimulatory activity. Our data showed that these CAR-T cells co-expressing CD30 ICD have stronger proliferation ability and cytokine secretion function. The results of in vitro experiments showed that CD30 signaling improved the cytotoxicity of CAR-T cells and reduced the expression of exhaustion-related markers. In mouse models of orthotopic renal cancer, lung metastasis, and hematologic malignancies, these CAR-T cells showed better expansion capability and superior antitumor activity. Sequencing results suggest that CD30 signaling may enhance the function of CAR-T cells by increasing the activation of the nuclear factor κB (NF-κB) pathway. Further mechanistic experiments confirmed that the NF-κB pathway is significantly activated in CAIX.CD30(ICD) CAR-T cells compared to CAIX CAR-T cells. Reversal experiments demonstrated that NF-κB pathway inhibitors can reverse the effector function of CAIX.CD30(ICD) CAR-T cells, while CAIX-IKKβ CAR-T cells with self-activated NF-κB pathway also exhibit significant functional advantages. By integrating autonomous costimulatory signaling, we demonstrated improved CAR-T cell persistence, proliferation, and antitumor activity across multiple preclinical models, highlighting the therapeutic potential of this approach for both hematologic malignancies and solid tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ac29293da6b6a8904e88a64c1141351751a57d10" target='_blank'>
              Enhancement of CAR-T cell efficacy and persistence via CD30 costimulation and NF-κB signaling
              </a>
            </td>
          <td>
            Yang Su, Guang Yang, Bi Chen, Yiguan Qian, Wenjie Ma, Xiaotian Jiang, Qing Yu, Yang Li, Luwei Xu
          </td>
          <td>2025-11-13</td>
          <td>Molecular Cancer</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="ABSTRACT Mucosal‐associated invariant T (MAIT) cells are a highly conserved population of immune cells that can be activated via the major histocompatibility complex class I‐related protein pathway or cytokine pathways, playing a central role in immune surveillance. This review provides comprehensive information on their thymic developmental origin, tissue‐specific distribution, and microbial regulatory networks, with a focus on analyzing the bidirectional regulatory mechanisms in diseases. In infectious diseases, MAIT cells eliminate pathogens through the rapid release of cytokines; however, sustained antigen exposure leads to functional exhaustion. In autoimmune diseases, their migration disorders and proinflammatory cytokine secretion of MAIT cells exacerbate tissue damage. In the tumor microenvironment, they play a paradoxical role, being capable of mediating antitumor effects while also being reprogrammed into a protumor phenotype. Based on their tissue targeting ability and functional plasticity, we discuss novel strategies for targeted therapy, including engineering chimeric antigen receptor–MAIT cells to enhance tumor killing, blocking exhaustion pathways to reverse functional impairment, and regulating the microbiota–metabolic axis to reprogram cell activity. This review integrates cutting‐edge evidence, reveals the translational potential of MAIT cells as a cross‐disease regulatory hub, and provides a theoretical framework for precision immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b35d66b0d36f247e296da89c6cdd92c5b6962ca6" target='_blank'>
              Mucosal‐Associated Invariant T Cells: Origins, Biological Functions, Diseases, and Therapeutic Targets
              </a>
            </td>
          <td>
            Cheng Zhu, Qian Huai, Yishan Du, Xingyu Li, Fumin Zhang, Yongkang Zhang, Mengwei Wu, Ying Dai, Xiaolei Li, Hanren Dai, Hua Wang
          </td>
          <td>2025-11-01</td>
          <td>MedComm</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Immunotherapy is currently effective in less than half of patients with solid tumors, and most responders develop secondary progression. High infiltration of the tumor microenvironment (TME) with CD8+ cytotoxic T cells (CTLs) and low infiltration with regulatory T cells (Treg) predicts the patients’ responses to immunotherapy and long-term outcomes. To identify the mechanisms regulating long-term stability of CTL infiltration, we analyzed the impact of CTL-produced cytokines on the TME by co-culturing patient-isolated ascites cells with activated T cells. Unexpectedly, we observed that activated CTLs selectively induce cytotoxic T cell-attracting chemokines but not chemokines that attract T regulatory cells in ovarian cancer TME and tumor-associated myeloid cells, resulting in recruitment of additional CTLs without Tregs. This selectivity resulted from the unique dependence of CCL22 induction on both canonical and alternative NF-κB and the suppression of alternative NF-κB signaling by T cell-released IFNγ. Our data demonstrate that T cell-produced IFNγ suppresses alternative NF-κB signaling in TME-associated myeloid cells, allowing for the induction of CTL-attracting chemokines with the concomitant suppression of Treg-attracting CCL22. These novel functions of IFNγ and activated T cells in regulating the balance between canonical and alternative NF-κB signaling in myeloid cells provide new opportunities to enhance and stabilize the selective CTL influx in the TME.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e5a5a14adab24415a821ab9194596f9d27a53e37" target='_blank'>
              IFNγ-mediated suppression of alternative NF-κB in tumor-resident myeloid cells promotes selective recruitment of cytotoxic but not regulatory T cells
              </a>
            </td>
          <td>
            Adam Brinkman, Ravikumar Muthuswamy, Bowen Dong, Robert P Edwards, Pawel Kalinski
          </td>
          <td>2025-10-09</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>25</td>
        </tr>

        <tr id="Adoptive T cell therapies (ACT) have revolutionized the management of hematologic malignancies; however, their efficacy in solid tumors remains limited. Accumulating evidence implicates the tumor microenvironment (TME) - a highly complex and immunosuppressive niche as a major barrier to their effectiveness. In this review, we propose that the next generation of ACT will require a fundamental shift from a reductionist focus on T cell engineering alone to an integrated approach that considers the interactions between immune cells and the TME. A comprehensive literature review identified several emerging strategies to enhance the efficacy of ACT, including reprogramming tumor vasculature, repolarizing immunosuppressive myeloid and stromal cells, leveraging oncolytic viruses to remodel antigen presentation, inducing acute sterile inflammation, and targeting the physical properties of the extracellular matrix. While many of these approaches remain in early-stage development, some have already progressed to clinical trials, indicating their potential for clinical translation. Additionally, we found that conventional therapies, such as surgery, chemotherapy, and radiotherapy, can be strategically integrated with ACT to improve therapeutic outcomes. These findings highlight a shift in the field toward more integrative approaches. Future advances will likely depend on reprogramming the TME to support T cell persistence and functions. Addressing these interconnected challenges will require closer collaboration between immunology, oncology, and bioengineering disciplines.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5845940292899bbb8a96147c6b79326179c978e6" target='_blank'>
              Reprogramming the tumor microenvironment to boost adoptive T cell therapy
              </a>
            </td>
          <td>
            Maria Fernanda Meza Pacheco, Lee-Hwa Tai
          </td>
          <td>2025-10-23</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/52dc3bfdad50b0fd78eb4f0222adb5e891503e09" target='_blank'>
              CD36 is a metabolic checkpoint for Th2 cell tissue residency during allergic airway inflammation
              </a>
            </td>
          <td>
            A. Krone, Simon Schreiber, Nouria Jantz-Naeem, Anja Sammt, Jan Dudeck, Konstantinos Katsoulis-Dimitriou, A. Goihl, Oliver Hihn, Linda Black, Tobias Franz, Jonas Negele, Camilla Merten, Anna Marks, B. Schraven, Martin Böttcher, S. Sandmann, Julian Varghese, Thomas Tüting, D. Mougiakakos, Jens Schreiber, R. Geffers, Andreas Müller, Dirk Reinhold, Melanie Fachet, S. Stegemann-Koniszewski, A. Dudeck, B. Weigelin, S. Kahlfuss
          </td>
          <td>2025-09-20</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>69</td>
        </tr>

        <tr id="Success of cancer immunotherapy (CIT) is intricately influenced by the tumor microenvironment (TME), a complex ecosystem that encompasses immune cells, stromal elements, and extracellular components. Despite the clinical breakthroughs of immune-checkpoint inhibitors (ICIs), adoptive cell therapies, cancer vaccines, and other immunotherapeutic interventions, many patients fail to respond and eventually die. Emerging evidence points to cancer stem cells (CSCs) as critical drivers of immune evasion, therapy-resistance, and tumor relapse. CSCs modulate the TME by secreting immune-suppressive factors, recruiting regulatory immune cells, and inducing phenotype-switching of anti-tumor TME subsets, thereby creating a protective niche that hinders immune surveillance. Conversely, the TME protects CSCs through hypoxia, altered metabolism, and immuno-suppressive cell populations. This bi-directional crosstalk supports tumor progression and provides resistance to immunotherapeutic strategies mainly by: (i) escaping immune-recognition and inhibiting active T cells via high immune-checkpoint molecule expression, (ii) creating immunosuppressive pro-tumor environment, and (iii) evading immune-mediated apoptosis of CSCs along with therapy-induced enrichment of their pool. Targeting CSCs in concert with reprogramming the TME via CSC-directed agents, metabolic modulators, or combinatorial immunotherapies, therefore, offers a promising avenue to overcome immunotherapy-resistance and achieve durable clinical responses. This review discusses the deeper mechanistic understanding of CSC-TME interactions, in light of designing next-generation immunotherapies with broader efficacy across diverse tumor types.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/aca3d3e4dee0506258a76ae1d6a57f98c14366a7" target='_blank'>
              Cancer Stem Cells Decide the Fate of Cancer Immunotherapy by Remodeling Tumor Microenvironment
              </a>
            </td>
          <td>
            S. Chakraborty, Udit Basak, S. Mukherjee, Sumoyee Mukherjee, Tanya Das
          </td>
          <td>2025-09-01</td>
          <td>Cancer Control: Journal of the Moffitt Cancer Center</td>
          <td>1</td>
          <td>7</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9df59581d16bbc7c53120355c1f9a6d0a14f9300" target='_blank'>
              The Role of Inflammation in CMML Pathobiology and Progression
              </a>
            </td>
          <td>
            Niraj Neupane, E. Padron
          </td>
          <td>2025-10-09</td>
          <td>Current Hematologic Malignancy Reports</td>
          <td>0</td>
          <td>51</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c7fdd50ef3604bb5496e43d50c930df247607fa0" target='_blank'>
              Adenosine-specific transcriptional programs in murine connective tissue type mast cells
              </a>
            </td>
          <td>
            Qihua Liang, Volodymyr Tsvilovskyy, Anouar Belkacemi, Merima Bukva, Christin Richter, Nicole Ludwig, Andreas Keller, M. Freichel
          </td>
          <td>2025-11-11</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="Background Despite the notable success of programmed death ligand 1 (PD-L1)/programmed death 1 (PD-1) immune checkpoint blockade in cancer, resistance remains a substantial challenge. Combining immune checkpoint blockade with direct targeting of effector T cells to tumor cells might improve outcome for a broader spectrum of patients with cancer. Phosphoantigen-responsive Vγ9Vδ2-T cells are potent immune cells that play a pivotal role in tumor immunosurveillance and can coordinate downstream immune activity. Here, we explored whether a Vδ2 bispecific T cell engager (bsTCE) directed against PD-L1 could combine lysis of PD-L1+ tumor cells with PD-L1 immune checkpoint blockade. Methods PD-L1 specific single domain antibodies (VHHs) were tested for binding to PD-L1 and their ability to interfere with PD-1 binding and function. One PD-L1 VHH was selected for fusion to a Vδ2-T cell receptor specific VHH (PD-L1xVδ2 bsTCE) and tested for its ability to activate Vγ9Vδ2-T cells and lyse melanoma cell lines, as well as patient-derived renal cell carcinoma (RCC) and metastatic melanoma cells. These patient-derived tumor suspensions were also used to explore effects on CD4+ and CD8+ T cells and myeloid cells. Infiltration of Vγ9Vδ2-T cells and tumor kill was tested in a three-dimensional tumor spheroid melanoma model. Results A PD-L1xVδ2 bsTCE was generated and shown to block PD-1 binding resulting in the release of PD-1+ cells from PD-L1 mediated inhibition. The PD-L1xVδ2 bsTCE also mediated robust Vγ9Vδ2-T cell activation, efficient lysis of RCC and melanoma cell lines and/or patient-derived tumor cells, and infiltration of Vγ9Vδ2-T cells into a three-dimensional melanoma spheroid model. Of interest, exposure of co-cultures of Vγ9Vδ2-T cells and patient-derived tumor suspensions to the PD-L1xVδ2 bsTCE resulted in upregulation of activation markers on tumor-infiltrated CD4+ and CD8+ T cells and lysis of PD-L1+ myeloid cells with a shift in the myeloid compartment from macrophage-like cells to more mature dendritic cells with costimulatory molecule expression. Conclusions A PD-L1xVδ2 bsTCE was generated that acts as PD-1/PD-L1 immune checkpoint inhibitor, enhances Vγ9Vδ2-T cell activation, infiltration and tumor lysis and reshapes the tumor microenvironment towards a more proinflammatory state. By targeting both PD-L1 expressing tumor and myeloid cells, it addresses key challenges of current therapies and thereby offers a promising novel therapeutic strategy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/45e254ff0cd2f6e1d2390b4f7c4c0ffff07130de" target='_blank'>
              PD-L1 directed bispecific Vδ2-T cell engager combines lysis of PD-L1 expressing tumor cells with PD-1 immune checkpoint inhibition and modulation of the tumor immune microenvironment
              </a>
            </td>
          <td>
            L. King, Myrthe Veth, Marieke Roos, George L Scheffer, Marko A Popovic, Tanja D de Gruijl, H. J. van der Vliet
          </td>
          <td>2025-10-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>41</td>
        </tr>

        <tr id="Background Despite comparable survival benefit has been obtained, the drug resistance remarkably reduced lenvatinib clinical efficacy. Here, we aimed to identify the potential mechanism by which cysteine and glycine-rich protein 2 (CSRP2) regulates the development of hepatocellular carcinoma (HCC) and participates in the resistance to lenvatinib. Methods We harnessed RNA sequencing, multiplex immunofluorescence staining, and hydrodynamic tail vein (HTV) injection HCC model to systematically explore the function of CSRP2 in HCC progression. To precisely delineate how immunosuppressive macrophages, influenced by CSRP2-regulated C-C motif chemokine ligand 28 (CCL28) signaling, respond to lenvatinib-induced cytotoxicity, we established an in vitro co-culture system and conducted functional cytotoxicity assays. Results Using RNA sequencing, multiplex immunofluorescence staining and HTV injection HCC mouse model, we identified CSRP2 as one of the most significantly upregulated genes in HCC tissues. CSRP2 overexpression drives anti-lenvatinib resistance by inducing high levels of tumor-associated macrophages (TAMs) infiltration and reshaping an immunosuppressive microenvironment. Then flow cytometry, mass spectrometry and chromatin immunoprecipitation were conducted to clarify the underlying mechanism of CSRP2. We showed CSRP2 promotes phosphorylation of activating transcription factor 2 (ATF2) at Thr69/71, leading to the transcriptional activation of CCL28 expression. HCC-derived CCL28 recruits TAMs to drive immunosuppression and anti-lenvatinib tolerance. BI6901, a potent and selective CCR10 antagonist, blocked TAMs recruitment and enhanced T-cell activation. Combining CCR10 inhibition improved the therapeutic benefit of anti-lenvatinib in HCC. Conclusions These results illustrate that CSRP2 regulates the tumor microenvironment to promote HCC growth and drive lenvatinib tolerance via the CSRP2/ATF2/CCL28 axis. Targeting this pathway could synergize with lenvatinib to treat HCC more effectively.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/646010ea35e5f944e326bc9fb7b7f5f1bbb8f30b" target='_blank'>
              Targeting immunosuppressive macrophages by CSRP2-regulated CCL28 signaling sensitizes hepatocellular carcinoma to lenvatinib
              </a>
            </td>
          <td>
            Changzhou Chen, Sheng Su, Pengcheng Wang, Xinming Ye, Songyang Yu, Yu Gong, Zehuan Li, Jia Li, Zhiqiang Hu, Xiaowu Huang
          </td>
          <td>2025-10-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="ABSTRACT Dendritic cells (DCs) are professional antigen‐presenting cells (APCs) that play a central role in regulating immune responses by linking innate and adaptive immunity. In recent decades, substantial progress has been made in understanding the development, classification, and diverse functions of DCs. However, a comprehensive overview integrating recent advances in the biology and therapeutic targeting of DCs remains lacking. This review systematically summarizes the origin, developmental pathways, and subset heterogeneity of DCs, including classical type 1 and 2 DCs, plasmacytoid DCs, monocyte‐derived DCs, and Langerhans cells. Moreover, it further details the core biological functions of DCs, including antigen capture, migration, and maturation; antigen presentation; activation of adaptive immunity; induction of immune tolerance; and modulation of innate immune responses. The pathological roles of DCs in diseases such as cancer, diabetes, and infectious diseases are discussed, highlighting emerging DC‐based therapeutic strategies. Importantly, this review provides a summary of both preclinical studies and clinical trials involving DC‐targeted therapies, offering a translational perspective. This work aims to deepen the understanding of DC immunobiology and to provide a valuable foundation for the development of novel DC‐based immunotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f0e677608689fc4d137f5dd944e3591ee29e3ed6" target='_blank'>
              Dendritic Cells: Origin, Classification, Development, Biological Functions, and Therapeutic Potential
              </a>
            </td>
          <td>
            Fangfang Jin, Lingxiang Xie, Hongqi Zhang, Xiang Fan, Jiaxing Tian, Wei Liu, Yang Xiao, Xinrong Fan
          </td>
          <td>2025-11-01</td>
          <td>MedComm</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Regulatory T cells (Treg cells or Tregs), a subset of CD4⁺ T cells with immunosuppressive properties, are essential for immune homeostasis and self-tolerance. Characterized by their immunosuppressive capabilities and reliance on the transcription factor Foxp3 (Forkhead box protein P3), Tregs employ multiple mechanisms, including cytokine secretion, metabolic control, and cell contact inhibition, to restrain excessive immune activation to prevent autoimmunity while maintaining tissue repair processes. However, dysregulation in their frequency or function—whether deficiency or hyperactivity—is implicated in diverse pathologies, spanning autoimmune disorders, cancer progression, transplant rejection, and emerging associations with neurological and cardiovascular diseases. Thus, Treg-targeted strategies represent a promising approach for restoring immune balance under various conditions. This review synthesizes current knowledge on Treg biology, from their discovery and definition of markers to their new regulatory mechanisms. We further explore the roles of Tregs across diseases, emphasizing their context-dependent therapeutic potential. Strategies to deplete or inhibit Tregs in cancer immunotherapy contrast with approaches to expand or stabilize their function in autoimmunity and transplantation. However, challenges persist, including achieving tissue-specific targeting, ensuring the functional stability of engineered Tregs, and minimizing off-target effects. By integrating mechanistic insights with translational innovations, this review provides a roadmap for advancing Treg-based therapies, ultimately aiming to restore immune equilibrium in a disease-specific manner.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4664303d5c8731e32a24c5f6aff938bbbbb96dc7" target='_blank'>
              Regulatory T cells in homeostasis and disease: molecular mechanisms and therapeutic potential
              </a>
            </td>
          <td>
            Lingling Wang, Ying Liang, Chunxia Zhao, Peijun Ma, Shulin Zeng, Dongen Ju, Minggao Zhao, Min Yu, Yun Shi
          </td>
          <td>2025-10-14</td>
          <td>Signal Transduction and Targeted Therapy</td>
          <td>2</td>
          <td>7</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/47c5e8a658084ff1675ec010b34b843ae8e69de3" target='_blank'>
              Atomistic TCR-ligand interactions instruct memory T-cell differentiation
              </a>
            </td>
          <td>
            A. Akitsu, Kemin Tan, R. J. Mallis, Matthew A. Booker, J. Duke-Cohan, K. Brazin, Evan H Kirkpatrick, Andrew N. Parkins, Sarita Aryal, V. Cinella, Jonathan J Lee, Kaveri I. Uberoy, Jenna K. Koenig, Matthew Biddle, Cameron M. Messier, P. Lizotte, M. Tolstorukov, Wonmuk Hwang, Matthew J Lang, Ellis L. Reinherz
          </td>
          <td>2025-11-06</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>31</td>
        </tr>

        <tr id="B cell maturation antigen (BCMA) has emerged as a prominent immunotherapeutic target in multiple myeloma (MM) due to its restricted expression on MM cells, plasma cells and mature B cells, with minimal presence in other normal tissues. In this study, we demonstrate through RNA sequencing and flow cytometry analyses of acute myeloid leukemia (AML) cell lines and primary patient samples that BCMA is also a relevant AML-associated antigen. Its robust surface expression on AML cells positions it as a promising candidate for targeted immunotherapy. Functionally, our findings indicate that BCMA in AML operates similarly to its role in MM – engaging the NF-kB pathway upon ligand binding, thereby activating gene expression programs that support leukemia cell survival and proliferation. We assessed several BCMA-targeted immunotherapeutic strategies, including bispecific T-cell engagers (TCE) and chimeric antigen receptor (CAR) transduced T-cells, NK-cells, and macrophages. We found that TCE treatment and BCMA CAR engineering markedly improved effector cell mediated cytotoxicity against AML cells, underscoring BCMA’s potential as a viable therapeutic target in AML. Furthermore, BCMA- directed TCE therapy significantly augmented the anti-leukemic activity of adoptively transferred CD8+ T-cells in a human AML xenograft model. Taken together, these findings support BCMA as a novel immunotherapeutic target in AML. Leveraging existing BCMA-directed treatments developed for MM could enable rapid clinical translation and broaden immunotherapy options for patients with AML.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/436fa158d1ac2800e0090f3db5638326935534d4" target='_blank'>
              B cell maturation antigen is a novel target for immunotherapy of acute myeloid leukemia
              </a>
            </td>
          <td>
            Ashley Varkey, Manpreet Bariana, Mark Batistick, John Church, Elena Cassella, Shaina A. Anuncio, Shabnam Samimi, Alexander J Vallone, Zephyr Hameem, Sarvarinder K. Gill, James McCloskey, Yiming Chen, Ming Tan, M. Albitar, Benjamin Tycko, Kar F Chow, Giuditta Mantile-Selvaggi, David S Siegel, Johannes L Zakrzewski
          </td>
          <td>2025-10-24</td>
          <td>Journal of Hematology & Oncology</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e8782e43d5a359ec11f1397979fbb249cbe9fbe7" target='_blank'>
              Adoptive cell therapy using T cell receptors equipped with ICOS yields durable anti-tumor response
              </a>
            </td>
          <td>
            Alexandre Marraffa, C. Berrevoets, Margherita Mosiello, R. Wijers, Daphne Roelofs, Mandy van Brakel, Kim Kroese, Marlies J. W. Peeters, Wim Dik, A. Kunert, Rachel Judith Mary Abbott, Dora Hammerl, C. Schliehe, R. Debets
          </td>
          <td>2025-10-15</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>26</td>
        </tr>

        <tr id="Type I interferon (IFN) has long been known as a critical component of the molecular machinery that first responds to viral infection in multicellular eukaryotes. More recently, type I IFN signaling has also emerged as a common process in the microenvironment of naturally developing neoplasms, as well as tumors responding to (immuno)therapy. In this setting, robust, acute but ultimately resolving type I IFN responses appear to support natural and therapy-driven cancer immunosurveillance by a number of mechanisms, including an accrued propensity of malignant cells to arrest their proliferation and undergo apoptotic cell death, as well as broad immunostimulatory effects on CD8+ cytotoxic T lymphocytes (CTLs), natural killer (NK) cells, dendritic cells (DCs) and tumor-associated macrophages (TAMs). Conversely, weak, indolent and ultimately non-resolving type I IFN responses de facto facilitate tumor progression, not only by promoting stemness in malignant cells (which is associated with increased metastatic dissemination and resistance to therapy), but also by favoring the establishment of a highly immunosuppressive lymphoid and myeloid tumor microenvironment. Here, we provide a critical discussion of the context-dependent impact of type I IFN signaling on cancer progression and response to treatment, focusing on the tumor-intrinsic and extrinsic factors that may account for such a heterogeneity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d2e617f9f9711708567426eb2cf65f4ef606f0b6" target='_blank'>
              Context-dependent impact of type I interferon signaling in cancer
              </a>
            </td>
          <td>
            Ainhoa Ruiz-Iglesias, Emma Guilbaud, Lorenzo Galluzzi, Santos Mañes
          </td>
          <td>2025-10-30</td>
          <td>Molecular Cancer</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Trained immunity is reshaping our understanding of host defense by demonstrating that innate immune cells once thought to lack memory can be reprogrammed to mount heightened responses to subsequent challenges. Unlike tolerance, differentiation, or priming, trained immunity relies on epigenetic and metabolic rewiring of resident myeloid cells, particularly in mucosal barriers such as the skin, gut, and lungs, where these cells provide continuous protection against toxins and pathogens. Here, we review recent advances showing how an initial stimulus endows monocytes and macrophages with long-lasting functional changes that can be either protective or maladaptive upon re-exposure. We highlight therapeutic opportunities that harness trained immunity to boost vaccine efficacy and discuss strategies to modulate this program in cancer and hyper-inflammatory disorders. Finally, we propose new directions for enhancing or dampening trained immunity to promote human health.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/57f6e83421893f19b268537080a2332361f2582c" target='_blank'>
              Innate immune memory: The evolving role of macrophages in therapy
              </a>
            </td>
          <td>
            Payal Damani-Yokota, Kamal M. Khanna
          </td>
          <td>2025-11-14</td>
          <td>eLife</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="B7 homolog 3 (B7-H3, CD276) has emerged as a promising target for chimeric antigen receptor (CAR) T cell therapy, with limited expression in normal tissues and high level cell-surface expression across various tumor types. Clinical studies are ongoing, with a focus on pediatric cancers. As an immune checkpoint molecule of the B7-CD28 family, B7-H3 has a proposed immune-modulatory role, though the precise nature of B7-H3-mediated cell interactions and functional contributions to immune responses are contradictory and likely context-dependent. Within tumors, B7-H3 is expressed also on non-tumor cell types in the tumor microenvironment (TME), including myeloid immune cells, endothelial cells of abnormal vasculature and cancer-associated fibroblasts. Consequently, CAR T cells directed against B7-H3 will not only target tumor cells but also components of the TME, which will affect the nature and outcome of B7-H3-targeted therapeutic immune responses. Here we review the expression of B7-H3 protein in pediatric solid tumors and in various cell types known to infiltrate the TME of solid tumors. On this background, we discuss the potential of B7-H3-targeted CAR T cells to reshape the TME and the key challenges and future directions to improve B7-H3-targeted CAR T cell therapy for pediatric patients with solid cancers.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/649b83099536525155f2e82b6d45425c1ee80892" target='_blank'>
              B7-H3 in the tumor microenvironment: Implications for CAR T cell therapy in pediatric solid tumors
              </a>
            </td>
          <td>
            Lena Jansen, J. Wienke, Ronja Molkenbur, Claudia Rossig, Ramona Meissner
          </td>
          <td>2025-10-11</td>
          <td>Cancer Metastasis Reviews</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="Megakaryocytes (MKs) have traditionally been viewed as terminal hematopoietic cells responsible solely for platelet production. However, recent advances in imaging and single-cell transcriptomics have revealed substantial heterogeneity among MK populations and diverse functions beyond thrombopoiesis. MKs actively participate in innate and adaptive immunity, modulate the hematopoietic stem cell (HSC) niche, and adapt to physiological and pathological stimuli. Located in distinct anatomical sites such as bone marrow and lung, MKs exhibit compartment-specific specializations that enable them to serve as critical integrators of hemostatic, immune, and regenerative processes. Experimental models using human pluripotent stem cells and inducible MKs have enhanced mechanistic insights, while innovative bioreactor platforms and xenotransplantation strategies advance translational applications in platelet production and therapy. Furthermore, immune MK subsets derived from pluripotent stem cells show promising therapeutic potential for modulating inflammation and autoimmune diseases. Continued exploration of MK diversity, tissue-specific roles, and intercellular communication will unlock new opportunities for leveraging MK plasticity in regenerative medicine, immunotherapy, and hematologic disorders, repositioning these versatile cells as central players in systemic homeostasis and defense.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a42ed6c49b37f5e87fc8596501cc105433a716fc" target='_blank'>
              Emerging Roles of Megakaryocytes in Immune Regulation and Potential Therapeutic Prospects
              </a>
            </td>
          <td>
            Seungjun Kim, Kiwon Lee
          </td>
          <td>2025-10-27</td>
          <td>Cells</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Circulating lymphocytes are essential for the immune response to helminth infections, as they secrete cytokines and thus coordinate subsequent immunological processes. In canine angiostrongylosis, a potentially fatal disease caused by the metastrongylid nematode Angiostrongylus vasorum, the underlying immune mechanisms driving disease progression remain poorly understood despite the severe clinical consequences. Canine peripheral blood mononuclear cells (PBMCs) were isolated from healthy dogs and stimulated with three different antigens of A vasorum, including adult excretory-secretory products (ESP), adult full-worm somatic antigen, and first-stage larval (L1) somatic antigen. Temporal dynamics and magnitude of relative cytokine expression (IFNγ, TNF, IL-4, IL-6, IL-10, IL-13) was evaluated after 4 h, 24 h, and 5 days of antigen exposure via quantitative reverse transcription PCR. To determine whether the cytokine expression changes translated into shifts in circulating mononuclear cell subsets or proliferative activity, phenotypic characterisation by flow cytometry was conducted after a 72 h stimulation with L1 antigen or ESP, and compared to unstimulated controls. Early responses varied across antigen types, with ESP promoting a regulatory cytokine profile with modest upregulation of IL-4, IL-6, and IL-10, and downregulation of IFNγ, TNF, and IL-13. Adult antigen induced increased expression of all examined cytokines, while L1 antigen triggered the strongest inflammatory response compared to the other antigens. At 24 h, all responses were amplified, particularly those to L1 and adult antigen, and showed a shift towards a Th2 cytokine profile with increased IL-4 and IL-13 expression. By five days, IL-4 and IL-13 remained predominant. No change in the relative abundance of major immune cell populations (CD4⁺ T cells, CD8⁺ T cells, B cells, neutrophils, monocytes, and CD14⁻ CD22⁻ antigen-presenting cells) was observed in flow cytometry following stimulation. However, a notable increase in Ki67 expression, a marker of cell proliferation, was detected in CD8⁺ T cells after L1 antigen stimulation. Distinct cytokine profiles elicited by different A. vasorum antigens suggest that the parasite’s modulation of host immunity and induction of stage-specific responses are key to persistence and clinical presentation of canine angiostrongylosis. Further investigation into the antigenic components and immune pathways may lead to tailored therapies, improved clinical management, and to a deeper understanding of stage-specific aspects of helminth infections.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/966d24f4232243990a6917d702fdc78980641c19" target='_blank'>
              In vitro cytokine response of circulating mononuclear cells from healthy dogs to stage-specific antigens of Angiostrongylus vasorum
              </a>
            </td>
          <td>
            Janine Hertaeg, U. Salazar, J. vom Berg, S. Leibundgut-Landmann, Andreas W. Oehm, Manuela Schnyder
          </td>
          <td>2025-10-02</td>
          <td>BMC Veterinary Research</td>
          <td>0</td>
          <td>40</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a0e9995149be3f5f4e294cf956aefcac608aaab2" target='_blank'>
              Mesenchymal Stromal Cells Immunosuppress Osteoarthritis Synovial Fluid Tolerized Monocytes via IL-6
              </a>
            </td>
          <td>
            M. Rasti, A. Barazandeh, K. Robb, Rachel Low, R. Gandhi, Sowmya Viswanathan
          </td>
          <td>2025-09-26</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) is a rare, aggressive subtype of diffuse large B-cell lymphoma characterized by a profoundly immunosuppressive tumor microenvironment. PD-L1 overexpression by tumor cells is a recognized immune escape mechanism and may underlie resistance to cellular therapies, including CAR T-cell therapy. We report a case of a 29-year-old woman with refractory stage IV-B THRLBCL treated with anti-CD19 CAR T-cell therapy (varnimcabtagene autoleucel), who achieved an initial response (day +28) but experienced disease progression by day +100 despite robust CAR T-cell expansion. Peripheral blood analysis revealed persistent absolute B-cell aplasia, while bone marrow biopsy confirmed CD19-positive disease. Comparative immunohistochemistry demonstrated markedly increased PD-L1 expression in post-CAR T-cell samples, suggesting adaptive immune resistance via PD-1/PD-L1-mediated CAR T-cell inhibition. Nivolumab was initiated at month +4 to overcome this checkpoint-mediated resistance. Notably, a complete metabolic response was documented on PET/CT after four doses of nivolumab (month +6). The patient remains in sustained remission, with persistent B-cell aplasia, four years post-intervention. This case provides clinical and pathological evidence supporting the use of immune checkpoint blockade to rescue CAR T-cell efficacy, highlighting the potential of this synergistic approach in THRLBCL and possibly other B-cell malignancies exhibiting similar immune evasion.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/30bbc27d73802edea098491ebe987fd06d629f31" target='_blank'>
              Combining CAR T-Cell Therapy and Nivolumab to Overcome Immune Resistance in THRLBCL: A Case Report
              </a>
            </td>
          <td>
            Daniel Munárriz, O. López-Godino, N. Martínez-Cibrian, N. Albiol, H. Brillembourg, Sergio Navarro-Velázquez, M. Español-Rego, Sebastián Casanueva, Lucía García-Tomás, Guillermo Muñoz-Sánchez, L. Alserawan, D. Benitez-Ribas, L. Magnano, J. Correa, A. Rivero, P. Mozas, Eva Giné, L. Rodríguez-Lobato, A. Martínez-Roca, Mercedes Montoro-Lorite, P. Ayora, Jordi Esteve, Laura Frutos, Olga Balagué-Ponz, Á. Urbano-Ispizua, E. A. González-Navarro, Manel Juan, Julio Delgado, V. Ortiz-Maldonado
          </td>
          <td>2025-09-23</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>23</td>
        </tr>

        <tr id="Tertiary lymphoid structures (TLSs) are ectopic lymphoid aggregates that develop in non-lymphoid organs under pathological conditions of chronic inflammation, such as cancer, autoimmune diseases, chronic infections, organ transplantation, and age-related disorders. TLSs produce various cytokines and chemokines, and orchestrate local adaptive immune responses by serving as sites for antigen presentation. TLSs have attracted significant attention because of their multifaceted roles in various diseases. However, the diversity in cellular composition, development, and maturation of TLSs, depending on the disease context and organ, makes it challenging to fully understand their characteristics. Several basic and clinical studies have demonstrated the clinical and pathophysiological roles of TLSs, revealing both their protective and harmful effects. In cancer, TLSs generally activate anticancer immune responses, leading to the suppression of tumor growth. Additionally, they contribute to host defense against pathogens in infectious diseases. Conversely, they can provide a niche for autoantibody production, exacerbating autoimmune diseases and chronic rejection in transplanted organs. In age-related diseases, they may prolong tissue inflammation and hinder tissue repair. The pathophysiological significance of TLSs has prompted the development of therapeutic strategies that target their formation and maturation. However, their potential systemic immunological effects must be carefully considered. Recent advances in single-cell omics technologies have facilitated a deeper understanding of the diverse cellular components of TLSs and their cell–cell interactions, which may contribute to the development of TLS-specific therapies. The fact that TLSs can only be identified using invasive diagnostic methods remains a barrier to further research. Advances in artificial intelligence-driven pathology diagnostics and improvements in imaging technologies for noninvasive detection are expected to accelerate TLS research. Categorizing various conditions with TLSs as 'TLS-related diseases' could deepen our understanding of TLS pathophysiology and lead to the development of novel therapeutic strategies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d68ec50d653bb294f0085e58df7b58caa3d717c9" target='_blank'>
              The roles of tertiary lymphoid structures in orchestrating immune responses in peripheral organs
              </a>
            </td>
          <td>
            Keisuke Taniguchi, Takahisa Yoshikawa, M. Yanagita
          </td>
          <td>2025-09-30</td>
          <td>Inflammation and Regeneration</td>
          <td>0</td>
          <td>51</td>
        </tr>

        <tr id="Despite the tremendous amount of basic knowledge in cancer immunity gained and many transitional approaches attempted, current cancer immunotherapies are still far from reaching universal effectiveness. Therefore, next‐generation cancer immunotherapies would emerge from deepened mechanistic insights on the full spectrum of cellular and molecular interactions between cancer cells and their immune sentinels. This review embarks on an exhaustive exploration of the cardinal immunological principles that catalyze robust cancer surveillance and their potential escapes and recapitulate the state‐of‐art understanding of both receptors and corresponding immune cell types involved. Both tumor intrinsic and tumor microenvironmental mediators of immune escapes are outlined in the context of current clinic applications. Following emphasizing the exceptional requisites that effective cancer immunity cycle must meet, specific cellular subsets crucial for igniting tumor immunity, notably effector and helper T cells alongside antigen presentation cells are examined, focusing on their close interactions in both antigen‐dependent and ‐independent manners. Such intricate interactions form dynamic immune hubs at the tumor site, holding promising key functionality in rendering effective cancer retreat. Grounded on these recent insights, refined immunotherapeutic strategies, especially those bolstering priming based anticancer effector functions are advocated.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f990253e887853735c5cfb22dba0a88f9cacde71" target='_blank'>
              Immune Surveillance and Immune Escape in Cancer: Mechanisms and Immunotherapy
              </a>
            </td>
          <td>
            Ying Peng, Linsheng Zhan, Jianxiang Shi, Jie Wang, Yueying Li, Xiangdong Sun, J. Lv, Huiyu Yang, Zan Qiu, Xingzhao Liu, Chenyan Li, Shanshan Gong, Wen Jia, Huiying Wang, Yuqi Zhao, Bin Zhang, Wei Guo, Jiancheng Guo, Jian Shang, Qianqian Zhou, Yanan Yang, Feng Gao
          </td>
          <td>2025-10-01</td>
          <td>MedComm</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Multiple sclerosis (MS) is a chronic, immune‐mediated autoimmune disease characterized by the infiltration of autoreactive T cells and other inflammatory immune cells from the periphery into the central nervous system. Currently, there is no cure for MS, and treatment consists of disease‐modifying therapies (DMTs), most of which modify or delete specific immune cell populations. These populations express crucial MS treatment‐associated receptors, which may be differentially expressed in each patient, and thus each drug may affect individuals differently. Here, we developed the first comprehensive 24‐parameter flow cytometry immunophenotyping panel to evaluate treatment‐associated receptor expression on the major MS‐associated immune cells in whole blood. Analyzing whole blood samples from treatment‐naïve individuals with MS using this panel, we demonstrated that expression levels of these receptors vary between individuals. Response to the chosen DMT treatment also differed across participants. When monitoring the receptor expression during the course of treatment, we detected an increased response to treatment when receptor expression was elevated at the start of treatment. This panel reliably detects these receptors in MS treatment‐naïve participants and enables monitoring of their expression throughout treatment. This tool will enable deep interrogation of the immune receptors targeted by MS therapies and highlights that treatment‐associated receptor expression levels might be used to predict or correlate with treatment response.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/019f2dcb4e902228e625f81330b78afadd2958ea" target='_blank'>
              Monitoring Treatment‐Associated Receptor Expression in Multiple Sclerosis Using a Newly Developed Panel for Spectral Flow Cytometry
              </a>
            </td>
          <td>
            Katharina Robichon, Jennifer Taylor, Imogen Milner, Kathryn E Hally, A. L. La Flamme
          </td>
          <td>2025-09-23</td>
          <td>Cytometry Part A</td>
          <td>1</td>
          <td>27</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cda9104b6dcba78728f099ec4f0c6e0fcb044ff6" target='_blank'>
              LCK deficiency in CD8 T cells leads to reduced proliferation and increased effector T-cell formation in mice
              </a>
            </td>
          <td>
            Valeria Uleri, Vojtech Racek, Marta Popovic, Anna Morales Mendez, Veronika Niederlova, Arina Andreyeva, Juraj Michalik, N. Woessner, Michaela Krupkova, R. Sedláček, Susana Minguet, Ondřej Štěpánek
          </td>
          <td>2025-10-02</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>38</td>
        </tr>

        <tr id="
 Immunotherapy has revolutionized cancer treatment but remains ineffective against glioblastoma (GBM), where the immunosuppressive tumor microenvironment (TME) limits therapeutic success. While B-cells influence immune checkpoint blockade (ICB) responses in peripheral tumors, their role in GBM remains poorly understood. Here, we demonstrate that myeloid-derived TGFβ signaling drives B-cell dysfunction in GBM, and dual blockade of αVβ8-mediated TGFβ activation and PD-1 synergistically enhances anti-tumor immunity. Using spatial transcriptomics and multiplex immunofluorescence, we identified myeloid-B cell crosstalk via TGFβ as a key immunosuppressive axis in GBM. Myeloid cells, particularly bone-derived macrophages, localized near B-cells and induced TGFβ1-dependent suppression, impairing B-cell expansion and function. Genetic (Tgfbr2 knockout in B cells) or pharmacological (αVβ8 blockade) TGFβ inhibition expanded intratumoral B-cells and synergized with PD-1 blockade, achieving 60% tumor eradication in murine GBM models—an effect entirely dependent on B-cells, as their depletion abolished therapeutic efficacy. Mechanistically, dual therapy rescued B-cell function, reducing their suppression of CD8⁺ T-cell cytotoxicity and promoting plasmablast differentiation. Notably, surviving mice developed immunological memory, which was lost upon B-cell depletion, highlighting their role in sustained anti-tumor immunity. Dual αVβ8/PD-1 blockade uniquely enhanced CD8⁺ T-cell proliferation and granzyme B expression while fostering a Th17-polarized CD4⁺ T-cell response. Intratumorally, plasmablast differentiation increased without systemic effects, suggesting localized immune reprogramming. Partial efficacy in RagKO mice indicated ancillary innate immune contributions, but B-cells were the dominant mediators of therapeutic response. Our findings establish TGFβ inhibition as a strategy to reverse B-cell dysfunction in GBM and demonstrate that dual αVβ8/PD-1 blockade reinvigorates anti-tumor immunity through coordinated B and T-cell activation. This work positions B-cells as pivotal targets for improving immunotherapy in GBM and supports clinical translation of integrin-based combination therapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0f92e9df002b9f4c1e4b3d01b295b43d6dc46434" target='_blank'>
              TMIC-81. Targeting TGFβ-mediated B cell suppression enhances anti-PD-1 efficacy in glioblastoma
              </a>
            </td>
          <td>
            D. Hou, Si Wang, Brandyn Castro, Joshua Katz, Mark Dapash, V. Arrieta, G. Vázquez-Cervantes, Hanxiao Wan, Leah K. Billingham, Rebecca Du, Alina R Murphy, Aurora Lopez-Rosas, Yu Han, R. Patel, Tzu-yi Chia, C. Dmello, Peng Zhang, Dean Sheppard, A. Sonabend, J. Miska, M. Lesniak, D. Heiland, Catalina Lee-Chang
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>43</td>
        </tr>

        <tr id="The tumor microenvironment (TME), comprising malignant and non-transformed cells like immune cells, endothelial cells, and cancer-associated fibroblasts, significantly affects tumor growth and progression. Tumor cells manipulate the TME by releasing chemokines and inhibitory cytokines, reprogramming surrounding cells to support their survival and evade immune detection. Innate immune cells within the TME play dual roles, either promoting or inhibiting tumor progression, impacting immunotherapy outcomes. Recent studies highlight the influence of innate immune cells in shaping the TME and the pivotal role of tumor-derived microRNAs (miRNAs) in modulating these cells. miRNAs regulate gene expression and enhance tumor immune evasion, angiogenesis, drug resistance, and invasion. Their tumor-specific expression patterns suggest potential as biomarkers and therapeutic targets. This study focuses on how miRNAs affect innate immune cells like macrophages, dendritic cells, myeloid-derived suppressor cells, and natural killer cells, contributing to immunosuppressive or immunogenic environments. Understanding miRNA-mediated interactions between cancer and immune cells opens new possibilities for improving targeted immunotherapy and advancing cancer treatments.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3e85aa9b654355b3e4b7e9a3784ef3b6054fa10e" target='_blank'>
              Ambivalent roles of miRNAs in cancer development via modulating tumor-associated innate immune cells
              </a>
            </td>
          <td>
            Bahar Naseri, Amirhossein Mardi, N. Shekari, Neda Shajari, Samin Abdolzadeh, Hossein Khorramdelazad, Amirhossein Hatami-Sadr, Milad Taghizadeh Anvar, Mohammad Reza Javan, Amirhossein Heibatollahi, Javad Masoumi, Farid Ghorbaninezhad, B. Baradaran
          </td>
          <td>2025-10-04</td>
          <td>BioImpacts</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Abstract Tumor-associated macrophages (TAMs) are a heterogeneous population of immune cells that play a pivotal role in the tumor microenvironment (TME) of lung cancer. TAMs, which include both monocyte-derived macrophages (MDMs) and tissue-resident macrophages (TRMs), exhibit distinct functions that influence tumor progression, metastasis, and response to therapy. Recent studies have highlighted the spatiotemporal heterogeneity of TAMs, with MDMs primarily promoting tumor growth and immune suppression, while TRMs contribute to tissue homeostasis but can be reprogrammed to support tumor progression. Both subtypes contribute to the formation of an immunosuppressive TME, facilitate tumor metastasis through matrix remodeling, and contribute to therapeutic resistance by modulating the efficacy of chemotherapy, radiation therapy, and immunotherapy. Understanding the specific roles and heterogeneity of MDMs and TRMs as components of TAMs in lung cancer opens avenues for targeted therapies, such as inhibiting their recruitment, reprogramming their polarization, or blocking their pro-tumorigenic functions. This review synthesizes current knowledge on TAMs in lung cancer, highlighting their dual roles and the potential for developing novel therapeutic strategies that target these macrophages to improve patient outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a6e2f9f46ddfaa767b71c9b54ed7074ef5a63bbe" target='_blank'>
              Tumor-Associated Macrophages in Lung Cancer: Origins, Functional Heterogeneity, and Therapeutic Implications
              </a>
            </td>
          <td>
            Yeqing Tao, Jian Xiao, Yafang Li, Aiping Zou
          </td>
          <td>2025-10-01</td>
          <td>Journal of Inflammation Research</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9b45c60a9d94e12e7e1d28a6e644df21d580f8a0" target='_blank'>
              Homocitrullinated Peptides Drive Pro-Inflammatory T-Cell Responses in a Humanized Mouse Model of Rheumatoid Arthritis
              </a>
            </td>
          <td>
            Sofya Ulanova, Jaspreet Kaur, S.M. Mansour Haeryfar, Lisa Cameron, Ewa Cairns, Lillian Barra
          </td>
          <td>2025-10-31</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="CD8+ T lymphocytes are central effectors of anticancer immunity. Their abundance and spatial distribution within solid tumors are strongly correlated with patient prognosis and response to immune-checkpoint inhibitors (ICIs). Tumors have been categorized into “hot,” “excluded,” and “cold” types based on the infiltration patterns of CD8+ T cells, which reflect the underlying immune contexture and therapeutic potential. However, many tumors remain resistant to T-cell infiltration, posing a significant barrier to immunotherapy. This review systematically outlines the seven critical steps of the Cancer-Immunity Cycle that govern CD8+ T-cell infiltration: antigen release, antigen processing and presentation, T-cell priming, trafficking through the vasculature, tumor infiltration, target recognition, and cytolytic activity. At each step, tumor-intrinsic and microenvironmental barriers—including low tumor mutational burden, defective antigen-presenting machinery, immunosuppressive cytokines (e.g., TGF-β, IL-10), abnormal vasculature, fibroblast-derived extracellular matrix, and inhibitory cell populations (e.g., Tregs, MDSCs, TAMs)—can stall the immune response. We further discuss the roles of immune-checkpoint signaling, metabolic competition, and suppressive cell networks in shaping T-cell exhaustion and exclusion. Cutting-edge technologies—such as single-cell RNA-sequencing, spatial transcriptomics, imaging mass cytometry, and TCR repertoire profiling—have revealed spatial and functional heterogeneity within intratumoral CD8+ T cells and informed the design of rational combination therapies. Understanding and targeting these barriers is critical for converting immune-cold tumors into immune-infiltrated, therapy-responsive states. We conclude with a perspective on the future of immunoengineering and immune-atlas integration to optimize CD8+ T-cell–based interventions in solid tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/efa77bd4c813b73b425c3c8514e6eec6c6ede00f" target='_blank'>
              Infiltration characteristics and regulatory mechanisms of CD8+ T lymphocytes in solid tumors: spatial distribution, biological functions, and interactions with the immune microenvironment
              </a>
            </td>
          <td>
            Ouyang Peng, Jianhong Zhang, Xiao He, Congcong Yang, Dingcheng Zeng, Daofeng Xu
          </td>
          <td>2025-10-01</td>
          <td>Frontiers in Immunology</td>
          <td>1</td>
          <td>1</td>
        </tr>

        <tr id="Pancreatic cancer (PC) is highly lethal because of its immunosuppressive tumor microenvironment and resistance to immunotherapy. This study explored the role of NAT10-mediated N4-acetylcytidine (ac4C) RNA modification in pancreatic cancer progression and immune evasion. NAT10 (N-acetyltransferase 10) is overexpressed in pancreatic cancer tissues and correlates with poor prognosis. Mechanistically, NAT10 stabilizes ETS2 mRNA through ac4C acetylation, forming a positive feedback loop that upregulates NAT10 and PD-L1, thereby suppressing CD8 + T cell infiltration and promoting immune evasion. In addition, NAT10 stabilizes KRT8 mRNA via ac4C acetylation, which drives cancer cell proliferation and metastasis. Single-cell RNA sequencing analysis revealed enhanced interactions between pancreatic cancer epithelial cells with high NAT10 and KRT8 expression, and T cells, thereby providing new insights into the immune microenvironment. In vivo, NAT10 knockdown significantly inhibited tumor growth, enhanced CD8 + T cell infiltration, and reduced lung metastasis. Notably, combination therapy with an NAT10 inhibitor and anti-PD-L1 antibody demonstrated superior antitumor efficacy compared to monotherapy. In conclusion, NAT10 promotes pancreatic cancer progression and immune evasion by regulating the ETS2-PD-L1 axis and stabilizing KRT8 mRNA, highlighting its potential as a therapeutic target for overcoming immunotherapy resistance. NAT10 Promotes Pancreatic Cancer Immune Suppression via ac4C-Mediated Regulation of the ETS2-PD-L1 Axis and KRT8. NAT10-ETS2 Positive Feedback Loop Amplifies Malignant Progression and Immune Suppression. Combination Therapy Targeting NAT10 and PD-L1 is More Effective Than Monotherapy. NAT10 Promotes Pancreatic Cancer Immune Suppression via ac4C-Mediated Regulation of the ETS2-PD-L1 Axis and KRT8. NAT10-ETS2 Positive Feedback Loop Amplifies Malignant Progression and Immune Suppression. Combination Therapy Targeting NAT10 and PD-L1 is More Effective Than Monotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c951bb8bf1251b97d59abbba4bcbb756ec39a09f" target='_blank'>
              Targeting the ac4C ‘Writer’ NAT10 enhances pancreatic cancer immunotherapy via dual modulation of CD8+ T cells and tumor cells
              </a>
            </td>
          <td>
            Leisheng Wang, Enhong Chen, Shuo Zhang, Wen Xiang, Hao Ye, Yifei Fu, Shiwei Xu, Qin Wang, Yue Tao, Dongjie Yang, Youzhao He, Shudong Hu, Yong Mao, Hao Hu
          </td>
          <td>2025-11-07</td>
          <td>Cell Death & Disease</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Background: Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide, with chronic liver inflammation being a major risk factor. Tertiary lymphoid structures (TLS) have been associated with improved survival and better response to immune checkpoint inhibitors in several cancers. However, their role in HCC remains unclear, and findings are often contradictory. Methods: The study investigated the presence and composition of TLSs across multiple liver disease models, including livers containing HCC. TLSs were characterized to identify the essential cellular components for functional lymphoid activity. The functional role of age-associated B cells (ABCs) was further explored by blocking T-bet expression in B cells, thereby preventing their differentiation into ABCs. Results: TLS frequency was increased in livers containing HCC. Characterization confirmed the presence of key immune cell subsets supporting lymphoid function. Blocking T-bet in B cells led to a reduction in ABCs, which resulted in smaller TLS, a specific decrease in hepatic B cells, and reduced tumor lesion size in HCC-bearing mice. Conclusions: These findings demonstrate that ABCs promote TLS formation and growth, facilitating B-cell recruitment to the liver and supporting HCC progression. Targeting T-bet–dependent ABC differentiation may represent a novel strategy to limit TLS formation and slow HCC progression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e21fbe2d38cd74b5f2d808bff239d29949051ea0" target='_blank'>
              Age-associated B cells enhance tertiary lymphoid structures in the liver and promote HCC formation
              </a>
            </td>
          <td>
            Anne E Morsing, Kenneth Green, Signe Clausen, Camilla R Benjaminsen, Mathilde S. Blaavand, Julia K Demtröder, Johannes Skraep, Lisbeth Jensen, Peter Breining, Mads Kjølby, Mikkel Vendelbo, S. Degn, Martin K Thomsen
          </td>
          <td>2025-09-22</td>
          <td>Hepatology Communications</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="Simple Summary Autoimmune diseases happen when the immune system attacks the body’s own tissues, causing chronic inflammation and damage. Macrophages, a type of immune cell, can either fuel inflammation or promote healing. They communicate with other cells through tiny packages called exosomes, which carry proteins and genetic signals. Exosomes from inflammatory macrophages can worsen tissue damage, while those from healing macrophages help calm inflammation and repair tissues. Research in conditions like rheumatoid arthritis, lupus, multiple sclerosis, inflammatory bowel disease, type 1 diabetes, and psoriasis shows these dual roles. Scientists are now exploring how to use macrophage exosomes as targeted therapies, either harnessing naturally healing exosomes or engineering them to deliver treatments. Understanding and applying this system could lead to safer, more precise, and personalized treatments, improving patient outcomes and reducing side effects from conventional drugs. Abstract Autoimmune diseases result from dysregulated immune responses that mistakenly attack the body’s own tissues, causing chronic inflammation and progressive damage. Macrophages, with their remarkable plasticity, play key roles in both promoting and resolving inflammation, with pro-inflammatory M1 and anti-inflammatory M2 states shaping disease outcomes. Macrophage-derived exosomes have emerged as important mediators of intercellular communication, reflecting the functional state of their parent cells while influencing recipient cell behavior. Exosomes from M1 macrophages amplify inflammation through cytokines and microRNAs, whereas M2-derived exosomes support tissue repair and immune regulation. Studies in rheumatoid arthritis, lupus, multiple sclerosis, inflammatory bowel disease, type 1 diabetes, and psoriasis highlight their dual roles in pathology and resolution. In addition, macrophage exosomes can be engineered to deliver targeted therapeutic molecules, offering cell-free interventions with advantages in specificity, biocompatibility, and immunomodulation. This review summarizes current insights into macrophage-derived exosomes, their role in autoimmune pathogenesis, and emerging strategies to harness their therapeutic potential, highlighting their promise as precision-guided treatments for autoimmune diseases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a3edc816b764e90d140606f27c0294f3df653118" target='_blank'>
              Polarized Macrophages and Their Exosomes: Implications for Autoimmune and Immune-Mediated Diseases
              </a>
            </td>
          <td>
            Vincent G. Yuan
          </td>
          <td>2025-10-01</td>
          <td>Biology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="


 Tumor-associated myeloid populations contribute significantly to immunosuppression and treatment resistance in glioblastoma (GBM). While the pro-tumorigenic influence of tumor-associated neutrophils (TANs)—including their role in promoting angiogenesis, immunosuppression, and immune checkpoint expression—is well documented, their potential anti-tumoral functions remain insufficiently investigated.



 This study employed CT2A syngeneic murine models of GBM to investigate the immunological and oncological consequences of systemic neutrophil depletion. Anti-Ly6G antibodies were administered intraperitoneally to selectively eliminate circulating neutrophils. Tumor progression was monitored through in vivo bioluminescence imaging (IVIS), while immune profiling was conducted using flow cytometry on samples from the brain, blood, and spleen.



 Over a 21-day period, IVIS imaging revealed signficantly elevated radiance in neutrophil-depleted mice relative to controls, indicating enhanced tumor burden (mean radiance fold-change: 2.7; p = 0.042). Kaplan-Meier analysis showed that neutrophil-depleted animals had significantly shortened survival (median: 19 vs. 24 days; log-rank p = 0.0058). Importantly, this reduction in survival was not observed in neutrophil-depleted mice lacking tumors, suggesting that the neutrophil effect is context-dependent within the GBM tumor microenvironment (TME). Flow cytometric analysis confirmed effective peripheral neutrophil depletion, with CD45⁺Ly6G⁺CD11b⁺ cells reduced from 3.1% to 0.03% (p < 0.001). Additionally, a trend toward reduced brain-infiltrating CD8⁺ T cells was observed in the absence of neutrophils (p = 0.0553).



 Our findings present one of the first reported pre-clinical evidence that TANs may exert protective, anti-tumoral effects within the GBM TME. Neutrophil depletion not only accelerated tumor progression and impaired survival but also disrupted immune equilibrium in the brain. These data support a paradigm shift in which TANs may be leveraged or reprogrammed as therapeutic agents in future GBM immunotherapies. Continued investigation is warranted to delineate the molecular basis of TAN plasticity and their potential role in reshaping anti-GBM immunity.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/225247f6ba2e8abda8f3fd79dd3a30a5922e4a2d" target='_blank'>
              TMIC-43. Tumor-Associated Neutrophils: A Double-Edged Sword in Glioblastoma Progression
              </a>
            </td>
          <td>
            Matthew A Abikenari, John Choi, Ravi Medikonda, Lily H Kim, Rohit Verma, Andrew Tran, Shreyas Annagiri, Michael Lim
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2d337f9005b90e93fdf29316d67b193863ed97ca" target='_blank'>
              CAR T-cells dysfunction in the central nervous system is mediated by BBB-induced activation-induced cell death
              </a>
            </td>
          <td>
            Yarden Aharony-Tevet, O. Ravid, A. Yanir, Amilia Meir, Hadar Levi, Daniel Burstein, Aviya Amram, Tamar Feuerstein, S. Izraeli, Itzik Cooper, E. Jacoby
          </td>
          <td>2025-10-21</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>28</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b55c35cb06dbcb951b8f88a8b1249e1f91df0097" target='_blank'>
              Chronic Myelomonocytic Leukemia Microenvironment in Disease Progression and Therapy: Focus on Stepwise Reconfiguring of Myeloid-Immune Cell Interactions Driving Immune Tolerance
              </a>
            </td>
          <td>
            A. Alsugair, Abhishek Mangaonkar
          </td>
          <td>2025-09-26</td>
          <td>Current Hematologic Malignancy Reports</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Cancer continues to be a significant global health issue, influenced by genetic mutations and external factors like carcinogenic exposure, lifestyle choices, and chronic inflammation. The myelocytomatosis (MYC) oncogene family, including c-MYC, MYCN, and MYCL, is essential in the development, progression, and metastasis of various cancers such as breast, colorectal, osteosarcoma, and neuroblastoma. Beyond its well-known roles in cell growth and metabolism, MYC significantly shapes the tumor immune microenvironment (TIME) by altering immune cell dynamics, antigen presentation, and checkpoint expression. It contributes to immune evasion by upregulating checkpoints such as programmed death-ligand 1 (PD-L1) and cluster of differentiation (CD)47, suppressing antigen-presenting major histocompatibility complex (MHC) molecules, and promoting the recruitment of suppressive immune cells such as regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs). While direct targeting of MYC has proven challenging, recent advances in therapeutic strategies, including MYC-MYC-associated factor X (MAX) dimerization inhibitors, bromodomain and extra terminal domain (BET) and cyclin dependent kinase (CDK) inhibitors, synthetic lethality approaches, and epigenetic modulators, have shown promising results in preclinical and early clinical settings. This review discusses MYC's comprehensive impact on TIME and examines the promising therapeutic strategies of MYC inhibition in enhancing the effectiveness of immunotherapies, supported by recent preclinical and clinical findings.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ec1348f06f8cc8d1b1f7ddaa9bea0e5801ca6bda" target='_blank'>
              The Role of MYC in Tumor Immune Microenvironment Regulation: Insights and Future Directions.
              </a>
            </td>
          <td>
            B. Nirala, Jason Yustein
          </td>
          <td>2025-09-23</td>
          <td>Frontiers in bioscience</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Oncolytic viruses have strong potential as immunotherapies. By causing cancer cells to die and relieve antigens, these viruses can stimulate robust, systemic immune responses that may eliminate disseminated disease and prevent recurrence. Unfortunately, clinical trials using oncolytic viruses have not induced clearance of metastasis or protection from recurrence. Likewise, the combination of the only FDA-approved oncolytic virus— Talimogene laherparapvec—with immune checkpoint blockade did not improve progression-free or overall survival. Because of these disappointing clinical trials, we sought to measure the ability of oncolytic viruses to induce cancer antigen presentation and the elicitation of cancer antigen-specific immune responses. Our data revealed that despite improved antigen presentation by dendritic cells, priming of cancer antigen-specific T cells was limited. However, viral antigen-specific T cells did develop and were in a phenotypic state to induce an effective response against virally infected cells. These preclinical results were mirrored in human peripheral blood samples. Overall, these data show that oncolytic virus treatment induces a response against the virus itself, but not cancer antigen, explaining the lack of response in metastatic disease. These interesting findings identify a critical mechanism that needs to be overcome to increase the efficacy of oncolytic virus therapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1b544a70dccd03164f04725c5cdca907b0116514" target='_blank'>
              The anti-virus T cell response dominates the anti-cancer response in oncolytic virus therapy
              </a>
            </td>
          <td>
            Meghan J O'Melia, K. Sierra-Davidson, Miranda A. Robert, Lutz Menzel, Lingshan Liu, Pin-Ji Lei, Lance L. Munn, T. Padera, Sonia Cohen
          </td>
          <td>2025-09-24</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>45</td>
        </tr>

        <tr id="Melanoma, the deadliest form of skin cancer, poses a significant challenge due to its genetic heterogeneity and high metastatic potential. While cytotoxic T cell (CTL)‐based immunotherapies have made remarkable progress in recent years, the therapeutic potential of natural killer‐(NK) cells is increasingly recognized. However, resistance mechanisms to both CTL‐ and NK‐cell‐mediated immunotherapies hinder effective treatment. To evaluate the exclusive role of NK‐cells in anti‐melanoma immunity, we performed 2D and 3D co‐culture‐based cytotoxicity assays under varying conditions. Our findings revealed a protective phenotype in melanoma cells following prolonged exposure to primary NK‐cells. By combining experimental data with bioinformatic analyses, we identified key genes and pathways involved in melanoma cell adaptation to NK‐cell‐mediated killing (NKmK). We found that cytokines such as IFNγ play a major role in suppressing NKmK with MHC II surface expression being a critical factor. Targeting the master regulator CIITA, which governs MHC II expression and is affected by IFNγ, significantly reduced melanoma cell resistance to NKmK. This study provides potential strategies to overcome resistance to NK‐cell‐based immunotherapies and offers novel insights into melanoma immune escape mechanisms.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5764eda312a5162e966ee86f3fed7809fb2be1df" target='_blank'>
              The IFNγ‐CIITA‐MHC II axis modulates melanoma cell susceptibility to NK‐cell‐mediated cytotoxicity
              </a>
            </td>
          <td>
            Lena C M Krause, Rixa-Mareike Köhn, Christian Ickes, Julia Lenger, Jonas Fischer, Sabrina Cappello, Ivan Bogeski
          </td>
          <td>2025-10-13</td>
          <td>Molecular Oncology</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Faust Akl et al. revealed in Nature a paradigm-shifting mechanism distinct from myeloid-driven immunosuppression, whereby glioblastoma induces T-cell apoptosis via tumor-derived IL-11, prompting astrocytes to reprogram into immunosuppressive tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)+ effectors, thereby establishing astrocytes as active immunomodulators. Therapeutically, herpes simplex virus type 1 (HSV-1) (anti-TRAIL) achieves a dual therapeutic effect, offering novel strategies to overcome glioblastoma (GBM)'s evasion tactics.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3ee38de781ba115c0898771e91e1d944adf21efa" target='_blank'>
              Beyond Passive Bystander: Glioblastoma-Educated Astrocyte Suppressing T Cell.
              </a>
            </td>
          <td>
            Yuan-Yuan Wang, Weilin Jin
          </td>
          <td>2025-10-31</td>
          <td>Frontiers in bioscience</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/800df405d30231ac02cdb58b2d65d8cdd052e790" target='_blank'>
              Optimized Ex Vivo Differentiation of CD103+ Dendritic Cells and High-Efficiency Retroviral Transduction of Mouse Bone Marrow HSCs
              </a>
            </td>
          <td>
            Mukta Asnani, Jie-Ying Yang
          </td>
          <td>2025-09-23</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="
 Although immunotherapy has transformed cancer treatment, glioblastoma (GBM) remains stubbornly resistant due to multiple immunosuppressive mechanisms. Our previous work identified polyamine metabolism as a key driver of this immunosuppression, with difluoromethylornithine (DFMO) improving survival in a T and B cell-dependent manner. However, DFMO alone, or in combination with PD-1/PD-L1 blockade, failed to yield durable benefits. This suggests the emergence of adaptive resistance mechanisms. To investigate this, we performed single-cell RNA sequencing (scRNA-seq) on DFMO-treated tumors, revealing increased T-cell inflammation and IFN-γ-driven gene expression. Surprisingly, the most upregulated gene was apolipoprotein D (ApoD), a lipid transport protein that sequesters arachidonic acid (AA). AA is an inflammatory lipid essential for T-cell-induced IFN-γ-STAT1-dependent ferroptosis of tumor cells during immunotherapy. Notably, this STAT1-ApoD axis was also acutely induced in response to other immunotherapies in murine GBM models. We therefore hypothesized that IFN-γ–induced ApoD expression represents a potential mechanism of tumor immune evasion. Our preliminary findings show that ApoD overexpression protects tumor cells from AA-induced lipotoxicity and ferroptotic cell death, decreasing survival in GBM mouse models, which was dependent on intact adaptive immunity. ApoD-overexpressing tumors displayed a higher myeloid-to-CD8⁺ T cell ratio and increased expression of immune checkpoints and suppressive markers, indicating a more immunosuppressive microenvironment. Collectively, our study demonstrates ApoD as a critical adaptive responder to inflammatory stress in GBM. Ongoing research will further explore ApoD-targeted interventions, including lipid nanoparticle-mediated siRNA delivery. We will investigate the intrinsic role of ApoD in controlling tumor cell susceptibility to ferroptosis, and, in parallel, examine its extrinsic effects as a secreted factor that reshapes the immune microenvironment by suppressing T cell function and promoting myeloid immunosuppression. This may lead to future therapies that enhance immunotherapy efficacy in GBM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/002ee8adc2baa74e88b71b10cd71ff6d47d4f268" target='_blank'>
              TMIC-82. Sequestration of inflammatory lipids as an immune evasion mechanism in glioblastoma
              </a>
            </td>
          <td>
            Tzu-yi Chia, Chao Wei, Leah K. Billingham, Suzi Delay, Lauren Boland, Nishanth S. Sadagopan, Jay Subbiah, Si Wang, Hanxiao Wan, Jiawei Huo, J. Duffy, Alina R Murphy, Rebecca Du, Joshua Katz, Aurora Lopez-Rosas, Yu Han, G. Vázquez-Cervantes, Hardik Shah, Peng Zhang, Irina V Balyasnikova, M. Lesniak, Catalina Lee-Chang, J. Miska
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>28</td>
        </tr>

        <tr id="Diffuse large B-cell lymphoma and follicular lymphoma exhibit complex metabolic and immune microenvironments that influence disease progression and treatment response. Metabolic reprogramming, including glycolysis, amino acid, and lipid metabolism, supports tumor growth while suppressing anti-tumor immunity. Immune components such as tumor-infiltrating lymphocytes and checkpoint molecules (PD-L1, LAG-3, TIM-3) further modulate prognosis. Elevated tumor metabolic volume and glycolytic activity correlate with aggressive disease and poor outcomes. Conversely, high TIL density often predicts better responses. Integrating metabolic and immune biomarkers enhances risk stratification and therapeutic strategies, highlighting the potential for combined metabolic inhibitors and immunotherapies to improve precision medicine in lymphoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/35d2711154e88d30ee1749837827464d818a40eb" target='_blank'>
              Metabolic-immune axis in the tumor microenvironment: a new strategy for prognostic assessment and precision therapy in DLBCL and FL
              </a>
            </td>
          <td>
            Chengqian Chen, Wei Guo, Haotian Wang, Luming Cao, Out Bai
          </td>
          <td>2025-10-01</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="


 Glioblastoma, the most common and lethal primary brain tumor, creates profound immunosuppression that has resisted clinical interventions. The mechanisms behind immunotherapy failures in glioblastoma remain unclear. We conducted a systematic comparison of different immunotherapeutic approaches in mouse models to better understand treatment responses.



 Using multiomic single-cell analysis and spatial profiling, we evaluated GL261 glioma-bearing mice treated with anti-PD-L1 antibodies, NKG2D-CAR-expressing T cells, natural killer (NK) cells, or macrophages.



 All treatment models induced immune cell migration through chemotaxis. Additionally, PD-L1 and CAR T cell treatments led to an exhaustion-associated T cell signature alongside increased cytotoxic T cell presence. Further, we observed higher numbers of immunomodulatory lymphocytes and macrophages associated with these two immunotherapies. CAR macrophages and CAR NK cells exhibited enhanced cytotoxic gene signatures without increasing T cell numbers. Also, the immunomodulatory macrophage response appeared attenuated in CAR NK cells and macrophages. Notably, CAR NK cells demonstrated an enhanced antiviral response with interferon-beta expression that was not observed in other models.



 While PD-L1 and CAR cell treatments successfully polarized the lymphoid compartment toward cytotoxic phenotypes, these approaches alone appear insufficient as they were accompanied by pronounced immunomodulatory cell responses. CAR NK cells and macrophages were characterized by attenuated immunomodulatory responses. Our findings suggest that cytotoxic lymphocytes alone fail to override tumor-associated immune suppression. This is in line with recent evidence on T helper cell roles in CAR therapy. Future immunotherapy approaches should balance cytotoxic and helper lymphocyte populations while enhancing inflammatory macrophages to overcome the immunosuppressive environment of glioblastoma
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/dde65cb7289ab4952a15cc4d954df652b303b749" target='_blank'>
              P08.22.B SYSTEMATIC COMPARISON OF IMMUNOTHERAPIES IN GLIOBLASTOMA REVEALS DISTINCT IMMUNE RESPONSE PATTERNS
              </a>
            </td>
          <td>
            Y. Liu, T. Look, J. Fang, A. Dalmau Gasull, M. Prinz, T. Weiss, R. Sankowski
          </td>
          <td>2025-10-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Background Notch receptor–ligand interaction is ubiquitous and fundamental for coordinating cellular differentiation and determining cell fate for the development of various tissues and organs. Aberrant mutations in the Notch cascade result in various pathophysiological disorders, including cancer. Diverse aspects of carcinogenesis regulated by Notch include the shaping of anti-tumour T-cell immunity through antigen-presenting cell (APC)–T cell interaction and effector functions. Chief content Notch depends on juxtacrine and paracrine signalling to influence intercellular communications in the tumour microenvironment. Several preclinical and clinical studies have revealed Notch as a bi-effector molecule, which has a differential effect depending on the immune contexture of the tumour microenvironment. The Notch cascade serves as an effective therapeutic target in preventing off-target cell death and promoting tumour-specific T-cell priming. Conclusion This review revolves around Notch crosstalk with respect to the interaction between T-cell populations and other intratumoral cellular components, including professional antigen-presenting cells like dendritic cells, macrophages, B cells, immunosuppressive myeloid-derived suppressor cells, and cancer stem cells. It also summarizes the impact of targeting Notch signalling within intratumoral T cells in combination with traditional oncotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/92825b4437029c71e3d8e60010a04449b9771802" target='_blank'>
              Notch signalling in T cells: bridging tumour immunity and intratumoral cellular crosstalk
              </a>
            </td>
          <td>
            J. Sultana, Pritha Roy Choudhury, S. Bera, M. Chakravarti, A. Guha, Prodipto Das, J. Das, Gayatri S Iyer, A. Sarkar, S. Dhar, N. Ganguly, R. Baral, A. Bose, S. Banerjee
          </td>
          <td>2025-10-02</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>29</td>
        </tr>

        <tr id="ABSTRACT Cancer cell therapies have primarily focused on engineering autologous αβ T cells with chimeric antigen receptors (CARs), achieving clinical success against hematologic malignancies. However, their effectiveness against solid tumors is limited by challenges such as antigen escape, suppression by the metabolically hostile tumor microenvironment (TME), and manufacturing difficulties. γδ T cells are unconventional T cells with innate tumor-targeting capabilities independent of MHC class I, making them an emerging candidate for allogeneic cell therapy. While the Vδ1 T cell subset has shown promising anti-tumor killing their clinical application has been hindered by difficulties in achieving robust expansion for therapeutic use. Here, we evaluated the potential of K562 feeder cells expressing membrane-bound IL-21 (K562-mb-IL-21) to expand and activate γδ T cells from peripheral blood. Our findings show that this method preferentially expands Vδ1 T cells, resulting in an activated phenotype characterized by enhanced expression of NK cell activation receptors, innate cytotoxicity against breast and ovarian cancer cells, and sustained metabolic function in patient-derived ascites TME. When engineered with a CAR, Vδ1 T cells exhibited further enhanced anti-tumor efficacy in an immunodeficient NRG xenograft model of human ovarian cancer. These findings highlight K562-mb-IL-21 expanded peripheral blood Vδ1 T cells as a promising ‘off-the-shelf’ allogeneic therapy for solid tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/77c16d6eb788d2732f6ee6e30d90854137c90319" target='_blank'>
              IL-21-reprogrammed Vδ1 T cells exert killing against solid tumors which is enhanced by CAR arming for off-the-shelf immunotherapy
              </a>
            </td>
          <td>
            Ana L. Portillo, Misaal Mehboob, Genesis Snyder, Adnan Moinuddin, Tyrah M. Ritchie, Elizabeth Balint, Allyson E. Moore, Mohammadamin Sookhaklari, Jonathan L. Bramson, Dean A Lee, Meisam Naeimi Kararoudi, A. Ashkar
          </td>
          <td>2025-09-25</td>
          <td>Oncoimmunology</td>
          <td>0</td>
          <td>56</td>
        </tr>

        <tr id="Tolerogenic dendritic cells (tolDCs) that dampen T cell responses can be induced from blood monocytes in vitro using factors such as Vitamin D3 (VitD), dexamethasone, IL‐10, or rapamycin. However, challenges remain in obtaining robust and efficient generation of cell therapy‐based tolDCs without compromising their viability. We recently reported that CCR2‐dependent recruitment of monocytic cells, with the capacity to dampen T‐helper responses, occurs in mice treated with a single‐stranded oligonucleotide (ssON). Here, we investigated the effects of this immunomodulatory noncoding ssON on differentiating human monocytes towards DC in the presence of IL‐4 and GM‐CSF (moDC). The moDC differentiated in the presence of ssON upregulated CD1a but also increased their expression of PD‐L1. The differentiation of monocytes to moDC in the presence of ssON introduced transcriptomic changes, many of which overlapped with VitD‐moDC and resulted in moDCs with altered lipopolysaccharide (LPS)‐responsiveness. Moreover, ssON‐moDC exhibited a low capacity to stimulate alloreactive T cells in vitro and instead promoted the induction of CD4+FoxP3+CD25+ T cells. Experiments using chemical reagents support a role for PPAR‐γ in the generation of ssON‐moDC. Collectively, our data show that monocytes differentiated with IL‐4, GM‐CSF, and ssON generate cells with phenotypic and functional characteristics of tolDCs.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a7fee9e6189995b66ddd3a571d7811184f6d38e1" target='_blank'>
              Induction of Tolerogenic Dendritic Cells by a Noncoding Oligonucleotide
              </a>
            </td>
          <td>
            Kahkashan Kamal, James Trumbo, Elina Richardsdotter-Andersson, Marie Wahren-Herlenius, A. Spetz
          </td>
          <td>2025-10-01</td>
          <td>European Journal of Immunology</td>
          <td>0</td>
          <td>25</td>
        </tr>

        <tr id="Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide, thus, there is an urgent need to develop more effective therapeutic options for this dismal condition. Tumor-infiltrating lymphocytes (TILs) are associated with improved response to immune checkpoint blockade in HCC, but their low abundance in most cases limits their therapeutic efficacy. Here, we demonstrate, in mice, that low-dose intratumoral immunovirotherapy with the trivalent measles, mumps, and rubella vaccine (MMR) induces superior tumor-growth delay and extended host survival compared to individually administered vaccines for measles, mumps, or rubella viruses. Further, our results show that MMR therapy synergizes with PD-1 and CTLA-4 blockade to reprogram the tumor microenvironment, resulting in increased CD8+ TIL infiltration and reduced PD-1 expression on TILs, among other effects. These changes in the immunological landscape translated into greater survival and more durable tumor-specific and memory immune responses for hosts. Comprehensive toxicology analysis revealed no evidence of MMR-induced liver or kidney toxicity after intrahepatic administration. This work reinforces an unrecognized role of MMR plus ICB in reprogramming the immune landscape in HCC through multimodal immune activation, providing a strong rationale for further development of MMR-based therapies for HCC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a0ee9f74230079389edd57b51b6b1e849660e18a" target='_blank'>
              Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
              </a>
            </td>
          <td>
            M. Tesfay, Aleksandra Cios, K. U. Ferdous, Randal S. Shelton, Bahaa Mustafa, Camila C Simoes, Murat Gokden, I. Miousse, Kimberly J. Krager, Marjan Boerma, Alicja Urbaniak, Anuradha Kunthur, S. Obulareddy, Joshua M. Eichhorn, Steven R Post, J. C. Chamcheu, Omeed Moaven, C. Chabu, D. Duda, Matteo Conti, Bruno Nardo, Rang Govindarajan, M. Fernandez-Zapico, Lewis R. Roberts, M. Borad, Martin J Cannon, Alexei G. Basnakian, B. Nagalo
          </td>
          <td>2025-10-09</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>63</td>
        </tr>

        <tr id="Head and neck squamous cell carcinoma (HNSCC) remains a clinically challenging malignancy due to its intratumoral heterogeneity, aggressive progression, and resistance to multimodal treatment. Extracellular vesicles (EVs)—including exosomes and microvesicles—have gained attention as active contributors to these phenotypes by mediating intercellular signaling and molecular cargo transfer. HNSCC-derived EVs carry oncogenic and drug resistance proteins, along with microRNAs that promote immune evasion and EMT. Enrichment of microRNAs including miR-21, miR-214, and miR-221/222 within EVs supports angiogenesis, apoptosis evasion, and immune suppression. EV-associated PD-L1 impairs antigen presentation and T cell activity, contributing to resistance to checkpoint blockade. Additionally, EVs promote epithelial-to-mesenchymal transition and extracellular matrix remodeling, facilitating invasion and pre-metastatic niche formation. Through modulation of T cell function, macrophage polarization, and stromal recruitment, EVs help establish an immune-tolerant microenvironment. This review synthesizes current knowledge on the mechanistic roles of EVs in HNSCC and discusses their potential as diagnostic biomarkers and therapeutic targets.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c7df2b73b6506222f4ea27062d1fe7a35aaa3c4f" target='_blank'>
              Extracellular vesicles in head and neck cancer: mediators of oncogenesis, immune evasion, and therapy resistance
              </a>
            </td>
          <td>
            Jillian Dean, Tobias Niederegger, Cosima C. Hoch, Bhagvat J Maheta, Barbara Wollenberg, F. Mrosk, G. Hundeshagen, M. Richter, M. Heiland, J. Voss, Adriana C. Panayi, S. Koerdt, Leonard Knoedler
          </td>
          <td>2025-09-19</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="B-cell lymphoma, the most common subtype of non-Hodgkin lymphoma, presents major therapeutic challenges due to molecular heterogeneity and high relapse rates. While autologous hematopoietic stem cell transplantation (ASCT) has been a cornerstone for relapsed/refractory (R/R) B-cell lymphoma, its efficacy is often compromised by minimal residual disease (MRD) persistence and an immunosuppressive tumor microenvironment. Chimeric antigen receptor (CAR)-T cell therapy has transformed treatment paradigms but faces limited long-term durability due to antigen escape and T-cell exhaustion. The integration of ASCT with CAR-T therapy may offer a complementary approach to address these limitations, leveraging ASCT-induced immune reconstitution to enhance CAR-T-cell persistence and reprogram the tumor milieu. Emerging clinical evidence supports this approach, indicating improved disease control and progression-free survival. Although preliminary clinical outcomes are encouraging, unresolved challenges persist, particularly in terms of cumulative toxicity, optimal therapeutic sequencing, CAR-T-cell longevity, and financial feasibility associated with these advanced therapies. This review provides a comprehensive overview of mechanistic synergies between ASCT and CAR-T therapy, critically evaluates emerging clinical evidence on treatment sequencing, and explores innovative strategies to increase safety, efficacy, and accessibility.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8dabb02a640eb6c1d29c8aa3a2cf213056349991" target='_blank'>
              Autologous stem cell transplantation meets CAR-T therapy: A synergistic strategy for B-cell lymphoma
              </a>
            </td>
          <td>
            Xumeng Zhao, Jiaying Wu, Xiaojian Zhu, Yi Xiao
          </td>
          <td>2025-10-01</td>
          <td>Cell Transplantation</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Background Hidradenitis suppurativa is a chronic inflammatory skin disease marked by immune dysregulation and elevated pro-inflammatory cytokines. While biologics like adalimumab target specific pathways, their limited efficacy highlights the need for broader immunomodulatory treatments. Mesenchymal stem/stromal cells (MSCs) have shown promise due to their immunosuppressive properties and ability to modulate both innate and adaptive immunity. This study investigates the effects of naïve (n-MSCs) and cytokine-preactivated (a-MSCs) placental MSCs on the immune responses in HS. Methods MSCs were isolated from healthy term placentas and either used naïvely or preactivated with IFN-γ and TNF-α. Peripheral blood mononuclear cells (PBMCs) from HS patients (n=3) and healthy donors (n=3) were co-cultured with n-MSCs, a-MSCs, or adalimumab. Additionally, lesional, perilesional, and healthy 4 mm in diameter skin punch biopsies from 10 HS patients and 3 controls were cultured in a transwell system with the same interventions. Flow cytometry assessed lymphocytes proliferation and T cell subsets while Luminex assays measured cytokine levels. Results Both n-MSCs and a-MSCs significantly inhibited lymphocytes proliferation and shifted T cell populations, increasing CD4+ and decreasing CD8+ T cells. The a-MSCs notably reduced IL-17A and IFN-γ in PBMC co-cultures; n-MSCs had partial effects. HS skin explants exhibited elevated IL-1β, IL-10, and IL-17A compared to healthy skin. The n-MSCs markedly reduced all three cytokines in lesional and perilesional tissues. Moreover, a-MSCs selectively increased IL-10 in lesional skin. Conclusion Placental MSCs, especially in their naïve form, demonstrate potent immunomodulatory effects by reducing pro-inflammatory cytokines and altering T cell dynamics in HS. Compared to adalimumab, MSCs offer a broader immunoregulatory profile, suggesting their potential as a multitarget therapy for HS. These findings support further clinical investigation of MSC-based treatments in managing this complex disease.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d4cb6cdfad318a7b210877ac681ae8053e3e6ed3" target='_blank'>
              In vitro and ex vivo immunomodulatory effects of human placental mesenchymal stem cells in hidradenitis suppurativa
              </a>
            </td>
          <td>
            Vaiva Jariene, Paulius Valiukevičius, Rūta Insodaitė, Ugne Janonyte, R. Mačiulaitis, Justinas Mačiulaitis, A. Vitkauskiene, Evelina Žemaitė, C. Zouboulis, S. Valiukevičienė
          </td>
          <td>2025-09-25</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>26</td>
        </tr>

        <tr id="ABSTRACT Cancer‐associated fibroblasts (CAFs) are pivotal stromal components that shape the tumor microenvironment through their remarkable heterogeneity and dynamic functions. This review comprehensively examines the biology of CAFs, starting with their diverse cellular origins and induction mechanisms via key signaling pathways. We highlight the spatial‐temporal heterogeneity of CAF subsets and propose an updated classification system that encompasses eight functionally distinct subtypes based on recent single‐cell transcriptomic studies. The tumor‐promoting roles of CAFs are explored in depth, including their contributions to tumor behavior through novel mechanisms such as neutrophil extracellular traps formation, and multidrug resistance via metabolic reprogramming. A major focus is placed on CAF‐mediated immunotherapy resistance through immune checkpoint regulation, recruitment of immunosuppressive cells, and metabolite secretion. This review also highlights key technologies that are advancing CAF research, including patient‐derived 3D models, artificial intelligence‐enhanced spatial multiomics, clustered regularly interspaced short palindromic repeats (CRISPR)‐engineered mouse systems, and machine learning approaches for analyzing CAF heterogeneity and function. Finally, we evaluate therapeutic strategies targeting CAF activation, secreted factors, and immune crosstalk, while critically analyzing ongoing clinical trials. Overall, this review not only clarifies the biology of CAFs but also provides a translational framework for developing next‐generation stromal‐targeted therapies to overcome treatment resistance in cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e1dae86be5576422570b1acdcb11b97738bdec4b" target='_blank'>
              Cancer‐Associated Fibroblasts: Origin, Classification, Tumorigenicity, and Targeting for Cancer Therapy
              </a>
            </td>
          <td>
            Chang Fan, Wenlong Zhu, Yuan Chen, Wanwan Zhu, Jin Ding
          </td>
          <td>2025-10-28</td>
          <td>MedComm</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Non-small cell lung cancer (NSCLC) remains the most prevalent and lethal form of lung cancer worldwide. Among the diverse components of the tumor microenvironment, tumor-associated macrophages (TAMs) are increasingly recognized as key regulators of NSCLC progression, metastasis, and treatment resistance. TAMs, particularly those polarized toward the M2-like phenotype, facilitate tumor growth through immunosuppression, angiogenesis, epithelial–mesenchymal transition, and extracellular matrix remodeling. They promote immune evasion via PD-L1, IL-10, and TGF-β signaling, and confer chemoresistance through activation of the IL-6/STAT3 and P2X7/STAT6 pathways. Moreover, high infiltration of M2-TAMs and their expression of immune checkpoint ligands have been associated with poor prognosis and, paradoxically, with improved response to PD-1/PD-L1 blockade in certain patients. Emerging therapeutic strategies aim to reprogram TAM phenotypes, inhibit their recruitment, or selectively suppress their immunosuppressive functions. However, challenges such as macrophage plasticity, lack of specific biomarkers, and potential systemic toxicity remain significant barriers. This review provides a comprehensive overview of the biological functions, mechanistic roles, and clinical implications of TAMs in NSCLC, highlighting both their value as prognostic indicators and their potential as therapeutic targets in the era of precision oncology.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a4441ad90191ecc9c56fe31f7ae42ae5d7cc0668" target='_blank'>
              Targeting tumor-associated macrophages in non-small cell lung cancer: mechanisms, prognosis, and therapeutic opportunities
              </a>
            </td>
          <td>
            Dameng Hao, Shengjie Chen
          </td>
          <td>2025-09-22</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5efa7f94822ae99000facb8bcf334e922c852364" target='_blank'>
              Directing fratricide within T cell products using an anti-uPAR chimeric antigen receptor to drive the production of potent therapeutic cells
              </a>
            </td>
          <td>
            Lauren Sarko, David Givand, Claire Shepley, Brendan Rattin, Allen Attar, Rachel Taylor, Benjamin Kutler, Roshini M. Traynor, Anika Upadhyaya, Mackenzie Mnuk, Cavin Gehrke, Nat Murren, Tyler K. Ulland, Theresa Kotanchek, Krishanu Saha
          </td>
          <td>2025-10-25</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Innate immune cells and pathways are central to shaping the tumor microenvironment (TME), where they influence tumor growth, metastasis, and responsiveness to immunotherapy. Although research on innate immunity in cancer has expanded considerably, the mechanisms driving immune dysfunction remain incompletely understood. This review summarizes current knowledge on the functional states of innate immune cells within the TME and highlights how metabolic reprogramming contributes to immune suppression and tumor progression. We further discuss recent advances in therapeutic strategies targeting innate immune pathways, emphasizing their translational potential. Importantly, we also examine unresolved controversies and knowledge gaps across innate immune cells, metabolic networks, and innate immune factors such as complement and cytokines, outlining key challenges for clinical translation. By linking mechanistic insights with emerging interventions and identifying future directions, this review provides a framework for integrating innate immunity into next-generation cancer treatment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c04681fced7ce655cf3c2cb9b142258798132d57" target='_blank'>
              Innate immunity in tumors: roles and therapeutic targets
              </a>
            </td>
          <td>
            Songze Leng, Yuyue Ren, Yao Tian, Weiwei Zhao, Yue Mou, Xingyu Chen, Hong Zhou, Wei Wang
          </td>
          <td>2025-10-22</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Introduction Crohn’s disease (CD) is a relapsing inflammatory disease that is currently not curable. Despite the availability of anti-inflammatory treatments, 30–60% of patients develop resistance, necessitating the need for novel therapeutic approaches. Data from colitis models in mice indicate that granulocytemacrophage colony-stimulating factor (GM-CSF)-activated monocytes (GMaMs) may serve as a promising cellular therapy. However, it remains unclear whether inflammatory mediators, medication, or intrinsic defects impair the functionality of monocytes in active CD (aCD), potentially affecting their therapeutic efficacy. Methods Monocytes from 8 aCD patients and healthy donors (HDs) were activated in vitro with GM-CSF, and their migratory capacity, adherence, metabolic activity, surface marker expression, and cytokine release were assessed. Cells were stimulated with lipopolysaccharides (LPS) to evaluate their inflammatory response. Results The GMaM phenotype was characterized by increased metabolic activity, enhanced production of inflammatory cytokines, stronger adhesion, and remodeling of surface receptors involved in T-cell activation, compared to naïve monocytes. These features were largely comparable between aCD patients and HDs. LPS stimulation of GMaMs from both groups resulted in a significant production of pro-inflammatory and chemotactic cytokines, particularly interleukin (IL)-8 and monocyte chemotactic protein 1. Both are crucial recruiters of neutrophils and monocytes. Notably, monocytes from aCD patients showed an increased IL-10 response to GM-CSF, while the LPS-induced tumor necrosis factor-alpha and interferon-gamma release were reduced compared to HDs. Discussion Peripheral monocytes from aCD patients retain functional responsiveness to GM-CSF activation, displaying preserved migratory, adhesive, metabolic, and cytokine responses. Differences in cytokine production by aCD monocytes may reflect disease-specific regulation, but do not appear to limit their suitability as cellular therapeutics.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a144942872b55d9aca9ca371e925b5fb9f47b96d" target='_blank'>
              Peripheral monocytes from Crohn’s disease patients retain functional responsiveness to GM-CSF during active disease
              </a>
            </td>
          <td>
            Paul P Winkel, Wendy Bergmann-Ewert, Johannes Reiner, A. Huth, Dana Kleimeier, Rosaely Casalegno Garduño, I. M. Wrobel, G. Domanska, Jan Däbritz, E. Wirthgen
          </td>
          <td>2025-09-23</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="


 Glioblastoma (GB) is a lethal primary brain tumor frequently driven by amplification and aberrant activation of the epidermal growth factor receptor (EGFR). Tumor-associated myeloid cells (TAMs) comprise the majority of tumor infiltrating leukocytes (TILs) and secrete inflammatory molecules that promote tumor growth including IL-6, IL-1β, and EGF, a canonical EGFR ligand. These TAMs orchestrate a suppressive tumor immune microenvironment (TIME) with poor T cell infiltration. However, whether EGFR activation plays a direct role in mediating TAM recruitment and phenotype is poorly understood.



 We leveraged the MADR-mEGFRvIII murine GB model which expresses constitutively active mEGFRvIII under a tetracycline-off promoter. Orthotopic MADR-mEGFRvIII-bearing mice were treated with doxycycline (dox) for one week followed by flow cytometric TIME profiling. Tumor conditioned media (CM) and orthotopic tumor lysates were assessed via ELISA and cytokine array. Lymphocytes (CD4, CD8, NK) were depleted via antibody administration. Magnetically isolated CD45+ TILs from MADR-mEGFRvIII and newly diagnosed (nd) GB patient tumors with known EGFR status underwent bulk or single-cell RNA sequencing.



 Immunophenotyping of TILs from MADR-mEGFRvIII tumors revealed EGFR activation is associated with significantly enhanced F4/80+ myeloid cell infiltration. Assessment of MADR-mEGFRvIII tumor CM identified EGFR-dependent secretion of myeloid chemoattractants CCL2 and CXCL10 in vitro, which was corroborated in tumor lysates from mice. Further, sequencing of TILs revealed EGFR activation is significantly associated with interferon (IFN)-stimulated gene (ISG) expression in both brain-resident microglia and monocytic macrophages. Lymphocyte depletion prior to tumor implantation did not affect the EGFR-driven induction of ISGs in TILs, suggesting type I IFN is responsible for the observed TAM phenotype. Pan-IFNα and IFNβ ELISAs confirmed type I IFN was not present in tumor CM, indicating IFN is secreted by other constituents in the TIME. Importantly, ndGB patient TILs were assessed to determine if EGFR activation is associated with TAM ISG expression in human GB. Indeed, significant differential expression of numerous ISGs including IRF7, IFI44, and MX1 was observed in TAMs from EGFR activated tumors compared to wild type further supporting the concept that EGFR orchestrates the induction of a chronic TAM IFN response in GB.



 Our results indicate tumor-intrinsic EGFR activation promotes TAM recruitment via CCL2 and CXCL10 secretion and potentiates robust induction of type I IFN signaling within the TIME, ultimately resulting in a TAM phenotype characterized by ISG expression. Therapeutically targeting this EGFR-driven tumor-TAM crosstalk may be a viable strategy to reduce immunosuppression arising from chronic IFN signaling.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0bb75248939bcd6df103aac0aac16aeca77d9ce5" target='_blank'>
              P02.31.B INDUCTION OF A CHRONIC INTERFERON STIMULATED TUMOR-ASSOCIATED MYELOID CELL PHENOTYPE IS DIRECTLY ORCHESTRATED BY ABERRANT TUMOR-INTRINSIC EGFR-ACTIVATION IN GLIOBLASTOMA
              </a>
            </td>
          <td>
            M. Pioso, M. Li, K. Grausam, J. Breunig, D. Nathanson, R. Prins
          </td>
          <td>2025-10-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="The Interferon-Stimulated Gene 15 (ISG15) has a key role during viral infections, since it can modify and regulate the expression of proteins from the host and from viruses. Isg15−/− mice are more susceptible to infectious diseases. ISG15 is induced by type I Interferons (IFN-I) and apart from defense against pathogens, it can also play an important function in cancer or immune-mediated inflammatory diseases. Previous studies reported that ISG15 expression is increased in post-synaptic dendritic cells (DCs) upon interaction with CD4 + T cells. However, data regarding the role of ISG15 in DCs are scarce. The present study assesses the function of ISG15 in DCs activation, migration and ability to mediate T cell activation using bone marrow-derived DCs (BMDCs) and stimulation with lipopolysaccharide (LPS). Activation of DCs was not impaired but tended to be lower in Isg15-deficient mice, as observed by reduced CD40 induction in Isg15−/− BMDCs. Isg15−/− BMDCs induced less proliferation and Granzyme B expression in co-cultured CD8 + T cells. Interestingly, Isg15−/− BMDCs secreted reduced levels of the pro-inflammatory cytokines IL-1β and IL-12 upon LPS stimulation. Mechanistically, our data suggest that ISG15 regulates Caspase-1 activity in DCs leading to lower IL-1 β secretion. In conclusion, this study reveals an essential role for ISG15 modulating DCs inflammatory activity and raises new questions regarding the specific mechanisms of how this protein regulates innate immune responses.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/05fa00535a2acdc99ae44733e69601b7e28b4dad" target='_blank'>
              ISG15 modulates inflammatory profiles and ability to activate CD8 + T cells in bone marrow-derived dendritic cells
              </a>
            </td>
          <td>
            P. Martínez-Fleta, Clara Pertusa, Irene Fernández-Delgado, R. Izquierdo-Serrano, M. Ramírez-Huesca, Nieves Fernández-Gallego, D. Calzada-Fraile, Elena Moya-Ruiz, Raquel Castillo-González, Susana Guerra, E. Martín-Gayo, F. Sánchez-Madrid
          </td>
          <td>2025-10-24</td>
          <td>Cellular and Molecular Life Sciences: CMLS</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="Chronic myeloid leukemia (CML) is a malignant clonal proliferative disease originating from hematopoietic stem cells. While treatment with tyrosine kinase inhibitors (TKIs) effectively eliminates the majority of leukemia cells in patients, residual leukemia cells can still be detected in those achieving deep molecular remission, ultimately leading to drug resistance or relapse. But the exact mechanism is unclear. In recent years, the immune microenvironment has been a hot research topic in hematologic malignancies. CML patients exhibit abnormalities in antitumor immunity. Myeloid-derived suppressor cells (MDSCs), which possess immune-suppressing functions, inhibit the proliferation and activation of CD4+/CD8+ T cells, Tregs, B cells, and NK cells, and play a central role in the antitumor immune response in a wide range of cancers. Abnormalities in numbers and functions of MDSCs are exhibited in CML patients, which affect the immune status of CML patients through multiple mechanisms. This review summarizes the biological properties of MDSCs, their alterations in CML patients, their roles and specific mechanisms in the development of CML, and how these mechanisms can be leveraged to develop new therapeutic strategies, aiming to provide novel insights and approaches for the treatment of CML.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/bc96fb2e2a382163dd0d6a3fe8a72e0940472ac8" target='_blank'>
              Advancing our understanding of the influence of myeloid-derived suppressor cells in chronic myeloid leukemia
              </a>
            </td>
          <td>
            Xing Meng, Yue Zhang, Hong Xu, Yanyan Zhang, Hao He, Jianmin Ma, Xiaoyan Zhang
          </td>
          <td>2025-09-19</td>
          <td>Journal of Cancer Research and Clinical Oncology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/13803e7a45b223704e5dd94cfb872f40cfec3de9" target='_blank'>
              Beadex modulates hematopoiesis and innate immune defense against microbial infection in Drosophila melanogaster
              </a>
            </td>
          <td>
            Sakshi Jain, Kashish Salian, Vrushti Shah, U. Nongthomba
          </td>
          <td>2025-10-14</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="Interferon-gamma (IFN-γ), as a pleiotropic cytokine, plays a pivotal role in antitumor immunity. Its remarkable immunostimulatory, antiproliferative, and pro-apoptotic effects make it a promising candidate for tumor immunotherapy. Here, we highlight the dual role of IFN-γ in the tumor microenvironment during tumor development and treatment. IFN-γ can enhance antigen presentation, boost cytotoxic T cell and natural killer cell activity, and inhibit angiogenesis, promoting tumor regression and correlating with favorable therapeutic outcomes. However, prolonged exposure may induce the upregulation of immune checkpoint molecules such as programmed death-ligand 1, trigger T cell exhaustion, and recruit regulatory T cells, phenomena associated with the development of treatment resistance in cancer therapy. This dual nature poses significant challenges for harnessing IFN-γ in tumor treatment, necessitating an in-depth understanding of its mechanisms within specific microenvironments. Although numerous studies have explored IFN-γ-based tumor therapies, their outcomes have been inconsistent. Thus, although IFN-γ-based therapeutic strategies hold considerable promise, their clinical translation requires precise modulation to fully exploit its antitumor effects while mitigating potential protumor risks. See also the graphical abstract(Fig. 1).">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e48bdd0772c494cb7597b77c69e2cc5a685517ff" target='_blank'>
              IFN-gamma in the tumor microenvironment: dual roles in cancer progression and therapy
              </a>
            </td>
          <td>
            Jiahui Cui, Yi Zhang, Li Yang
          </td>
          <td>2025-10-14</td>
          <td>EXCLI Journal</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="


 Despite the clinical success of immune checkpoint inhibitors (ICIs), therapeutic resistance and the unpredictable development of immune-related adverse events (irAEs) remain major challenges. While the use of ICIs in combination can improve treatment efficacy, this also leads to an increase in the frequency and severity of irAEs. This has created an urgent need to enhance anti-tumor immunity without triggering immunotoxicity. However, current preclinical models are limited in their ability to model both ICI efficacy and irAE development. This is due to mouse strains commonly used for studying anti-tumor immunity, such as C57BL/6 and BALB/c mice, being resistant to ICI-induced irAEs and failing to recapitulate the full spectrum of clinical responses seen in patients with cancer. To overcome these limitations, we generated transplantable, syngeneic tumor models with variable ICI responses using the autoimmune-prone non-obese diabetic (NOD) mouse. The NOD model, which spontaneously develops multiple autoimmune diseases, exhibits a broad range of irAEs following ICI treatment with a shared etiology to clinical conditions. This approach offers insight into how genetic predisposition to autoimmunity influences both ICI response and irAE susceptibility, enabling us to explore how autoimmune-associated host-intrinsic factors uniquely alter the tumor microenvironment and contribute to ICI resistance. In ICI-resistant NOD tumors, CD8+ T cells exhibited a naïve-like phenotype, marked by elevated TCF-1 and reduced PD-1 and CTLA-4 expression, compared to ICI-sensitive tumors. Despite comparable CD8+ T cell frequency and number, these phenotypic differences led us to investigate other immune cell populations that regulate ICI response and CD8+ T cell activation. Single-cell RNA sequencing and spectral flow cytometry revealed enrichment of immunosuppressive γδ T cells in ICI-resistant tumors. These γδ T cells highly expressed the transcription factors RORγt+ and TCF1+ and lacked expression of T-bet and the mouse Vγ1 TCR chain, suggesting that distinct γδ T cell subsets may play different roles in tumor control. Functionally, antibody-mediated blockade of the γδ T cell receptor (γδTCR) significantly improved tumor control in ICI-resistant, but not ICI-sensitive, models, implicating γδ T cells in promoting tumor growth. Tumors enriched with immunosuppressive RORγt+ and TCF1+ γδ T cells also exhibited increased B cell infiltration. In B cell-deficient NOD mice, γδ T cells skewed toward T-bet and Vγ1 expression, which correlated with enhanced CD8+ T cell activation. These findings reveal a coordinated immunosuppressive network between γδ T cells and B cells that limits anti-tumor immunity. Given their roles in promoting autoimmunity, these cell types may represent therapeutic targets to boost anti-tumor immunity and overcome ICI resistance without exacerbating irAEs.



 Camille Hansen, Arabella Young. Immunosuppressive γδ T cells limit anti-tumor immunity in ICI-resistant tumors from autoimmune-prone mice [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity; 2025 Sep 24-27; Montreal, QC, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2025;13(9 Suppl):Abstract nr B006.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/20c2f1122af538bc8b86e2d6ae32fff845b95bc3" target='_blank'>
              Abstract B006: Immunosuppressive γδ T cells limit anti-tumor immunity in ICI-resistant tumors from autoimmune-prone mice
              </a>
            </td>
          <td>
            Camille Hansen, Arabella Young
          </td>
          <td>2025-09-24</td>
          <td>Cancer Immunology Research</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="


 CD8 T cells are effector cells of the adaptive immune system responsible for mediating protective immune responses in cancer. However, CD8 T cells can also be critical drivers of pathologic responses including autoimmunity. A key feature of these cells is that they must infiltrate tissues to execute their primary function of cell killing. It is well established that naive T cell responses do not originate in these tissues. Rather, prior to antigen-driven activation, naïve T cells are restricted to lymph nodes, spleen, and blood. T cell activation by cognate antigen drives expression of multiple immune checkpoint inhibitors, including programmed cell death protein-1 (PD-1) and/or cytotoxic T lymphocyte associated protein-4 (CTLA-4), as well as migration to nonlymphoid tissues. Work over the last two decades has harnessed T cell effector activities by blocking PD-1 and/or CTLA-4, which has revolutionized cancer care and demonstrated remarkable efficacy in diverse cancer types. However, many patients do not respond to checkpoint blockade therapy, and worse, other patients develop autoimmune-like immune-related adverse events (irAEs), limiting the utility of this approach. To maximize the therapeutic benefit of checkpoint blockade without accelerated irAE development, targeted approaches are needed to increase recruitment of protective CD8 T cells to tumors while preventing pathogenic T cell entry into sensitive tissues. However, an inability to granularly measure recruitment into non-lymphoid tissues has created a significant gap in knowledge in: 1) how checkpoint inhibitors impact T cell entry rates into tissues, 2) whether these entry rates are different for tumors and lesional irAE tissues, 3) where recruited cells localize, and 4) the precise functional contributions of recruited versus resident T cells in driving tumor regression or autoimmunity. To fill this gap in knowledge, we are utilizing an intravenous antibody labeling approach to mark CD8 T cells in the blood prior to entry into tissues, an approach which enables a 72-hour window to track tissue entry. Using this approach in the preclinical setting, we are interrogating how PD-1 inhibitors impact CD8 T cell recruitment to tumors as well as the pancreas in the context of Type 1 Diabetes. In our tumor studies, we have found that PD-1 inhibitors induce an increase in the number of recently recruited CD8 T cells, and that these recruited T cells have a less exhausted phenotype than the T cells that have been in the tumor for longer. In our diabetes studies, we have found that PD-1 inhibitors impact CD8 T cells both in the periphery and the pancreas, and in some mice cause an increase in migration to the pancreas. These studies support a model where peripheral CD8 T cell recruitment can positively contribute to productive anti-tumor immunity but can also exacerbate autoimmunity. Thus, our studies emphasize the doubled-edged nature of T cell recruitment, and our future studies will examine ways to both improve recruitment to tumors and mitigate recruitment to lesional irAE tissues.



 Oluwatoyosi Adewunmi, Arielle G. Dessens, Aloukick K. Singh, Autumn M. Sunderland, Sanjana Ananthula, Rachel M. Morris, Jason M. Schenkel, Kristen E. Pauken. Leveraging peripheral leukocyte recruitment to improve efficacy and mitigate toxicities following checkpoint blockade [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity; 2025 Sep 24-27; Montreal, QC, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2025;13(9 Suppl):Abstract nr B001.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7cd824c6703eab6c26623afbbb67ccbb6990fccd" target='_blank'>
              Abstract B001: Leveraging peripheral leukocyte recruitment to improve efficacy and mitigate toxicities following checkpoint blockade
              </a>
            </td>
          <td>
            O. Adewunmi, Arielle G. Dessens, A. Singh, Autumn M. Sunderland, Sanjana Ananthula, Rachel M. Morris, Jason M. Schenkel, Kristen E. Pauken
          </td>
          <td>2025-09-24</td>
          <td>Cancer Immunology Research</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Immune cell migration plays a pivotal role in coordinating inflammatory responses and maintaining immune surveillance. Here, we provide a comprehensive overview of the migratory behaviors of key immune cell subsets, including Th1, Th2, regulatory T cells, macrophages, dendritic cells, and neutrophils and the molecular mechanisms that guide their trafficking from lymphoid organs to inflamed tissues. We highlight the stepwise migration cascade: priming in secondary lymphoid organs, trafficking through blood vessels, adhesion to endothelium, and extravasation into tissues. Each step is critically regulated by chemokines, selectins, integrins, and proteases. We also examine current pharmacological strategies that target immune cell migration in inflammatory diseases, such as integrin blockers and chemokine receptor antagonists, emphasizing both therapeutic potential and clinical limitations. In addition, we discuss emerging technologies including intravital imaging, CRISPR-based screening, and computational modeling that provide novel insights into immune cell dynamics and may guide the development of next generation migration-targeted therapies. Overall, this review integrates fundamental immunological principles with translational medicine by identifying key challenges, unresolved controversies, and future directions in the therapeutic modulation of immune cell migration.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7b35de878e1a4e6dc7dfbb8b9e6a7a5a5cdb3f5d" target='_blank'>
              Targeting immune cell migration as therapy for inflammatory disease: a review
              </a>
            </td>
          <td>
            Bingfeng Song, Wenbo Guo, Ying He, Xingli Yao, Jintang Sun, Shijun Wang
          </td>
          <td>2025-09-25</td>
          <td>Frontiers in Immunology</td>
          <td>1</td>
          <td>0</td>
        </tr>

        <tr id="


 Despite the clinical success of immune checkpoint inhibitors (ICIs), therapeutic resistance and the unpredictable development of immune-related adverse events (irAEs) remain major challenges. While the use of ICIs in combination can improve treatment efficacy, this also leads to an increase in the frequency and severity of irAEs. This has created an urgent need to enhance anti-tumor immunity without triggering immunotoxicity. However, current preclinical models are limited in their ability to model both ICI efficacy and irAE development. This is due to mouse strains commonly used for studying anti-tumor immunity, such as C57BL/6 and BALB/c mice, being resistant to ICI-induced irAEs and failing to recapitulate the full spectrum of clinical responses seen in patients with cancer. To overcome these limitations, we generated transplantable, syngeneic tumor models with variable ICI responses using the autoimmune-prone non-obese diabetic (NOD) mouse. The NOD model, which spontaneously develops multiple autoimmune diseases, exhibits a broad range of irAEs following ICI treatment with a shared etiology to clinical conditions. This approach offers insight into how genetic predisposition to autoimmunity influences both ICI response and irAE susceptibility, enabling us to explore how autoimmune-associated host-intrinsic factors uniquely alter the tumor microenvironment and contribute to ICI resistance. In ICI-resistant NOD tumors, CD8+ T cells exhibited a naïve-like phenotype, marked by elevated TCF-1 and reduced PD-1 and CTLA-4 expression, compared to ICI-sensitive tumors. Despite comparable CD8+ T cell frequency and number, these phenotypic differences led us to investigate other immune cell populations that regulate ICI response and CD8+ T cell activation. Single-cell RNA sequencing and spectral flow cytometry revealed enrichment of immunosuppressive γδ T cells in ICI-resistant tumors. These γδ T cells highly expressed the transcription factors RORγt+ and TCF1+ and lacked expression of T-bet and the mouse Vγ1 TCR chain, suggesting that distinct γδ T cell subsets may play different roles in tumor control. Functionally, antibody-mediated blockade of the γδ T cell receptor (γδTCR) significantly improved tumor control in ICI-resistant, but not ICI-sensitive, models, implicating γδ T cells in promoting tumor growth. Tumors enriched with immunosuppressive RORγt+ and TCF1+ γδ T cells also exhibited increased B cell infiltration. In B cell-deficient NOD mice, γδ T cells skewed toward T-bet and Vγ1 expression, which correlated with enhanced CD8+ T cell activation. These findings reveal a coordinated immunosuppressive network between γδ T cells and B cells that limits anti-tumor immunity. Given their roles in promoting autoimmunity, these cell types may represent therapeutic targets to boost anti-tumor immunity and overcome ICI resistance without exacerbating irAEs.



 Camille Hansen, Arabella Young. Immunosuppressive γδ T cells limit anti-tumor immunity in ICI-resistant tumors from autoimmune-prone mice [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity; 2025 Sep 24-27; Montreal, QC, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2025;13(9 Suppl):Abstract nr PR-07.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/bbe022036b51d679682bf7b2a75aa9588ca9caf8" target='_blank'>
              Abstract PR-07: Immunosuppressive γδ T cells limit anti-tumor immunity in ICI-resistant tumors from autoimmune-prone mice
              </a>
            </td>
          <td>
            Camille Hansen, Arabella Young
          </td>
          <td>2025-09-24</td>
          <td>Cancer Immunology Research</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/80cc91e3812f0ff8dec01eacf5a39094b7d42259" target='_blank'>
              Potentiating CAR-T bystander killing by enhanced Fas/FasL signaling mitigates antigen escape in heterogeneous tumors
              </a>
            </td>
          <td>
            Matthew J Lin, Joanna K Chorazeczewski, Gvantsa Pantsulaia, Alan Cooper, Moah Sohn, Sidorela Reci, Jaime Mateus-Tique, Nicole H Hirsh, Xinping Xie, Ivan Odak, Rudra Dutta, Daniel Charytonowicz, R. Upadhyay, Brian D. Brown, Miriam Merad, Morgan Huse, Justin Kline, Joshua D Brody
          </td>
          <td>2025-09-24</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="


 CD8 T cells are effector cells of the adaptive immune system responsible for mediating protective immune responses in cancer. However, CD8 T cells can also be critical drivers of pathologic responses including autoimmunity. A key feature of these cells is that they must infiltrate tissues to execute their primary function of cell killing. It is well established that naive T cell responses do not originate in these tissues. Rather, prior to antigen-driven activation, naïve T cells are restricted to lymph nodes, spleen, and blood. T cell activation by cognate antigen drives expression of multiple immune checkpoint inhibitors, including programmed cell death protein-1 (PD-1) and/or cytotoxic T lymphocyte associated protein-4 (CTLA-4), as well as migration to nonlymphoid tissues. Work over the last two decades has harnessed T cell effector activities by blocking PD-1 and/or CTLA-4, which has revolutionized cancer care and demonstrated remarkable efficacy in diverse cancer types. However, many patients do not respond to checkpoint blockade therapy, and worse, other patients develop autoimmune-like immune-related adverse events (irAEs), limiting the utility of this approach. To maximize the therapeutic benefit of checkpoint blockade without accelerated irAE development, targeted approaches are needed to increase recruitment of protective CD8 T cells to tumors while preventing pathogenic T cell entry into sensitive tissues. However, an inability to granularly measure recruitment into non-lymphoid tissues has created a significant gap in knowledge in: 1) how checkpoint inhibitors impact T cell entry rates into tissues, 2) whether these entry rates are different for tumors and lesional irAE tissues, 3) where recruited cells localize, and 4) the precise functional contributions of recruited versus resident T cells in driving tumor regression or autoimmunity. To fill this gap in knowledge, we are utilizing an intravenous antibody labeling approach to mark CD8 T cells in the blood prior to entry into tissues, an approach which enables a 72-hour window to track tissue entry. Using this approach in the preclinical setting, we are interrogating how PD-1 inhibitors impact CD8 T cell recruitment to tumors as well as the pancreas in the context of Type 1 Diabetes. In our tumor studies, we have found that PD-1 inhibitors induce an increase in the number of recently recruited CD8 T cells, and that these recruited T cells have a less exhausted phenotype than the T cells that have been in the tumor for longer. In our diabetes studies, we have found that PD-1 inhibitors impact CD8 T cells both in the periphery and the pancreas, and in some mice cause an increase in migration to the pancreas. These studies support a model where peripheral CD8 T cell recruitment can positively contribute to productive anti-tumor immunity but can also exacerbate autoimmunity. Thus, our studies emphasize the doubled-edged nature of T cell recruitment, and our future studies will examine ways to both improve recruitment to tumors and mitigate recruitment to lesional irAE tissues.



 Oluwatoyosi Adewunmi, Arielle G. Dessens, Aloukick K. Singh, Autumn M. Sunderland, Sanjana Ananthula, Rachel M. Morris, Jason M. Schenkel, Kristen E. Pauken. Leveraging peripheral leukocyte recruitment to improve efficacy and mitigate toxicities following checkpoint blockade [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity; 2025 Sep 24-27; Montreal, QC, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2025;13(9 Suppl):Abstract nr PR-10.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/bd96650135ea1d6c5e4e2bfdec0bd0131105df25" target='_blank'>
              Abstract PR-10: Leveraging peripheral leukocyte recruitment to improve efficacy and mitigate toxicities following checkpoint blockade
              </a>
            </td>
          <td>
            O. Adewunmi, Arielle G. Dessens, A. Singh, Autumn M. Sunderland, Sanjana Ananthula, Rachel M. Morris, Jason M. Schenkel, Kristen E. Pauken
          </td>
          <td>2025-09-24</td>
          <td>Cancer Immunology Research</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Cellular senescence has gradually been recognized as a key process, which not only inhibits the occurrence of early tumors but also promotes advanced malignant progression through secretory and immunomodulatory functions. Initially, cellular senescence manifested as irreversible cell cycle arrest, but now it encompasses a broader phenotype regulated by the p53-p21CIP1 and p16INK4A-Rb pathways. Although secretory phenotypes related to aging can recruit immune effectors to clear new tumor cells, persistent senescent cell populations often trigger chronic inflammation, promoting immune escape and fibrosis. In this review, we first discuss the molecular underpinnings of cellular senescence, highlighting its induction pathways and diverse physiological or pathological roles. We then examine the composition of the tumor microenvironment, where senescent cells accumulate and secrete pro-inflammatory cytokines, reshaping immune surveillance and extracellular matrix architecture. Against this backdrop, we explore how aging clocks refine our understanding of individual susceptibility to malignancy by distinguishing biological from chronological aging. We also present current therapeutic prospects, including senolytic agents targeting senescent stromal cells that promote tumor growth, and the utilization of aging clock metrics to tailor immunotherapies more effectively for older patients. Finally, we consider the major challenges facing clinical translation, from standardizing multi-omics data pipelines to clarifying the ethical implications of measuring biological age. By bridging senescence biology with geroscience and cutting-edge oncology, we posit that aging clocks may catalyze a transformation in cancer care, enabling more personalized, effective, and age-conscious treatment strategies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/711645efda189ccea0f3b80d8175c61e18d0416a" target='_blank'>
              Reprogramming cellular senescence and aging clocks for advanced cancer immunotherapy
              </a>
            </td>
          <td>
            Huiting Yang, Dong Liu, Liewang Qiu, Rui Wang, Chuchu Zhang, Danqing Yu, Qingping Zhong, Nitta Yuki, Zhentao Song, Taotao Zhu, Haixing Ju, Weifeng Hong, Ji Zhu
          </td>
          <td>2025-10-02</td>
          <td>Molecular Cancer</td>
          <td>1</td>
          <td>3</td>
        </tr>

        <tr id="As a key lymphocyte population in shaping and controlling adaptive immune response, T cells play an important immunomodulatory role in the early stages of autoimmune diseases. Although CD3+CD4−CD8− T (DNT) cells constitute only a small proportion of peripheral T lymphocytes, they may be closely linked to the occurrence and development of autoimmune diseases. However, the role of DNT cells in autoimmune disease pathogenesis still needs to be elucidated. In this review, we first present the origin, functions, and heterogeneity of DNT cells. We then summarize the role of DNT cells in the pathogenesis of various autoimmune diseases. Subsequently, we clarify the recent advances in the applications of DNT cell-based therapy for autoimmune diseases and outline potential drugs (including active ingredients extracted from Chinese medicinal treatments) and approaches that can target the proliferation and expansion of DNT cells. Lastly, the limitations and challenges of applying DNT-cell-based therapy are analyzed. In conclusion, we present an overview to further the understanding of the role of DNT cells in autoimmune disease pathogenesis and of DNT cells as a potential therapeutic tool for immune disorders.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/130f579f8c6e0a3374a93d0e8f2050f3b8d8e91f" target='_blank'>
              CD3+CD4−CD8− T cells: a new potential therapeutic target in treating autoimmune diseases
              </a>
            </td>
          <td>
            Xin Li, Di Guo, Isabelle Xinyue Zou, Lingyan Zhao, Na Yang, Yang Liu
          </td>
          <td>2025-09-26</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="


 Fractionated focal radiation therapy (RT) induces immunogenic cell death and activates the type I interferon pathway via the cGAS/STING pathway, promoting tumor antigen cross-presentation by conventional dendritic cells (cDCs) and driving tumor-specific T-cell activation. However, the impact of RT on tumor regression is often limited by its complex effects on the tumor immune microenvironment (TiME). Several studies have shown that RT increases both the frequency and functional activity of regulatory T cells (Tregs), due in part to their intrinsic radioresistance and to RT-induced modulation of recruitment signals such as TGFβ, CCL17, and CCL221-2. In a recent study, we showed that RT combined with immunotherapy can remodel the TiME3, et persistent infiltration of activated Tregs can dampen the full immunostimulatory effects of RT-driven viral mimicry responses4. Here, we evaluated whether combining RT with blockade of the myeloid checkpoint SIRPα could modulate Treg infiltration and activity. Using mouse models of luminal (TSA) and triple-negative (AT3) breast cancer, we tested RT in combination with a blocking anti-SIRPα antibody (MY1; SIRPα-b). While MY1 monotherapy showed minimal activity, its combination with RT led to enhanced regression of irradiated tumors and inhibition of non-irradiated (abscopal) tumor growth in both tumor models. This effect was lost upon conditional cDC depletion using Zbtb46-DTR mice, highlighting the importance of cDCs in mediating the therapeutic synergy. To dissect the immune mechanisms underlying this synergy, we performed single-cell RNA-sequencing and CITE-seq on CD45+ tumor-infiltrating cells from TSA tumors treated with RT ± SIRPα-b. We observed a significant reduction in Treg infiltration in SIRPα-b–treated tumors, with or without RT. Furthermore, expression of Treg activation markers OX40, CTLA-4, and GITR was reduced, particularly in the RT + SIRPα-b group. Among infiltrating CD45+ cells, expression of Treg recruiting Ccl22 and Ccl17 chemokines was observed only in a highly activated cluster of CCR7high cDCs expressing SIRPα, CXCL16, PD-L1, and IL-15Rα. Notably, expression of both chemokines was strongly decreased following SIRPα-b treatment, suggesting that SIRPα signaling supports Treg recruitment via this cDC population.Studies to understand the mechanisms of Treg recruitment to the tumor via chemokine secretion by CCR7high cDCs and their role in tumor regression after RT + SIRPα-b are underway. Intra-tumoral CCR7high cDCs are known to support the activation and cytotoxic function of CD8+ T cells and NK cells in the tumor through transpresentation of Il-155. Our results suggest that this population also plays a key immunoregulatory role in shaping the TiME. Targeting the CD47/SIRPα axis may thus improve RT efficacy by modulating the dual functions of CCR7high cDCs in both effector stimulation and Treg recruitment.
 1- PMID: 28970196 2- PMID: 30042205 3- PMID: 37620372 4- doi: 10.1038/s41392-023-01462-z 5- PMID: 34343496



 Maud Charpentier, Claire Lhuillier, Alicia Alonso, Doron Betel, Paul Zumbo, Maider Astorkia Amiama, Sergio Trombetta, Sandra Demaria. Myeloid checkpoint blockade potentiates radiotherapy by modulating dendritic cells and reducing Treg-driven immunosuppression [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity; 2025 Sep 24-27; Montreal, QC, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2025;13(9 Suppl):Abstract nr PR-13.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b0e1c2aec6f5f685b76f71084f5e90412842cab0" target='_blank'>
              Abstract PR-13: Myeloid checkpoint blockade potentiates radiotherapy by modulating dendritic cells and reducing Treg-driven immunosuppression
              </a>
            </td>
          <td>
            M. Charpentier, Claire Lhuillier, Alicia Alonso, D. Betel, P. Zumbo, Maider Astorkia Amiama, Sergio Trombetta, Sandra Demaria
          </td>
          <td>2025-09-24</td>
          <td>Cancer Immunology Research</td>
          <td>0</td>
          <td>40</td>
        </tr>

        <tr id="Gliomas present as highly heterogeneous and aggressive central nervous system (CNS) tumors with challenging diagnosis and management. Traditional and current therapies are lacking efficacy in overcoming the complex and dynamic behavior of gliomas and the local tumor microenvironment. Emerging research highlights the significant role of innate immune receptors including Toll-like, NOD-like and RIG-like receptors, as well as cGAS-STING receptors, scavenger and C-type lectin receptors in glioma development and progression. These receptors can both impact immune modulation as well as facilitate tumor growth through interactions with tumor-associated macrophages, myeloid-derived suppressor cells and cytokine networks, contributing to immune evasion in the tumor microenvironment. Herein, we discuss the main signaling pathways induced through innate immune receptors in gliomas along with their functional properties in glioma pathology while exploring current applications to treatment. Utilizing innate immune receptors as therapeutic targets holds great promise, especially when used along with traditional chemotherapy and radiation schemes, strengthening immune responses. Future studies focusing on the deeper understanding of innate immune receptors signaling and complexity are highly required to enable novel immunoregulatory treatment schemes for gliomas.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b2b7b3e02786ee96fe5c12a17a3e23bd5c3a936a" target='_blank'>
              Innate Immune Signaling in Gliomas: Regulatory Mechanisms and Targeting Potential in Tumor Progression
              </a>
            </td>
          <td>
            Edmund Jung, Sara Al Jadidi, C. Piperi
          </td>
          <td>2025-10-01</td>
          <td>Life</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="


 Despite promising safety profiles, B7-H3 CAR T cell therapies have yet to demonstrate meaningful clinical efficacy in diffuse intrinsic pontine glioma (DIPG), a devastating pediatric brain cancer characterized by a profoundly immunosuppressive tumor microenvironment (TME). This TME is dominated by tumor-associated macrophages (TAMs) and suppressive resident microglia that restrict CAR T-cell activation and persistence. Importantly, broad myeloid targeting risks eliminating macrophages essential for supporting T cell activation and anti-tumor immunity. We identified CD123 as a selective marker of suppressive TAMs in DIPG and hypothesized that dual targeting of CD123+ TAMs alongside B7-H3+ tumor cells would effectively remodel the TME, restore T cell function, and enhance therapeutic efficacy.



 Using immunocompetent DIPG models, we evaluated a sequential combination of CD123 and B7-H3 CAR T cells to remodel the TME and improve tumor control. In vitro assays included cytotoxicity, repeated antigen stimulation, and co-cultures with M1- or M2-polarized macrophages. Endpoints included TAM depletion, TME remodeling, tumor burden, and survival.



 In vitro, M2 macrophages suppressed B7-H3 CAR T cell proliferation, persistence, and cytokine secretion; these effects were reversed by co-treatment with CD123 CAR T cells. CD123 CAR T cells selectively depleted M2-like TAMs and microglia without cytotoxicity against B7-H3+ DIPG tumor cells. In vivo, CD123 CAR T cell treatment reduced immunosuppressive TAMs and shifted the tumor microenvironment toward a pro-inflammatory phenotype, as demonstrated by intracellular cytokine staining and comprehensive flow cytometry analyses. Notably, administration of CD123 CAR T cells after B7-H3 CAR T cell infusion failed to rescue antitumor activity. However, administering CD123 CAR T cells within a four-day window prior to B7-H3 CAR T cell infusion significantly enhanced tumor control. Dual CAR therapy substantially decreased tumor burden, limited suppressive myeloid and microglial infiltration, and improved T cell activation and persistence, resulting in extended survival compared to monotherapies, with some mice achieving durable tumor remission. Ongoing transcriptomic studies are underway to elucidate the mechanisms driving this robust, lasting antitumor immunity.



 Priming the TME with CD123 CAR T cells significantly improves B7-H3 CAR T cell efficacy in aggressive DIPG models. Dual targeting of CD123+ TAMs and B7-H3+ tumor cells reprograms the DIPG TME and enhances CAR T-cell function by overcoming immunosuppressive barriers while preserving supportive immune populations. This strategy offers a promising mechanistic approach to improving CAR T therapy in DIPG.



 Khatereh Khorsandi, Kaleem Coleman, Jaquelyn T. Zoine, M.Paulina Velasquez, Dalia Haydar. Reprogramming the Myeloid Tumor Microenvironment with CD123 CAR T Cells Enhances B7-H3 CAR T Cell Therapy in DIPG [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Discovery and Innovation in Pediatric Cancer— From Biology to Breakthrough Therapies; 2025 Sep 25-28; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl_2):Abstract nr A039-PR007.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9467562ec35cf64972931c9ccd0b2e56a2414e52" target='_blank'>
              Abstract A039-PR007: Reprogramming the Myeloid Tumor Microenvironment with CD123 CAR T Cells Enhances B7-H3 CAR T Cell Therapy in DIPG
              </a>
            </td>
          <td>
            Khatereh Khorsandi, Kaleem L Coleman, Jaquelyn T. Zoine, M. Velasquez, Dalia Haydar
          </td>
          <td>2025-09-25</td>
          <td>Cancer Research</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="


 Fractionated focal radiation therapy (RT) induces immunogenic cell death and activates the type I interferon pathway via the cGAS/STING pathway, promoting tumor antigen cross-presentation by conventional dendritic cells (cDCs) and driving tumor-specific T-cell activation. However, the impact of RT on tumor regression is often limited by its complex effects on the tumor immune microenvironment (TiME). Several studies have shown that RT increases both the frequency and functional activity of regulatory T cells (Tregs), due in part to their intrinsic radioresistance and to RT-induced modulation of recruitment signals such as TGFβ, CCL17, and CCL221-2. In a recent study, we showed that RT combined with immunotherapy can remodel the TiME3, et persistent infiltration of activated Tregs can dampen the full immunostimulatory effects of RT-driven viral mimicry responses4. Here, we evaluated whether combining RT with blockade of the myeloid checkpoint SIRPα could modulate Treg infiltration and activity. Using mouse models of luminal (TSA) and triple-negative (AT3) breast cancer, we tested RT in combination with a blocking anti-SIRPα antibody (MY1; SIRPα-b). While MY1 monotherapy showed minimal activity, its combination with RT led to enhanced regression of irradiated tumors and inhibition of non-irradiated (abscopal) tumor growth in both tumor models. This effect was lost upon conditional cDC depletion using Zbtb46-DTR mice, highlighting the importance of cDCs in mediating the therapeutic synergy. To dissect the immune mechanisms underlying this synergy, we performed single-cell RNA-sequencing and CITE-seq on CD45+ tumor-infiltrating cells from TSA tumors treated with RT ± SIRPα-b. We observed a significant reduction in Treg infiltration in SIRPα-b–treated tumors, with or without RT. Furthermore, expression of Treg activation markers OX40, CTLA-4, and GITR was reduced, particularly in the RT + SIRPα-b group. Among infiltrating CD45+ cells, expression of Treg recruiting Ccl22 and Ccl17 chemokines was observed only in a highly activated cluster of CCR7high cDCs expressing SIRPα, CXCL16, PD-L1, and IL-15Rα. Notably, expression of both chemokines was strongly decreased following SIRPα-b treatment, suggesting that SIRPα signaling supports Treg recruitment via this cDC population.Studies to understand the mechanisms of Treg recruitment to the tumor via chemokine secretion by CCR7high cDCs and their role in tumor regression after RT + SIRPα-b are underway. Intra-tumoral CCR7high cDCs are known to support the activation and cytotoxic function of CD8+ T cells and NK cells in the tumor through transpresentation of Il-155. Our results suggest that this population also plays a key immunoregulatory role in shaping the TiME. Targeting the CD47/SIRPα axis may thus improve RT efficacy by modulating the dual functions of CCR7high cDCs in both effector stimulation and Treg recruitment.
 1- PMID: 28970196 2- PMID: 30042205 3- PMID: 37620372 4- doi: 10.1038/s41392-023-01462-z 5- PMID: 34343496



 Maud Charpentier, Claire Lhuillier, Alicia Alonso, Doron Betel, Paul Zumbo, Maider Astorkia Amiama, Sergio Trombetta, Sandra Demaria. Myeloid checkpoint blockade potentiates radiotherapy by modulating dendritic cells and reducing Treg-driven immunosuppression [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity; 2025 Sep 24-27; Montreal, QC, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2025;13(9 Suppl):Abstract nr A023.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/acbd70f4779618ff4cf0238d208283c1e692a84a" target='_blank'>
              Abstract A023: Myeloid checkpoint blockade potentiates radiotherapy by modulating dendritic cells and reducing Treg-driven immunosuppression
              </a>
            </td>
          <td>
            M. Charpentier, Claire Lhuillier, Alicia Alonso, D. Betel, P. Zumbo, Maider Astorkia Amiama, Sergio Trombetta, Sandra Demaria
          </td>
          <td>2025-09-24</td>
          <td>Cancer Immunology Research</td>
          <td>0</td>
          <td>40</td>
        </tr>

        <tr id="Myeloid-derived suppressor cells (MDSCs) play critical roles in tumor immune evasion. These heterogeneous cells are broadly classified into granulocytic (G-MDSC), monocytic (M-MDSC), and their immature precursors, early-stage MDSCs (e-MDSCs). Elucidating their differentiation and expansion mechanisms is crucial for advancing cancer immunotherapy. This review examines the key signaling pathways (e.g., JAK/STAT, NF-κB, Notch), regulatory cytokines, metabolic factors, and epigenetic modifications central to MDSC biology. A comprehensive understanding of these intricate networks provides valuable insights into tumor immune evasion and facilitates the identification of novel therapeutic targets designed to overcome MDSC-mediated immunosuppression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4682b63ca9757bb9c1ba2dada7a0f722d5dd5cac" target='_blank'>
              Molecular mechanisms governing the differentiation and expansion of myeloid-derived suppressor cells
              </a>
            </td>
          <td>
            Ke Wang, Xiao Wang, Nan Sun
          </td>
          <td>2025-10-17</td>
          <td>Frontiers in Cell and Developmental Biology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="T cells play a central role in the immune response to gastric cancer, and their dysfunction directly contributes to immune escape from the tumor and limits the efficacy of immunotherapy. The immune microenvironment of gastric cancer consists of a wide range of cells and molecules, and this complex and dynamic environment exerts profound inhibitory effects on T cell function. upregulation of PD-1, CTLA-4, and other inhibitory molecules is a key mechanism of T cell depletion, and metabolic reprogramming and chronic antigenic stimulation further weaken the anti-tumor activity of T cells. In recent years, PD-1/PD-L1 inhibitors have demonstrated some efficacy in gastric cancer, but the problem of drug resistance remains prominent. To address these challenges, combinatorial therapeutic strategies have gradually become the focus of research, especially combining immune checkpoint inhibitors with chemotherapy, radiotherapy, or targeted therapy to enhance the antitumor effect of immunotherapy. This review delves into the molecular mechanisms of T-cell depletion and its impact in gastric cancer immunotherapy, and analyzes the potential application of biomarkers in predicting treatment response. By comprehensively analyzing T-cell depletion and the immune microenvironment in gastric cancer, this paper provides a theoretical basis for the development of future personalized combinatorial therapeutic strategies, with the aim of improving patient prognosis and enhancing the overall therapeutic efficacy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/98ef3d84371b71530557b38bd98704c81b59dc80" target='_blank'>
              Mechanisms and therapeutic strategies to reveal and overcome T-cell dysfunction in gastric cancer: translation from basic research to clinical application
              </a>
            </td>
          <td>
            Huanyu Luo, Jianxi Wu, Yalan Yan, Danqi Xu, Jieying Zhang, Xuancheng Zhou, Guanhu Yang, Xiaolin Zhong
          </td>
          <td>2025-09-30</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="Type 2 innate lymphoid cells (ILC2s) are critical mediators of type 2 immunity that play non-redundant context-dependent modulatory functions. Primarily associated with responses against helminths and allergens via the activation of a potent epithelial-ILC2 axis, a growing body of evidence also suggests that a crosstalk between ILC2 and T cells is equally important in maintaining tissue homeostasis. In barrier tissues and secondary lymphoid organs, ILC2s co-localize with T cells, forming hubs where bi-directional signals are exchanged. Here, we describe the diversity of functional interactions between ILC2s and T cells, detailing known contact-dependent and -independent mechanisms, including a relatively new and still poorly defined antigen-presenting function during inflammation. Understanding these complex interactions is necessary to fully elucidate how this specific crosstalk helps maintain tissue homeostasis and regulate inflammatory responses. Identifying the spatial and temporal specificities of these interactions will certainly open new avenues for future targeting of this axis to improve immune-mediated host protection.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/dc9091d8a7d8543597d9b4583a6f2834ed1e2f0b" target='_blank'>
              Unspoken words: decoding the dialog between type 2 innate lymphoid cells and T cells
              </a>
            </td>
          <td>
            Zahra Jamila Ikra, Qiutong Huang, Huiyang Yu, Gabrielle T. Belz, Craig N. Jenne, Nicolas Jacquelot
          </td>
          <td>2025-10-06</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>23</td>
        </tr>

        <tr id="The advent of immune checkpoint inhibition revolutionized cancer care, yet many people will fail to respond due to innate or acquired resistance. Combination therapies with immune checkpoint inhibitors are being explored to enhance their efficacy and improve patient outcomes. Focal adhesion kinase (FAK), known for its roles in cell adhesion and migration, has emerged as a potential therapeutic target due to the identification of its additional functions in cancer progression, including its ability to establish a pro-tumorigenic, immunosuppressive microenvironment. FAK has the ability to create physical barriers for immune cell infiltration and drug delivery through its regulation of blood vessel formation and extracellular matrix in the tumor stroma. Additionally, FAK has been reported to function both within tumor and immune cells to inhibit immune cell recruitment, stimulation, and function. Taken together, FAK functions within cancer to dampen immune surveillance and promote immune escape. As a result, there is mounting interest in the use of FAK inhibitors in combination with immune checkpoint inhibition for the treatment of solid tumors, and this strategy is actively being explored in the pre-clinical and clinical setting. This article reviews the ways in which FAK alters the tumor microenvironment and the cells within it in order to assess the clinical potential of co-targeting FAK and immune checkpoints.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/811d0bcf3e10ec88d0f902bce663b88c3e34d229" target='_blank'>
              Targeting FAK to Potentiate Immune Checkpoint Therapy in Solid Tumors
              </a>
            </td>
          <td>
            Karly A Stanley, Sheri L. Holmen
          </td>
          <td>2025-08-02</td>
          <td>Journal of cancer immunology</td>
          <td>1</td>
          <td>2</td>
        </tr>

        <tr id="


 Adoptive cell transfer-based immunotherapies have shown limited efficacy against most solid tumors. A key barrier to success is the immunosuppressive tumor microenvironment (TME). Beyond local effects, tumors induce systemic immune disturbances that further hinder anti-tumor immunity and promote disease progression. In this study, we investigate how tumor-driven systemic immunosuppression compromises the function of both endogenous and adoptively transferred natural killer (NK) cells, identifying potential strategies to enhance immunotherapeutic outcomes.



 We utilized syngeneic murine cancer models to systematically characterize alterations in immune cell populations within the circulation and spleen. Comprehensive and in-depth assessment of immune cell function, transcriptional activity, and metabolic state was performed using flow cytometry, Seahorse metabolic analysis, RNA sequencing, metabolic tracing, and ex vivo co-culture systems.



 In our PDAC mouse models, tumor burden elicited a robust systemic inflammatory response marked by expansion of myeloid lineage cells, particularly MDSCs, within the TME, peripheral blood, and spleen. Tumor growth led to reduced frequencies and functional deficits in both endogenous and adoptively transferred NK cells in circulation and spleen. Depletion of Gr-1+ MDSCs effectively restored NK cell effector functions. Mechanistic analyses demonstrated that MDSCs in tumor-bearing mice promote NK cell dysfunction through induction of lipid peroxidation. Notably, we observed pronounced upregulation of apolipoprotein E (ApoE)—a central lipid metabolism regulator—in MDSCs, which drove increased lipid oxidation and reactive oxygen species (ROS) production. Disruption of the ApoE-LDL receptor (LDLR) axis in MDSCs, achieved via genetic ablation, reprogrammed their metabolic activities and significantly reduced their immunosuppressive capacity toward both endogenous and transferred NK cells. Furthermore, pharmacological inhibition of lipid utilization rescued NK cell function and, when combined with NK cell adoptive transfer, produced synergistic anti-tumor effects in PDAC models.



 Our results emphasize the pivotal role of MDSC expansion in mediating systemic immunosuppression in tumor-bearing hosts. We identify the ApoE/LDLR axis as a promising therapeutic target to disrupt MDSC-driven immunosuppression, thereby enhancing the efficacy of NK cell–based immunotherapies. These findings underscore the importance of resolving systemic immune dysregulation in cancer patients to maximize the benefits of immunotherapy.



 Chao Xu, Hongyuan Chen, Liangjie Chi, Fangqin Xue, Chunbo He. Targeting the ApoE-LDLR pathway disrupts MDSC-mediated systemic immunosuppression and enhances the efficacy of NK cell immunotherapy [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity; 2025 Sep 24-27; Montreal, QC, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2025;13(9 Suppl):Abstract nr B026.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7a0540abd909233af3d6405eb6004cd58b6e6586" target='_blank'>
              Abstract B026: Targeting the ApoE-LDLR pathway disrupts MDSC-mediated systemic immunosuppression and enhances the efficacy of NK cell immunotherapy
              </a>
            </td>
          <td>
            Chao Xu, Hongyuan Chen, Liangjie Chi, Fangqin Xue, Chunbo He
          </td>
          <td>2025-09-24</td>
          <td>Cancer Immunology Research</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="


 Immune checkpoint inhibitors show minimal activity in patients (pts) with epithelial ovarian cancer (EOC), in part due to an immunosuppressive tumor microenvironment (TME). We are currently investigating the safety and preliminary efficacy of an autologous intraperitoneal cytokine-induced memory-like NK cell therapy in pts with recurrent EOC (NCT06321484). We aimed to define NK cell dysregulation in EOC ascites to inform potential mechanisms of resistance to NK cell therapies in the TME.



 Ascites and matched peripheral blood (PB) were collected from 4 pts with advanced EOC. O-link target 48 was performed on paired ascites and serum from 3 pts; Luminex was performed on ascites from 4 additional EOC pts. 10x Single cell RNA sequencing (scRNAseq) was performed on cells isolated from paired ascites and PB from 3 pts; downstream analyses were conducted using Seurat, ggplot2 and EnrichR using Wilcoxon rank sum test for significance.



 Consistent with prior studies, ascites-derived NK (A-NK) cells exhibited reduced cytotoxic capacity compared with matched PB- derived NK (PB-NK) cells. PB-NK cells showed activation (IFN-g release) and degranulation (CD107a+) in response to cytokine stimulation and target cell exposure, respectively; however matched A-NK cells did not respond to target stimulation. Multiplex immunoassays performed to identify ascites factors contributing to NK cell dysfunction showed enrichment of multiple immunomodulatory secreted factors including CXCL10, IL-6, TGF-b, VEGF-A, CXCL9, CCL2, and CCL8. In line with the functional data, scRNAseq analysis revealed lower expression of cytotoxicity-related genes (PRF1, GZMB, GZMA, GNLY, NKG7) in A-NK compared to PB-NK cells (p<0.0001, n=3 paired samples). Additionally, A-NK showed significant enrichment in type I interferon (IFN) signaling (p≤0.0001), suggesting chronic overstimulation. Flow cytometry revealed elevated CD69 (p<0.05) and NKG2A on A-NK, hallmarks of chronic overstimulation. In a module score analysis using genes for glycolysis and oxidative phosphorylation (e.g. CAPN5, STC2, VEGFA, HK2, CTH, GNE, GLRX, VLDR and CYC1, GRPEL1, TIMM17A), A-NK showed significantly lower expression than PB-NK (p<0.0001). To address this immune dysfunction, we engineered an IL-12-secreting CAR-NK cells targeting mesothelin that maintain high cytotoxic activity in the presence of EOC ascites. Notably, IL-12 CAR NK cells highly express the genes within our metabolic modular score, suggesting increased metabolic fitness.



 Ascites-derived NK cells demonstrate marked immune and metabolic dysfunction, and we hypothesize that IL12-engineering may overcome ascites-induced dysfunction via metabolic reprogramming. Ongoing efforts are focused on RNA and ATAC sequencing analyses of ascites-exposed IL-12-secreting CAR NK to elucidate epigenetic changes that mediate their resistance to the TME.



 Grace C. Birch, Mubin Tarannum, Maily Nguyen, Khanlinh Dinh, Mila Stanojevic, Ursula A. Matulonis, Rizwan Romee, Rebecca L. Porter. Ascites-derived natural killer (NK) cells exhibit chronic overstimulation and metabolic dysfunction in patients with advanced epithelial ovarian cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research; 2025 Sep 19-21; Denver, CO. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl):Abstract nr B062.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/bb6b7187b3a8993d43f3efb3c4cfbff661cd8daf" target='_blank'>
              Abstract B062: Ascites-derived natural killer (NK) cells exhibit chronic overstimulation and metabolic dysfunction in patients with advanced epithelial ovarian cancer
              </a>
            </td>
          <td>
            G. Birch, Mubin Tarannum, Maily Nguyen, K. Dinh, Mila Stanojevic, U. Matulonis, R. Romee, Rebecca L Porter
          </td>
          <td>2025-09-19</td>
          <td>Cancer Research</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="


 Adoptive cell transfer-based immunotherapies have shown limited efficacy against most solid tumors. A key barrier to success is the immunosuppressive tumor microenvironment (TME). Beyond local effects, tumors induce systemic immune disturbances that further hinder anti-tumor immunity and promote disease progression. In this study, we investigate how tumor-driven systemic immunosuppression compromises the function of both endogenous and adoptively transferred natural killer (NK) cells, identifying potential strategies to enhance immunotherapeutic outcomes.



 We utilized syngeneic murine cancer models to systematically characterize alterations in immune cell populations within the circulation and spleen. Comprehensive and in-depth assessment of immune cell function, transcriptional activity, and metabolic state was performed using flow cytometry, Seahorse metabolic analysis, RNA sequencing, metabolic tracing, and ex vivo co-culture systems.



 In our PDAC mouse models, tumor burden elicited a robust systemic inflammatory response marked by expansion of myeloid lineage cells, particularly MDSCs, within the TME, peripheral blood, and spleen. Tumor growth led to reduced frequencies and functional deficits in both endogenous and adoptively transferred NK cells in circulation and spleen. Depletion of Gr-1+ MDSCs effectively restored NK cell effector functions. Mechanistic analyses demonstrated that MDSCs in tumor-bearing mice promote NK cell dysfunction through induction of lipid peroxidation. Notably, we observed pronounced upregulation of apolipoprotein E (ApoE)—a central lipid metabolism regulator—in MDSCs, which drove increased lipid oxidation and reactive oxygen species (ROS) production. Disruption of the ApoE-LDL receptor (LDLR) axis in MDSCs, achieved via genetic ablation, reprogrammed their metabolic activities and significantly reduced their immunosuppressive capacity toward both endogenous and transferred NK cells. Furthermore, pharmacological inhibition of lipid utilization rescued NK cell function and, when combined with NK cell adoptive transfer, produced synergistic anti-tumor effects in PDAC models.



 Our results emphasize the pivotal role of MDSC expansion in mediating systemic immunosuppression in tumor-bearing hosts. We identify the ApoE/LDLR axis as a promising therapeutic target to disrupt MDSC-driven immunosuppression, thereby enhancing the efficacy of NK cell–based immunotherapies. These findings underscore the importance of resolving systemic immune dysregulation in cancer patients to maximize the benefits of immunotherapy.



 Chao Xu, Hongyuan Chen, Liangjie Chi, Fangqin Xue, Chunbo He. Targeting the ApoE-LDLR pathway disrupts MDSC-mediated systemic immunosuppression and enhances the efficacy of NK cell immunotherapy [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity; 2025 Sep 24-27; Montreal, QC, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2025;13(9 Suppl):Abstract nr PR-01.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/45b7331df483f27859df652eb5ed860e47a52d18" target='_blank'>
              Abstract PR-01: Targeting the ApoE-LDLR pathway disrupts MDSC-mediated systemic immunosuppression and enhances the efficacy of NK cell immunotherapy
              </a>
            </td>
          <td>
            Chao Xu, Hongyuan Chen, Liangjie Chi, Fangqin Xue, Chunbo He
          </td>
          <td>2025-09-24</td>
          <td>Cancer Immunology Research</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="
 Myeloid-rich microenvironment is a hallmark of glioblastoma (GBM), the most aggressive and lethal brain malignancies in adults, leading to profound immunosuppression and therapy resistance. Metabolic dysregulation in tumor-associated myeloid cells (TAMCs) has been recognized as a key player driving immune evasion and supporting their pro-tumorigenic roles. Our single-cell RNA sequencing analysis and multiplex immunofluorescence have demonstrated high overexpression of monocarboxylate transporter 4 (MCT4), a key lactate transporter, in TAMCs in both murine and human GBMs, which may greatly contribute to TAMC-mediated GBM immunosuppression. To enable a myeloid-specific targeting of MCT4 in GBM, we have developed MCT4 nano-therapeutics using our antibody-directed immune targeting (ADIT) nano-platform. Lipid nanoparticles were surface functionalized with anti-PD-L1 antibody and encapsulated with small interfering RNA (siRNA) that targets MCT4. Our data indicated a robust and durable MCT4 inhibition, achieving over 90% gene knockdown efficiency. In vitro, MCT4 nano-therapeutics effectively targeted and reprogrammed immunosuppressive TAMCs, and restored CD8+ T cell proliferation and activation. In vivo, MCT4 nano-therapeutics through intracranial administration significantly improved the anti-glioma effectiveness of radiotherapy in CT-2A glioma-bearing C57 mice, leading to enhanced brain tumor infiltration of effector CD8+ T cells and CD103+ dendritic cells as well as much prolonged animal survival. When further combined with anti-CTLA-4 immune checkpoint therapy, over 60% of mice were cured from CT-2A glioma, and the long-term survivor animals developed anti-glioma immunological memory. Besides intracranial injections, we have also demonstrated the effectiveness of MCT4 nano-therapeutics through a systemic intranasal delivery route. These findings altogether may highlight a great potential of targeting lactate transport for modulating myeloid-mediated GBM immunosuppression and create a new immunotherapeutic approach to improve the existing standard treatments and immunotherapies for GBM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3cbe44139c87ecba179bf8e865f8c5ead1c37390" target='_blank'>
              DDEL-27. Nano-therapeutic modulation of lactate transport in myeloid cells potentiates anti-tumor immunity and radiotherapy for glioblastoma
              </a>
            </td>
          <td>
            Hanchen Lin, Jiawei Huo, Xiaoyang Chen, Leah K. Billingham, H. Najem, Jingqi Sun, Caylee Silvers, Jianzhong Zhang, Rafał Chojak, Yu Han, Aurora Lopez-Rosas, Si Wang, Atique U. Ahmed, Catalina Lee-Chang, A. Heimberger, M. Lesniak, Pavithra Viswanath, J. Miska, Peng Zhang
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>28</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c95835bda755d7ba18f63f0c31d68e264e25b48c" target='_blank'>
              Antigen-presenting cells as arbiters of mucosal tolerance and immunity
              </a>
            </td>
          <td>
            Tilman L B Hoelting, Tyler Park, Chrysothemis C Brown
          </td>
          <td>2025-10-17</td>
          <td>Nature Immunology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Recently, we observed that pars planitis (PP) patients present alterations in peripheral blood (PB) Th17/Treg associated with dysregulation in the Th1 response. Yet, little is known about the systemic distribution of myeloid cells, which drive the recruitment and differentiation of the adaptive effectors toward pathogenic inflammatory Th1 and Th17 as well as regulatory lymphocytes in PP. Although myeloid populations in patients with uveitis have previously been addressed, the data did not provide an exact description of PP patients. Using flow cytometry, we evaluated monocyte and IDO-expressing monocyte-like myeloid-derived suppressor cell (MDSC) subpopulations in PB samples from 15 patients with different courses of PP (cystoid macular edema and non-macular edema subgroups; CME and nCME, respectively) and 17 healthy controls (HCs) in relation to the Th1, Th17, and immunoregulatory subsets. We observed that only PP patients from the CME subgroup presented a significantly higher fraction of CD16+ IDO-expressing MDSCs and intermediate CD14highCD16+ monocytes compared to the HCs; this corresponded with relative up-regulation of Th1 and Th17, and down-regulation of Treg. In addition, alongside the increased percentage of IDO-expressing CD16+ MDSCs, the MDSC compartment displayed an inappropriate level of IDO (more pronounced in the CD16− subset) only in CME patients. At the same time, the fraction of CD16− myeloid cells did not differ significantly among the patient cohorts and healthy participants. Our study is the first to evaluate subpopulations of circulating myeloid cells in PP patients and indicates that an increased fraction of CD16+ myeloid cells might reflect the immunological and clinical severity of PP.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8cd1fd2d076c43e8bd265181bbac902c87dc1f38" target='_blank'>
              Circulating CD16-Positive Monocyte-like Myeloid-Derived Suppressor Cells and Intermediate Monocytes Associated with Clinical and Immunological Complications in Pars Planitis Patients
              </a>
            </td>
          <td>
            A. Kosmaczewska, Joanna Przeździecka-Dołyk, L. Ciszak, Zofia Rojek-Gajda, I. Frydecka, A. Turno-Kręcicka, Marta Misiuk-Hojło, Edyta Pawlak
          </td>
          <td>2025-10-01</td>
          <td>Cells</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="Chronic neuroinflammation and neurodegeneration are critical but unresolved drivers of disability accumulation in progressive multiple sclerosis (MS). Chronic active white matter lesions, identifiable radiologically as paramagnetic rim lesions (PRL), indicate progression-relevant chronic neuroinflammation. Using single-cell transcriptomics (scRNAseq) and T-cell receptor sequencing (scTCR-seq), we profiled cerebrospinal fluid (CSF) and blood immune cells of 34 radiologically characterized adults with MS (17 untreated, 6 treated with B-cell-depletion) and 5 healthy controls. Coupled with proteomics, we found PRL-associated enrichment of interferon (IFN) signaling and upregulation of TCR signaling in CSF and blood. This was accompanied by clonal expansion of CD8+ T effector memory (TEM) cells, with the highly expanded clonal cells exhibiting T helper type 1 (TH1)-like and cytotoxic profiles. Validating the cytotoxic immune profile in blood using flow cytometry, we identified a cellular correlate of PRL exhibiting features of CD8+ TEMRA cells. Despite chronic B-cell depletion, PRL-associated neuroinflammation, driven by myeloid activation and CD8+ T-cell cytotoxicity, persisted. Serum and CSF proteomic networks showed PRL-pertinent signatures, including networks unaffected by B-cell depletion. CSF:serum protein ratios revealed compartmentalized myeloid activation in cases with PRL. Using in silico perturbation, we nominated therapeutic targets, including MYD88, TNF, MYC, TYK2, JAK2, and BTK, for alleviating chronic neuroinflammation in MS. Our findings highlight mechanisms of chronic neuroinflammation in MS and point to potential biomarkers for monitoring disease progression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1fa3caa3cc29a10980dc0ec5a031cd39c41d34cf" target='_blank'>
              Maintenance of chronic neuroinflammation in multiple sclerosis via interferon signaling and CD8 T-cell-mediated cytotoxicity
              </a>
            </td>
          <td>
            D. Reich, S. Raza, Yoshimi Enose-Akahata, Anna S Blazier, Lauren M. Guerra, E. Beck, M. Gaitán, Nyater Ngouth, Jefte M. Drijvers, E. Dammer, Devan Moodley, Kory Johnson, Martina Absinta, V. Ramaglia, J. Gommerman, Timothy J. Turner, Richard M. Ransohoff, Steven Jacobson, D. Ofengeim, Ellen Cahir-McFarland
          </td>
          <td>2025-09-25</td>
          <td>Research Square</td>
          <td>0</td>
          <td>50</td>
        </tr>

        <tr id="Among white blood cells (WBCs), neutrophils are the most abundant and multifunctional immune cells in the blood, which are also involved in diverse physiological and pathological processes, particularly affecting the deterioration of the tumor. Neutrophil extracellular traps (NETs), composed of chromatin DNA studded with granule proteins, play a crucial role in reactive sterile inflammation. Recently, neutrophils have garnered focus in cancer research due to their participation in cancer initiation, proliferation and metastasis. As important players in the tumor microenvironment (TME), tumor-associated neutrophils (TANs) are viewed as “a double-edged sword” in cancer pathophysiology.In this review, we introduce the NETs formation and associated signaling pathways. Meanwhile, recent studies on the mechanisms through by which neutrophils could promote tumors development will be described. Additionally, we outline the complex complicated molecular mechanisms underlying cancer therapy resistances and associated preface tumor treatment. Finally, we highlight latest advances in NETs-targeting treatment strategies designed to improve the efficacy of cancer therapies. The oncogenic effect of neutrophils is included. The formation of NETs promotes tumor initiation, metastasis and the therapy resistance of cancer conventional drugs. Almost all signaling pathways associated with NETs have been summarized in tumor progression and metastasis. We comprehensively discussed the important role of neutrophils in the development of cancer and proposed the strategy of reducing NETs formation in the future treatment of cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/efe8918cec0a80e34562dafad728e61b8804c7f1" target='_blank'>
              Neutrophils and neutrophil extracellular traps: double-edged swords in cancer pathophysiology and therapy resistance
              </a>
            </td>
          <td>
            Yao Shen, Huijie Fang, Huiqi Xie, Siqi Zhu, Xiaoqi Wang, Shuang Liu, Jiayu Sui, Yage Xu, Yunfei Bo, Junjie Zhao, Jiaqi Jin, Jingwen Du, Peng Huang
          </td>
          <td>2025-11-03</td>
          <td>Cell Communication and Signaling : CCS</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Dendritic cell-cytokine-induced killer (DC-CIK) therapy faces limitations due to antigenic heterogeneity and suboptimal immune activation. In this study, we developed a multi-antigen-loaded DC-CIK (Ag-DC-CIK) system that co-targets Wilms’ tumor 1 (WT1), mucin-1 (MUC1), and the TLR3 agonist poly(I:C) to improve therapeutic outcomes. Utilizing umbilical cord blood-derived DC and CIK cells, we demonstrated that Ag-DC-CIK significantly enhanced cytotoxicity, as evidenced by the lactate dehydrogenase (LDH) assay, and increased apoptosis induction, indicated by elevated Bax and reduced Bcl-2 expression, in various tumor cell lines (HeLa, HCT116, MKN45) and organoids generated from a gastric cancer patient. Furthermore, Ag-DC-CIK effectively suppressed tumor cell migration and reduced the viability of the organoid. In MKN45 xenograft models, Ag-DC-CIK treatment inhibited tumor growth without inducing systemic toxicity, as shown by decreased Ki67 cell proliferation. This tripartite strategy synergistically enhances DC-CIK therapy by expanding antigen recognition and augmenting immune responses, presenting a promising translational approach for the treatment of gastric cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e318f2131a737b9996c7083d77846317687dd300" target='_blank'>
              Dendritic Cell-Cytokine-Induced Killer Cells Co-Loaded with WT1/MUC1/Poly(I:C) Enhance Antitumor Immune Responses In Vitro and In Vivo
              </a>
            </td>
          <td>
            Huimin Liu, Chenlong Wang, Hongtao Chang, Liangliang Dong, Guoqing Yang, Cailing Tong, Lin Mao
          </td>
          <td>2025-09-24</td>
          <td>Biomolecules</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/670883db43566497565d37fb3fd302bbe45873a6" target='_blank'>
              αGalCer/CD1d treatment induces pro-inflammatory iNKT1-associated immune responses without aggravating doxorubicin-induced cardiotoxicity
              </a>
            </td>
          <td>
            Sarojini Singh, R. H. Nanjundappa, H. Kolla, Deepak S. Chauhan, Aahana Palyada, Prasanna Krishnamurthy, C. S. Umeshappa
          </td>
          <td>2025-09-21</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="
 Diffuse Intrinsic Pontine Glioma (DIPG) is a universally fatal pediatric brain tumor with median survival of less than 12 months. While chimeric antigen receptor (CAR) T-cell therapy shows promise, its efficacy in DIPG is limited by a profoundly immunosuppressive tumor microenvironment (TME). MicroRNAs (miRs), small non-coding RNAs that regulate gene expression, play critical roles in both gliomagenesis and immune regulation. Given their expression in both tumor and immune cells, miRs represent a novel, underexplored strategy to modulate the TME and enhance immunotherapy. We hypothesize that targeting dysregulated miR expression in DIPG can reprogram the TME to support CAR T-cell activation and persistence.To investigate the role of miRs in DIPG, we performed small RNA sequencing on post-mortem DIPG tumors and normal brain tissue. Tumors showed significant dysregulation of multiple miRs, including upregulation of immune-regulatory miR-103a, miR-23c, and miR-361—associated with TGF-β signaling and T-cell exhaustion. Gene Set Enrichment Analysis of miR targets revealed enrichment in immunosuppressive and inflammatory pathways, consistent with a chronically inhibited TME. Bulk RNA sequencing of the same samples confirmed elevated expression of immunosuppressive genes (IL10, FOXP3, PD-L1, CTLA-4). Integrated pathway analysis identified miR–mRNA networks involved in immune evasion and impaired immune cell recruitment.To assess therapy-induced changes in miR expression, we treated glioma-bearing mice with B7-H3 CAR T cells, control CARs, or left them untreated. Tumors harvested at defined timepoints were profiled for miRs. Principal Component Analysis revealed distinct clustering in B7-H3 CAR–treated tumors. Differential expression analysis identified therapy-associated miRs (including miR-344, let-7d, miR-99b, and miR-30c) implicated macrophage polarization and T-cell dysfunction.Together, our data suggests that miRs contribute to DIPG immune suppression and are dynamically regulated by CAR T-cell therapy. Ongoing studies aim to define how targeting specific miRs can enhance CAR T-cell function, offering a new avenue to improve outcomes in DIPG.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1cc42a6eb224fbecda3639ba97bdde9008c36d79" target='_blank'>
              IMMU-66. MicroRNA-Mediated Modulation of the Tumor Microenvironment: Enhancing CAR T-Cell Therapy for Diffuse Intrinsic Pontine Glioma
              </a>
            </td>
          <td>
            Kaleem L Coleman, Ryan Corbett, Bicna Song, J. L. Rokita, Dalia Haydar
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>18</td>
        </tr>

        <tr id="


 Myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) are major negative regulators of anti-tumor immunity. Identifying tumor secreting factors and signaling pathways that enhance their pro-tumorigenic activity could lead to new strategies to enhance immunotherapy efficacy. We have identified tumor-secreted epidermal growth factor-like 6 (EGFL6) as a new mediator of tumor immune suppression. In-vitro and ex-vivo analyses indicated that EGFL6 binds beta integrins to activate spleen tyrosine kinase (SYK) signaling, functioning as (i) a chemotactic factor for myeloid cell migration and (ii) a driver of their differentiation into immunosuppressive phenotypes. In syngeneic mouse models of ovarian cancer, EGFL6 expression promoted intra-tumoral accumulation of MDSCs and TAMs with high SYK, CXCL2, and IL-10 expression. In an immune ‘hot’ tumor model, EGFL6 completely abrogated the response to anti-PD-L1 therapy, whereas Egfl6 neutralization decreased the accumulation of tumor-infiltrating CD206+ TAMs and MDSCs and thereby restored the efficacy of a-PD-L1 therapy. Spatial transcriptomic datasets of human ovarian cancer tissues revealed strong correlation between tumor EGFL6 and myeloid cell SYK expression. Dual immunohistochemistry confirmed increased SYK+ macrophages in ovarian cancer compared to normal ovary. We therefore tested whether SYK inhibition could hinder EGFL6-induced signaling in myeloid cells and reprogram them from an immunosuppressive to an immunostimulatory phenotype. Treatment with the SYK inhibitor fostamatinib (R788) prolonged survival in Egfl6+/- ID8p53-/- tumor-bearing mice, reduced the number of intra-tumoral granulocytic MDSCs, and decreased VEGF, M-CSF, and CXCL5 levels in ascites. scRNA-seq revealed that SYK inhibition depleted specific CCL8+ TAM and CXCL2+ MDSC subsets, induced immunostimulatory myeloid cell populations, and reduced exhausted of TIGIT+CTL4+ CD8 T cells. These findings demonstrate that targeting the EGFL6-SYK axis, via EGFL6 blockade or SYK inhibition, can reprogram the ovarian tumor microenvironment to enhance anti-tumor immunity and restore responsiveness of “cold” tumors to immunotherapy.



 Sandra Cascio. Reprogramming tumor-associated myeloid cells to improve ovarian cancer therapies [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research; 2025 Sep 19-21; Denver, CO. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl):Abstract nr IA014.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/435cc8383bb8db54f60eb41477b03e6ce3d7d946" target='_blank'>
              Abstract IA014: Reprogramming tumor-associated myeloid cells to improve ovarian cancer therapies
              </a>
            </td>
          <td>
            S. Cascio
          </td>
          <td>2025-09-19</td>
          <td>Cancer Research</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="
 Introduction:
 Clonal hematopoiesis of indeterminate potential (CHIP) was recently shown to be an independent risk factor for immune checkpoint inhibitor (ICI)-associated myocarditis. However, the mechanisms by which CHIP may contribute to immune dysregulation in this context remain poorly understood.


 Research Questions:
 How does CHIP contribute to immune dysregulation in cancer patients receiving ICIs, and what cytokine-producing cell types and pathways drive CHIP-associated inflammation?


 Methods:
 To investigate this, we implemented the CellChat framework to single-cell RNA sequencing (scRNA-seq) data in order to infer and compare cell-cell communication networks. We analyzed scRNA-seq data from six post-ICI myocarditis patients, three of whom were CHIP-positive and three CHIP-negative from Yale. Using CellChat, we constructed condition-specific intercellular signaling networks and compared overall signaling activity, communication strength, and pathway usage across groups. We further validated the findings with two other cell-cell interaction analysis tools, DominoSignal and CellPhoneDB.


 Results:
 CHIP-positive samples exhibited a higher number (3440 vs 2466 CHIP vs no CHIP) and strength of ligand-receptor interactions compared to CHIP-negative samples (110 vs 75, CHIP vs no CHIP), indicating globally elevated intercellular signaling (Figure 1). Network and heatmap visualizations revealed increased cell-cell communication in CHIP positive patients compared to CHIP negative patients particularly among immune cell types, including monocytes, platelets, plasmacytoid dendritic cells, and naive B cells.

 Directional analysis showed enhanced outgoing signals from naive B cells and increased incoming signals to macrophages and plasmacytoid dendritic cells in CHIP-positive samples. Of note, increased platelet interactions with native CD4 and CD8 T cells were noted. Pathway-level analysis highlighted upregulation of pro-inflammatory and pro-platelet activation signaling, including TNF, CXCL, CD30, and CD40 (Figure 2).

 Conclusion:
 These findings suggest that CHIP is associated with a pro-inflammatory signaling environment that contributes to ICI myocarditis. These findings support its potential as a biomarker for risk stratification and as a target for pathway-specific anti-inflammatory therapies. For future directions, these results will be validated with external ICI myocarditis cohorts.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ce79ab7aac5ac9c41ed62f0e7b97d0591a2b1d9f" target='_blank'>
              Abstract 4366283: Increased Immune Cell-Cell Communication and Pro-Inflammatory Signaling in Clonal Hematopoiesis of Indeterminate Potential (CHIP)-Positive Peripheral Blood in Immune Checkpoint Inhibitor Myocarditis
              </a>
            </td>
          <td>
            Claire Qu, Nancy Manchanda, Alokkumar Jha, Jennifer Kwan
          </td>
          <td>2025-11-04</td>
          <td>Circulation</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Natural killer (NK) cells can protect from tumor‐transformed cells using a fine‐tuned machinery of activating and inhibiting receptors. An important activating receptor is Fc gamma receptor IIIa (FcγRIIIA or CD16A), which can trigger antibody‐dependent cellular cytotoxicity (ADCC) when recognizing antibody‐opsonized target cells. One strategy to boost ADCC responses may be achieved by inhibiting activation‐induced shedding of CD16A from the NK cell surface. However, previous preclinical studies have shown contrasting results regarding the effectiveness and limitations of this approach. Here, microchip‐based live cell‐imaging was used to assess the consequences of CD16A shedding inhibition on the dynamics of NK cell cytotoxicity. The bispecific innate cell engager acimtamig (AFM13) was superior to IgG1 monoclonal antibodies in ADCC and in increasing the fraction of cytotoxic NK cells and serial killers. Under conditions where CD16A shedding was inhibited, acimtamig still triggered ADCC; however, the ability to promote serial killing was reduced and associated with impaired NK cell detachment from target cells. These results demonstrate that CD16A shedding represents an intrinsic feature of NK cell biology that is critical to sustain the antitumoral cytotoxicity of NK cells. This has implications for CD16A engineering of NK cell products and their combination with CD16A‐directed NK cell engagers.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e3ea234090a8cbfc6704382b70aa73967a09c56d" target='_blank'>
              CD16A Shedding Regulates Innate Cell Engager‐Induced Serial Killing by Natural Killer Cells
              </a>
            </td>
          <td>
            Chiara Zambarda, K. Guldevall, Christian Breunig, Damien Toullec, P. A. Sandoz, V. Carannante, Shanshan Xu, Patrick Ross, Kyra Kuhnigk, Niklas Sandström, Jacopo Fontana, Susanne Wingert, S. Pinto, Julia Knoch, Alamdar Hussain, A. Wagner, J. Pahl, E. Alici, Joachim Koch, Björn Önfelt
          </td>
          <td>2025-10-01</td>
          <td>European Journal of Immunology</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="Immune tolerance in epithelial ovarian cancer (EOC) enables cancer cells to evade immune surveillance. Myeloid-derived suppressor cells (MDSCs), as crucial immunosuppressive regulators, shape the tumor microenvironment and contribute to resistance against immunotherapy. However, the regulatory mechanisms of MDSCs in ovarian cancer remain poorly understood. We examined the presence and distribution of MDSCs in peripheral blood and tumor tissues from EOC patients. Transcriptomic analysis was performed on ovarian cancer cells co-cultured with MDSCs. The role of Serum Amyloid A1 (SAA1) was investigated through in vitro functional assays, co-culture experiments, and in vivo mouse models. MDSCs were enriched in both peripheral blood and tumor tissues of EOC patients. SAA1 was significantly upregulated in ovarian cancer cells after interaction with MDSCs and confirmed in tumor samples and cell lines. Functionally, SAA1 promoted cancer cell proliferation, migration, and invasion. It also recruited MDSCs via TLR2/4, induced the differentiation of granulocyte-monocyte progenitors (GMPs), and stimulated IL-1β secretion, which in turn enhanced SAA1 expression, forming a positive feedback loop. In vivo, SAA1 promoted tumor progression and ascites formation. Clinically, high levels of SAA1, IL-1β, and CD33⁺ MDSCs correlated with poor survival. This study uncovers a novel SAA1–IL-1β feedback loop that promotes immunosuppression and progression in ovarian cancer. These findings provide insight into tumor–immune interactions and suggest a potential biomarker and therapeutic target for EOC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/57a48529273e668adcbf53929e1763b6ce9f687a" target='_blank'>
              Tumor cells promote immunosuppression in ovarian cancer via a positive feedback loop with MDSCs through the SAA1–IL-1β axis
              </a>
            </td>
          <td>
            Haoran Hu, Meiqin Yang, Baoyou Huang, Jianyi Ding, Yashi Zhu, Xinxin Xu, Bo Yin, Huijuan Zhou, Tiefeng Huang, Mengjie Li, Yifan Kou, Zilale Rahim, Ang Li, Wei Wang, Lingfei Han
          </td>
          <td>2025-09-30</td>
          <td>Journal of Experimental & Clinical Cancer Research : CR</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Immunosuppression within the tumor microenvironment (TME) profoundly inhibits anti-tumor immunity, presenting a formidable challenge in cancer therapeutics. Despite this recognized obstacle, multi-targeted immunomodulatory strategies remain elusive. Here we developed a novel mRNA-lipid nanoparticle (LNP) vaccine designed to reprogram key cellular mediators of immune suppression within the TME, including C-C motif chemokine ligand 22 (CCL22), transforming growth factor-β (TGF-β), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), Galectin-3, programmed cell death ligand 1 (PD-L1), indoleamine 2,3-dioxygenase 1 (IDO1), and arginase 1 (ARG1). This immunomodulatory vaccine was evaluated in a cohort of canines with spontaneous neoplasms, encompassing adrenal, hepatic, perianal, vulvar, and pulmonary malignancies. The vaccine demonstrated good tolerability, with only mild adverse events (Grade 1 anorexia, chills, and fatigue) observed in 25% of subjects (2/8). Remarkably, 75% of treated animals (6/8) achieved stable disease, with the median progression-free interval not yet reached a median follow-up of 168 days post-treatment initiation. Two dogs experienced disease progression. The overall disease control rate was 75%. In addition, vaccine administration reversed hematological and biochemical abnormalities and alleviated paraneoplastic syndromes associated with these malignancies. These findings demonstrate that our mRNA-LNP vaccine effectively exerts anti-tumor effects across various cancer types, offering a promising strategy for enhancing anti-tumor immunity in both veterinary and human oncology.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8fef4f03c94eaba07eeff2c05c0e60c396891042" target='_blank'>
              Immunomodulatory vaccine demonstrates therapeutic efficacy across cancer types
              </a>
            </td>
          <td>
            Tiyun Han, Guilai Liu, Chenyi Bao, Jian Zong, Caiyi Fei, Jing Li, Shi Xu, Qingbo Ma, Yingjuan Qian
          </td>
          <td>2025-10-31</td>
          <td>Scientific Reports</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Simple Summary Acute myeloid leukemia remains difficult to treat due to its high relapse rates after standard therapies. T-cell engagers are a promising new approach that redirects the body’s own T cells to attack leukemia cells by binding both T cells and specific markers to AML cells. Targets such as CD33, CD123, and others have been studied. Several TCE formats—including BiTEs and DARTs—are being developed to improve effectiveness and reduce side effects. However, no TCEs in AML have moved beyond early-stage (Phase I/II) clinical trials, mainly due to the lack of an optimal target in AML and safety concerns with immune-related side effects like cytokine release syndrome. This review explores the current progress, key targets, and challenges in developing TCEs for AML treatment. Abstract The treatment of acute myeloid leukemia (AML) remains challenging, largely due to high relapse rates following standard therapies. T-cell engagers (TCEs) offer a promising immunotherapeutic approach by redirecting T cells to recognize and kill AML cells. These therapeutic proteins bind CD3 to T cells and a tumor-associated antigen to AML cells, facilitating targeted immune activation. While CD33 and CD123 are the most commonly targeted AML antigens, others such as CD135, CD38, and CLEC12A/CLL-1 are being evaluated in preclinical and clinical studies. In parallel, various TCE formats—including BiTEs, DuoBodies, DARTs, and DARPin-based constructs—have been developed to optimize pharmacokinetics, stability, and immune engagement. Despite the growing number of TCEs entering clinical evaluation, none have advanced beyond early Phase (I/II) trials, primarily due to the lack of optimal target antigens and challenges in balancing antileukemic activity with the risks of immune-related toxicities such as cytokine release syndrome (CRS). This review aims to summarize the current landscape of TCE development in AML, highlighting key targets, formats, and challenges.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/bac31cf0d00849ef822f10610d70f5922a428ae0" target='_blank'>
              T-Cell Engagers in Acute Myeloid Leukemia: Molecular Targets, Structure, and Therapeutic Challenges
              </a>
            </td>
          <td>
            Hunter Daws, Kate Gallinero, Amanda Singh, Sanela Bilic
          </td>
          <td>2025-10-01</td>
          <td>Cancers</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Human cytomegalovirus (HCMV) establishes lifelong latency following primary infection, residing within myeloid progenitor cells and monocytes. To achieve this, the virus employs multiple immune evasion strategies. It suppresses innate immune signaling by inhibiting Toll-like receptor and cGAS-STING pathways. In addition, the virus suppresses major histocompatibility complex (MHC)-dependent antigen presentation to evade T cell recognition. As the downregulation of MHC molecules may trigger NK cell activation, the virus compensates for this by expressing proteins such as UL40 and IL-10, which engage inhibitory NK cell receptors and block activating signals, thereby suppressing NK cell immune surveillance. Viral proteins like UL36 and UL37 block host cell apoptosis and necroptosis, allowing HCMV to persist undetected and avoid clearance. In settings of profound immunosuppression, such as after allogeneic hematopoietic stem cell transplantation (allo-HSCT) or solid organ transplantation, slow immune reconstitution creates a window for viral reactivation. Likewise, immunosenescence and chronic low-grade inflammation during aging increases the risk of reactivation. Once reactivated, HCMV triggers programmed cell death, releasing viral PAMPs (pathogen-associated molecular patterns) and host-derived DAMPs (damage-associated molecular patterns). This release fuels a potent inflammatory response, promoting further viral reactivation and exacerbating tissue damage, creating a vicious cycle. This cycle of inflammation and reactivation contributes to both transplant-related complications and the decline of antiviral immunity in the elderly. Therefore, understanding the immune regulatory mechanisms that govern the switch from latency to reactivation is critical, especially within the unique immune landscapes of transplantation and aging. Elucidating these pathways is essential for developing strategies to prevent and treat HCMV-related disease in these high-risk populations.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c0c843dc82ca4b27cae84bc783dc80e13ac42440" target='_blank'>
              The Immunoregulatory Mechanisms of Human Cytomegalovirus from Primary Infection to Reactivation
              </a>
            </td>
          <td>
            Xiaodan Liu, Chang Liu, Ting Zhang
          </td>
          <td>2025-10-01</td>
          <td>Pathogens</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Tumor-associated macrophages (TAMs) are a dominant immune component within the glioma microenvironment and are increasingly recognized as key contributors to therapeutic resistance, the major challenge in glioma management. Understanding their role is critical for developing novel therapies. This review synthesizes current knowledge on TAM-mediated chemoresistance in glioma. TAMs originate from bone marrow-derived monocytes and resident microglia, exhibiting significant heterogeneity and plasticity, particularly between pro-inflammatory (M1) and pro-tumorigenic (M2) phenotypes. M2-like TAMs drive resistance through multiple mechanisms: (1) Modulating drug metabolism/clearance (e.g., via CYP450 enzymes and P-glycoprotein); (2) Secreting protumor factors (TNF-α, ILs like IL-4/IL-6/IL-10, chemokines like CCL5/CCL22, growth factors like VEGF/EGF) that activate survival pathways, induce immunosuppression, promote angiogenesis, and enhance epithelial-mesenchymal transition (EMT); (3) Interacting with glioma stem cells (GSCs) to maintain stemness; (4) Facilitating microenvironmental adaptation (e.g., hypoxia/HIF-1α response); (5) Remodeling the extracellular matrix (ECM) via MMPs, increasing stiffness and impairing drug penetration. Targeting TAMs offers promising approaches to overcome resistance. Strategies include: (1) Reprogramming M2 to M1 phenotypes using agonists (TLR, STING, CD40) or inhibitors (STAT3/STAT6); (2) Metabolic modulation (targeting glycolysis, fatty acid oxidation, glutaminolysis); (3) Blocking recruitment axes (CCL2/CCR2, CSF-1/CSF-1R, CXCL12/CXCR4); (4) Depleting M2-TAMs (e.g., trabectedin, CAR-T cells, M2pep-drugs); (5) Enhancing phagocytosis (anti-SIRPα/CD47, anti-SIGLEC). TAMs are pivotal mediators of chemoresistance in glioma through diverse molecular and cellular mechanisms. Targeting TAM recruitment, polarization, function, or metabolism represents a promising therapeutic avenue. However, the complexity of the glioma microenvironment and blood-brain barrier necessitate combination strategies for clinical translation. Further research is needed to optimize specificity and overcome challenges like compensatory pathways and drug delivery.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/af7b44f62f9ab81285800350b0fbea1b42e0f4e9" target='_blank'>
              Advances in tumor-associated macrophage-mediated chemotherapeutic resistance in glioma
              </a>
            </td>
          <td>
            Xuebo Liu, Qi Yu
          </td>
          <td>2025-09-26</td>
          <td>Frontiers in Cell and Developmental Biology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Neutrophil extracellular traps (NETs) are chromatin-based structures containing histones and granular proteases released during NETosis. They constitute a key antimicrobial defense mechanism while exposing pathogenic histones. While NET components effectively eliminate microorganisms, their pro-inflammatory and cytotoxic properties inflict significant damage on host endothelial cells and tissues. This damage contributes to diverse pathologies, including autoimmune diseases where NET-derived components act as autoantigens, as well as circulatory disorders, diabetes, and especially, cancer. Recent research has increasingly illuminated the critical connection between NETs and cancer progression, highlighting their role in promoting tumor development across all stages through inflammation and tissue injury. Consequently, targeting NET composition, formation, or release has emerged as a promising therapeutic strategy. These approaches effectively mitigate NET-mediated pathogenesis while circumventing the drawbacks of direct neutrophil depletion. Although translating these strategies into widespread clinical practice presents challenges, experimental studies demonstrate significant potential. This review examines the mechanisms by which NETs drive cancer, explores current therapeutic applications targeting NETs, and discusses both the prospects and challenges of this evolving anticancer approach.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cb6565abdf2b0ded2f30b2f8154776944adaf1ba" target='_blank'>
              Advances in the mechanism and therapeutic potential of neutrophil extracellular traps in cancer promotion
              </a>
            </td>
          <td>
            Xiaorui Li, Huilin Wang, Jingchang Li, Chuangchuang Li, Shuo Zhao, Qing Wang, Weihong Ren
          </td>
          <td>2025-09-22</td>
          <td>Frontiers in Oncology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Immunotherapies, including chimeric antigen receptor T-cell (CAR-T) therapy, represent a pivotal approach in the treatment of multiple myeloma (MM). However, the complex immunosuppressive tumor microenvironment (TME) poses significant challenges to their efficacy. Among the immunosuppressive cells in the MM TME, granulocytic myeloid-derived suppressor cells (G-MDSCs) are predominant; however, their functions remain incompletely understood. In this study, a comprehensive analysis of G-MDSCs was conducted using single-cell transcriptomic data from 7 MM patients before and post CAR-T therapy. Given the limited sample size and inter-patient heterogeneity, the findings should be regarded as exploratory and hypothesis-generating. The pathological activation and immunosuppressive roles of G-MDSCs were suggested to be potentially linked to patient prognosis. Functional enrichment analysis revealed that G-MDSCs are key modulators of immune responses within the TME. GSEA analysis suggested that G-MDSCs may regulate immune responses via the IFN-α/γ signaling pathway. Furthermore, G-MDSCs may facilitate immune evasion of MM cells by promoting cell proliferation through the IGF1-IGF1R axis and inhibiting T cells and other immune cells via the SIRPA-CD47 pathway. A risk prediction model based on G-MDSC gene signatures was constructed using RNA-seq and survival data from 713 MM patients, demonstrating high prognostic accuracy (AUC = 0.94) and validated by Kaplan-Meier analysis. Additionally, PTGS1 was identified as a key marker associated with high-risk groups, suggesting its potential as a therapeutic adjunct target to improve CAR-T treatment outcomes. Further in vitro experiments demonstrated that G-MDSCs may exert immunosuppressive functions through PTGS1 expression. Taken together, this study provides preliminary insights into the role of G-MDSCs in the MM TME and highlights potential therapeutic strategies to enhance CAR-T therapy efficacy, while acknowledging that larger and more diverse cohorts are required to substantiate these observations.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0e8ff33894cad405d661ae879b8aae448cec342e" target='_blank'>
              Functional Role of Granulocytic Myeloid-Derived Suppressor Cells in CAR-T Therapy: Insights from Single-Cell RNA Sequencing in Multiple Myeloma.
              </a>
            </td>
          <td>
            Chaoyu Zhang, Fang An
          </td>
          <td>2025-11-06</td>
          <td>Immunopharmacology and immunotoxicology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Simple Summary Chimeric Antigen Receptor (CAR)-T cell therapy has shown significant success in treating hematological cancers, but commercialized autologous CAR-T therapies face challenges such as high costs, manufacturing delays, complex standardization and the risk of tumor relapses due to single-antigen targeting. To address these issues, a novel allogeneic CAR-T therapy with broader target specificity was developed, optimizing its manufacturing process. Using CRISPR/Cas9, TCR and HLA class I complex expression were eliminated from donor T cells to reduce the risk of immune rejection and graft-versus-host disease. Additionally, NKG2D CAR, targeting eight ligands upregulated in both solid and hematological tumors, was lentivirally transduced. This study optimized CAR-T cell manufacture by testing various interleukin supplements (IL-2, IL-7/IL-15, IL-7/IL-15/IL-21). Results showed that IL-7/IL-15/IL-21 supplementation produced CAR-T cells with the most suitable characteristics in terms of genetic modification efficiency, cell proliferation, antitumor activity and memory profile. This new allogeneic NKG2D CAR-T therapy represents a promising universal treatment for a variety of cancers.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c8e4e75f43da33ddda8e85ac431c369c654f5ec0" target='_blank'>
              A Novel Early Memory-Enriched Allogeneic NKG2D CAR-T Cell Therapy Based on CRISPR/Cas9 Technology for Solid Tumors
              </a>
            </td>
          <td>
            C. Aparicio, Mónica Queipo, Marina Belver, Francisco Espeso, Julia Serna-Pérez, Lucía Enríquez-Rodríguez, Carlos Acebal, Álvaro Martín-Muñoz, A. Valeri, A. Leivas, Paula Río, Daniel J. Powell, Rosa Lobo-Valentín, David Arrabal, Joaquín Martínez-López, Ana Sánchez, Miguel Á. de la Fuente, Margarita González-Vallinas
          </td>
          <td>2025-09-30</td>
          <td>Cancers</td>
          <td>0</td>
          <td>18</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7b57751aab36ac04e8a63eba67519430470275ce" target='_blank'>
              Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial
              </a>
            </td>
          <td>
            Jingjing Feng, Dawei Huo, Ruimin Hong, Xuexiao Jin, H. Cao, Mi Shao, Rui Wen, Qiqi Zhang, Mingming Zhang, Shan Fu, Dongrui Wang, Huijun Xu, Guoqing Wei, Jiazhen Cui, Simao Huang, Dawei Cui, A. Chang, Zhihong Liu, Linrong Lu, Jin Lin, Yong-xian Hu, He Huang
          </td>
          <td>2025-09-24</td>
          <td>Nature Medicine</td>
          <td>2</td>
          <td>33</td>
        </tr>

        <tr id="


 Extracellular vesicles (EVs) have emerged as critical mediators of immune processes. However, the involvement of immunocytes derived EVs in the pathogenesis of acute kidney injury (AKI) remains largely unclear. This study aims to profile EV subpopulations constituting the renal microenvironment via single EV analysis to delineate the role of critical immunocytes derived EVs in AKI.



 Single-vesicle proteomic analysis using a proximity barcoding assay (PBA) was applied to characterize renal EVs in a murine ischemia-reperfusion injury (IRI) model (35 minutes of unilateral ischemia, sacrifice after 1 day). Surface proteomics of individual EV were captured using DNA-labeled antibody conjugates, converting protein expression into unique DNA barcodes (Fig. 1). Differential proteomic and enrichment analyses revealed distinct EV subpopulations with specialized functions, validated through Western blotting, nanoparticle flow cytometry, and immunohistochemistry. Functional characterization of the most prominent EV subset was performed via immunomagnetic isolation, co-culture assays, flow cytometry, ELISA, and a reporter mouse model, which enabled in vivo EV tracking and elucidated their roles in AKI.



 Using cell-specific markers, we traced the origins of EVs in the IRI microenvironment and identified increasing immunocytes derived EVs, predominantly from M1 macrophages, followed by dendritic cells, neutrophils, T cells, and B cells. Tubular epithelial and endothelial cells were the primary sources of EVs among renal parenchymal cells. Matrix analysis revealed eight major EV subpopulations, with ITGAM/HAVCR1-dominant EVs being the most abundant (33.63%). Proteomic analysis uncovered 14 upregulated proteins, with ITGAM emerging as the key protein which linked to T cell cytotoxicity, leukocyte-mediated cytotoxicity, antigen presentation, and positive regulation of immune responses. These findings highlight the potential role of EV subset derived from ITGAM+ innaute immune cells.
 ITGAM+ EVs was then purified with immunomagnetic bead isolation which was consequently characterized with nanoscale flow cytometry, identifying macrophages (F4/80+, 60.82%), neutrophils (Ly6G+, 55.64%), and dendritic cells (CD11c+, 34.24%) as primary sources from innate immunocytes. Functional assays demonstrated that IRI kidney-derived ITGAM+ EVs enhanced CD8+ T cell proliferation, with increasing TNF-α and IFN-γ secretion and reduction of IL-10.
 Proteomic analysis revealed S100A9 as remarkably upregulated in IRI-derived ITGAM+ EVs, with immunoelectron microscopy confirming its surface localization. Blockade of S100A9 suppressed TNF-α and IFN-γ cytokine secretion. Interestingly, stimulation with ITGAM+EVs induced a significant upregulation of IFN-γ expression in CD8+ T cells compared to recombinant S100A9 protein. Using an IRI model with ITGAM-CD63-PA-GFP transgenic mice, we observed increased secretion of ITGAM+ PA-GFP+EVs colocalized with CD8+ T cells in renal lymphatic vessels, with augmented renal inflammation and CD8+ T cell activation after AKI.



 This study profiled immune microenvironment constituted with immunocytes derived EV via single EV analysis in AKI. ITGAM+ EVs derived from immunocytes promoted CD8T cell activation through the membrane protein S100A9, providing new insights into the immune process of AKI.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7836316ffafd26513e5a286f62a65a568f74c2b0" target='_blank'>
              #2210 Extracellular vesicles derived from ITGAM + innate immune cells augmented renal inflammation via activating CD8+ T cells in acute kidney injury
              </a>
            </td>
          <td>
            Yuqi Fu, Anran Shen, Yan Bao, Tao-Tao Tang, Bicheng Liu, Linli Lv
          </td>
          <td>2025-10-01</td>
          <td>Nephrology Dialysis Transplantation</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Abstract Background Dual immune checkpoint blockade (IO/IO) has significantly improved overall survival in renal cell carcinoma (RCC), but only ∼50% of patients initially respond to treatment. Understanding the mechanisms underlying primary response and resistance is critical to improving therapeutic outcomes. Methods We developed a novel mouse model of sarcomatoid RCC (sRCC) by targeting Vhl, Bap1, and Cdkn2a/b, recapitulating the genomic and histological features and tumor microenvironment of human sRCC. Mice were treated with anti-CTLA-4 antibody. Tumor-infiltrating immune populations were analyzed using single-cell RNA sequencing and flow cytometry to evaluate T cell subsets and cytotoxic function. Results Anti-CTLA-4 treatment led to Treg depletion and an increase in activated Th1 cells. Importantly, only responder mice exhibited a selective expansion of TCF1+ CD4+ T cells. This was accompanied by increased granzyme B and perforin expression in effector CD8+ T cells, indicating enhanced cytotoxic activity. In contrast, non-responder mice lacked this TCF1+ CD4+ population and associated cytotoxic CD8+ responses. Conclusions Our findings reveal that Treg-depleting anti-CTLA-4 therapy promotes anti-tumor immunity by expanding a TCF1+ CD4+ T cell population that orchestrates CD8+ T cell responses. This mechanism offers a novel insight into immune modulation in sRCC and identifies a potential target to improve immunotherapy efficacy in RCC patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3aa635a80718bf4810ef5e37204ff599497c31dc" target='_blank'>
              47TCF1+ CD4+ T cells mediate response to anti-CTLA-4 therapy in a sarcomatoid RCC mouse model
              </a>
            </td>
          <td>
            Hui Jiang, Lynda Vuong, F. Kuo, Doris Zheng, Alex Penson, Jing Zhang, Shengyu Gao, Ankur Mascareno, Yingbei Chen, Yash S. Khandwala, Daniel Barbakoff, Andrea Lopez Sanmiguel, G. Luca Gusella, Ming Li, A. Hakimi
          </td>
          <td>2025-10-01</td>
          <td>The Oncologist</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="
 While therapies targeting T cell immune checkpoint receptors have demonstrated clinical efficacy for patients with brain metastases, adults with high-grade gliomas fail to benefit. We comprehensively profiled intratumoral and circulating T cells in patients with untreated brain tumors to identify immunological features which may account for this discrepancy. Tumor and blood samples were collected from 22 patients with newly diagnosed brain tumors (12 high-grade glioma and 10 brain metastases from non-small cell lung cancer [NSCLC]). We performed paired single-cell RNA and T cell receptor (TCR) sequencing and multiplexed flow cytometry to deeply profile intratumoral and circulating T cells. We used a high-throughput T cell antigen identification method to screen intratumoral TCRs against 3,726 putative neoantigens and 146 tumor-associated antigens. Publicly available bulk RNA sequencing datasets were analyzed for biomarker validation. In total, we examined 159,043 high-quality T cells. Tumor-infiltrating T cells in metastases were more abundant, more clonally expanded, and had a less diverse clonal repertoire. While circulating effector memory CD8+ T cells were differentially abundant in patients with brain metastases, no differences in the composition of CD8+ T cell subsets were observed in the tumor. In contrast, a clonally expanded, tumor-enriched population of CXCL13+CD4+ T cells were differentially abundant in metastases. CXCL13+CD4+ T cells highly expressed co-inhibitory receptors, effector cytokines, and interferon-stimulated genes. Of 44 TCRs derived from CXCL13+CD4+ T cells screened, 27.3% were reactive against tumor antigens (10 neoantigens and 2 tumor-associated antigens). Higher expression of the CXCL13+CD4+ T cell signature correlated with improved overall survival in NSCLC patients treated with immune checkpoint therapy. In summary, our study highlights distinct differences in both local and systemic adaptive immunity in patients with newly diagnosed brain tumors and identifies tumor antigen-reactive CD4+ T cells in immunogenic metastases as a potential predictive biomarker for immune checkpoint therapy response.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f69372ca124f13ed9d4da03e1122c759118d8b47" target='_blank'>
              IMMU-85. Uncovering differences in local and systemic immunity in human primary and metastatic brain tumors
              </a>
            </td>
          <td>
            Benjamin Lu, Berkay Yahsi, Liliana E. Lucca, Marcello DiStasio, Yang Liu, Jianlei Gu, Sagar Bhata, Mithila Kasbe, Jack Coburn, Anna Arnal-Estapé, Hongyu Zhao, Jennifer Moliterno, Veronica Chiang, A. Omuro, Mark Lee, David Hafler
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="Solid tumors often suppress antitumor immune responses by promoting various dysfunctional CD8+ T cell states, which limit the effectiveness of T-cell-based immunotherapy. However, the mechanisms that promote these states have not been fully characterized. It is demonstrated that spontaneous priming responses during tumor growth can produce memory T cell reservoirs that are conducive to poor proliferative responsiveness during boosting vaccination. Surprisingly, when type I interferon (IFN-I) signaling is impeded, boosting vaccination can elicit robust proliferative responses from tumor-primed memory T cells and promote tumor control. This is observed in multiple tumor types and target antigens. In contrast to conventional memory T cells, tumor-primed memory T cells are unique in their pre-encoded responsiveness to IFN-I and show enrichment of pathways pertaining to DNA repair and cell cycle arrest. Tumor-primed memory T cells up-regulate p21 expression and blockade of either p21 or IFN-I can alleviate this effect to improve their proliferative capacity during boosting vaccination. Characterization of tumor-primed memory T cells revealed transcriptional and phenotypic features of cellular senescence, where higher senescence severity correlated with higher responsiveness to IFNα/β receptor blockade. Overall, IFN-I hyperresponsiveness may be a unique feature of senescent tumor-primed memory T cells that can exacerbate their dysfunction during cancer vaccination.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8cb2455df0fef81e7cabdf5fd3952e0ae44f71bd" target='_blank'>
              Pre-Encoded IFN-I Sensitivity Exacerbates Memory T Cell Senescence in Solid Tumors.
              </a>
            </td>
          <td>
            Andrew Nguyen, Scott R Walsh, Li Deng, Lan Chen, Yonghong Wan
          </td>
          <td>2025-10-05</td>
          <td>Advanced science</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="


 Despite recent advances in triple-negative breast cancer (TNBC) biology and new therapies, this aggressive subtype remains difficult to treat. A key obstacle is the immunosuppressive tumor microenvironment (TME), often dominated by myeloid cells that impair anti-tumor immunity. Radiation therapy (RT), used as an in-situ vaccine, enhances tumor immunogenicity and has shown promise when combined with immune checkpoint blockade (ICB) in preclinical and clinical settings1-3. We previously found that combining RT with CTLA-4 blockade and a CD40 agonist antibody (CD40a), which activates myeloid cells, led to profound tumor regression and occasional complete responses in a rapidly metastasizing TNBC mouse model4. However, CD40a did not improve control of lung metastases beyond that achieved with RT and CTLA-4 blockade. In tumors, CD40a induced remodeling of dendritic cell and macrophage populations, along with enrichment in B cell–associated gene signatures. As CD40 signaling can promote either effector or regulatory B cell responses depending on context5, we hypothesized that triple therapy induces organ-specific B cell differentiation that may hinder systemic immune control. We first assessed systemic versus local effects of CD40a on B cells in naïve and tumor-bearing (4T1) mice. In both settings, CD40a expanded splenic B cells and increased MHC-II+ expression. In lungs, tumor implantation alone led to increased B cell infiltration, even without CD40a. However, these lung B cells showed reduced activation in untreated tumor-bearing mice, only partially restored by CD40a, suggesting a distinct, potentially immunosuppressive phenotype. To evaluate this in the context of RT + CTLA-4 blockade + CD40a, we analyzed B cells from lungs and tumors via multiparametric flow cytometry and observed that CD40a consistently shifted B cell profiles across compartments. Among B cells, we identified regulatory B cells (Breg) as expressing TIM1, CD138, CD5, CD39, and FasL. CD40a decreased Breg infiltration in tumors but significantly increased it in lungs. In both tissues, Breg marker expression correlated with tumor or lung burden. Given TIM1’s role in IL-10–producing Bregs—and its capacity to suppress T cells independently of IL-10—6-8 we tested a TIM1-blocking antibody in combination with RT + CTLA-4 blockade + CD40a. While TIM1 blockade did not enhance tumor control, it markedly reduced lung Bregs. Our data highlight organ-specific B cell responses following CD40a-based immunotherapy and suggest that lung-resident Bregs may limit systemic immune efficacy. Ongoing work focuses on defining mechanisms of Breg-mediated suppression and, in collaboration with bioengineers, on developing intra-tumoral delivery strategies to reduce systemic immunosuppressive effects of agents like CD40a. 1-PMID: 29180535 2-PMID: 33476307 3-PMID: 30397353 4-PMID: 37620372 5-PMID: 19265127 6-PMID: 25582854 7-PMID: 31511630 8-PMID: 31685302



 Maud Charpentier, David Sprott, Sandra Demaria. Tissue-Specific B Cell Differentiation Limits Anti-Tumor Efficacy of Radiation and Immunotherapy [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity; 2025 Sep 24-27; Montreal, QC, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2025;13(9 Suppl):Abstract nr B007.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0c36421ca4c9e00ab71754a147fca0a0213794c4" target='_blank'>
              Abstract B007: Tissue-Specific B Cell Differentiation Limits Anti-Tumor Efficacy of Radiation and Immunotherapy
              </a>
            </td>
          <td>
            M. Charpentier, David Sprott, Sandra Demaria
          </td>
          <td>2025-09-24</td>
          <td>Cancer Immunology Research</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/476c643da3b7bab359ba00f9ad0d1145a5743d99" target='_blank'>
              Mycobacterium tuberculosis-derived linoleic acid increases regulatory T cell function to promote bacterial survival within macrophages
              </a>
            </td>
          <td>
            Hongyu Cheng, Shenzhi Li, Hongjie Liu, Meiyi Yan, Jingxiang Wang, Jingping Huang, Shanshan Liu, Yifan Yang, Xinyu Cao, Pengfei Cui, Yuanna Cheng, Zhonghua Liu, Jie Wang, Xiaocheng Huang, Lin Wang, Lianhua Qin, Ruijuan Zheng, Carl G Feng, Qiang Zou, Yicheng Sun, Zhe Ji, Hua Yang, Baoxue Ge
          </td>
          <td>2025-10-10</td>
          <td>Nature Microbiology</td>
          <td>0</td>
          <td>33</td>
        </tr>

        <tr id="Background Chimeric antigen receptor T cell (CAR-T) therapy targeting cluster of differentiation 19 (CD19) has shown promise in treating B-cell acute lymphoblastic leukemia (B-ALL), but the long-term efficacy of CD19-targeted CAR-T therapy remains limited. Programmed cell death protein 1 (PD-1), an inhibitory receptor on activated T cells, engages programmed death ligand 1 (PD-L1) in the tumor microenvironment, suppressing CAR-T cell function by impairing key signaling pathways. To address this limitation, we investigated the effect of short hairpin RNA (shRNA)-mediated PD-1 knockdown on alleviating CAR-T cell exhaustion, preserving memory phenotype, and enhancing the long-term efficacy of CD19-targeted CAR-T cells. Methods To overcome this limitation, we employed shRNA to achieve PD-1 knockdown in CD19-targeting CAR-T cells. Following screening multiple shRNA candidates, we assessed the cytotoxicity, cytokine secretion, and proliferation of PD-1 knockdown CAR-T cells. Their memory phenotype, exhaustion marker, and cytolytic function were further evaluated after repeated antigen stimulation. Therapeutic efficacy and safety were validated in NOD.Cg-PrkdCscid Il2rgtm1/Vst (NPG) mice. Results PD-1 knockdown significantly enhanced CAR-T cell cytotoxicity and persistence against PD-L1+ RAJI (human Burkitt’s lymphoma cell line) cells. After three rounds of antigen stimulation, PD-1 knockdown CAR-T cells sustained cytotoxic activity, retained a memory-like phenotype, and displayed attenuated exhaustion markers. In vivo, they prolonged survival without inducing cytokine release syndrome (CRS), indicating improved efficacy and safety. Conclusions PD-1 knockdown mitigates tumor-induced T-cell exhaustion and represents a promising strategy to enhance the durability and potency of CAR-T cell therapy in cancer treatment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7328d5fdc7d923649d26fe2e8b57365952938c16" target='_blank'>
              shRNA-based PD-1 suppression preserves memory phenotype and function of CD19-targeted CAR-T cell
              </a>
            </td>
          <td>
            Jiaxuan Zhao, Han Wu, Zhe Sun, Yeting Cui, Nan Liu, Yixuan Wang, Youyong Wang, Jiangzhou Shi, Tongcun Zhang
          </td>
          <td>2025-10-01</td>
          <td>Translational Cancer Research</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Age-related accumulation of somatic mutations in hematopoietic stem and progenitor cells (HSPCs), causing clonal hematopoiesis (CH), often precedes the development of hematologic malignancies. Chronic inflammation and aberrant cytokine expression that are common in aging, contribute to clonal expansion and genomic instability. Acute myeloid leukemia (AML) is an (epi)genetically and physiologically diverse malignancy, characterized by clonal proliferation and incomplete differentiation of HSPCs. The innate immune system, with pattern recognition receptors (PRRs), plays a pivotal role in maintaining hematopoietic homeostasis. Dysregulated signaling through PRRs disrupts hematopoiesis, fostering malignant cell proliferation. In addition, cytokines and interferons exert multifaceted effects on HSPCs, impacting their proliferation, differentiation, and survival. Therapeutic approaches targeting innate immune pathways, offer promising avenues for treating hematologic malignancies. Understanding the intricate crosstalk between innate immunity and hematopoiesis would provide insights into novel therapeutic strategies for combating hematologic malignancies, offering hope for improved patient outcomes and survival. In this review, we discuss about the malfunctioning innate immune-inflammatory axes in the context of abnormal hematopoiesis and the therapeutic approaches that are utilizing/targeting these pathways with efficacy. This review delves into the derangements of innate immune and inflammatory pathways implicated in the development of AML and myelodysplastic syndromes (MDS), shedding light on the therapeutic strategies targeting these pathways.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/dde18cfb4c76b3db17292e304b00038b9b81709c" target='_blank'>
              Innate immune-inflammatory signaling milieu in myeloid leukemia and aging-associated clonal hematopoiesis pathologies
              </a>
            </td>
          <td>
            Satyaki Bhowmik, A. Bose, A. Sengupta
          </td>
          <td>2025-10-16</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="


 Ovarian cancer remains the most lethal gynecologic malignancy and a leading cause of cancer-related deaths among women. Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TILs) has shown success in melanoma and correlates with survival in ovarian cancer. However, its application remains limited, partly due to inefficient expansion of functional, tumor-specific T cells.



 We developed a novel ex vivo expansion platform for ovarian TILs, integrating metabolic and phenotypic reprogramming with selective enrichment for tumor-reactive populations. Tissue from nine patients with stage III/IV high-grade epithelial ovarian carcinoma was collected for banking, NGS, and TIL expansion. Four had matched TILs expanded pre- and post-neoadjuvant chemotherapy. The initial priming phase employed our published cytokine cocktail designed to induce Th1/17 and Th17/Tc17 polarization, to promote effector differentiation while preserving stemness. TILs were cultured for five days in this cocktail to enhance metabolic fitness and anti-tumor potential. CD137+ (4-1BB+) T cells were isolated based on activation-induced co-stimulatory expression and subjected to rapid expansion using a G-Rex-based bioreactor system with irradiated feeder cells, anti-CD3, and low-dose IL-2. Expanded TILs were characterized by multicolor flow cytometry, CD107a degranulation, IFN-γ ELISA, and single-cell RNA sequencing (scRNA-seq), and benchmarked against TILs expanded using the conventional protocol from NCI.



 Our approach reliably produced 15–20 billion viable TILs per patient within 30 days, achieving >95% viability and ∼2500-fold expansion. CD137+ enrichment enhanced tumor reactivity, as shown by increased IFN-γ secretion and degranulation with autologous tumor and high-grade serous ovarian cancer cell lines. scRNA-seq revealed enriched cytotoxic CD8+ T cells and mucosal-associated invariant T (MAIT) cells, with reduced FOXP3+ regulatory and non-cytotoxic CD4+ subsets, compared to TILs from matched blood, tumor, and those expanded with high-dose IL-2 in the NCI protocol. CD8+ proliferative and cytotoxic T cell subsets were enriched under the hybrid CD137-sorted protocol. Transcriptomic profiling showed that CD8+ proliferating T cells from the hybrid group downregulated key metabolic genes, including SLC7A5 and LDHB, suggesting a rewired metabolic state that may support persistence. Similarly, CD8+ cytotoxic T cells showed chromatin remodeling, with upregulation of histone demethylases KDM5A and KDM7A, and downregulation of CHD7 and JARID2, indicating transcriptional plasticity. MAIT cells also showed increased activation markers (IFNG, CCL20). Expanded TILs exhibited reduced expression of exhaustion markers PD-1 and CD38 at the protein level.



 Metabolic reprogramming combined with CD137-based enrichment enables robust expansion of metabolically reprogrammed, tumor-specific TILs from ovarian tumors. This strategy offers a promising foundation for advancing TIL-based ACT in ovarian cancer.



 Paramita Chakraborty, Stephanie Mills, Jadan Zavestoski, Satyajit Das, Suganya Subramanian, Nicolina Mascia, Jian Liu, Stefano Berto, Brian Orr, Shikhar Mehrotra, Stephanie Mills. Metabolic reprogramming of ovarian CD137+ TILs for treatment [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research; 2025 Sep 19-21; Denver, CO. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl):Abstract nr PR006.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2b37662ad71037e3dead97ad855c982dd8d046b2" target='_blank'>
              Abstract PR006: Metabolic reprogramming of ovarian CD137+ TILs for treatment
              </a>
            </td>
          <td>
            Paramita Chakraborty, Stephanie Mills, Jadan Zavestoski, Satyajit Das, S. Subramanian, Nicolina Mascia, Jian Liu, S. Berto, Brian Orr, Shikhar Mehrotra
          </td>
          <td>2025-09-19</td>
          <td>Cancer Research</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Head and neck squamous cell carcinoma (HNSCC) demonstrates suboptimal responses to current immune checkpoint inhibitors (ICIs), with objective response rates (ORRs) of merely 15-20%. The molecular mechanisms underlying these low ORRs remain incompletely defined. Here, two functionally distinct CD8⁺ T cell subsets are identified within the tumor microenvironment: precursor exhausted T (Texprog) cells and terminally exhausted T (Texterm) cells. Notably, although anti-PD-1 therapy reduced Texprog cell frequencies, it failed to reverse Texterm cells. Elevated Texterm cell infiltration correlated with advanced tumor-node-metastasis (TNM) staging and poor prognosis. Furthermore, non-responders exhibited significantly higher baseline Texterm proportions than responders before immunotherapy. Multivariate analysis established stromal Texterm cell density as both an independent prognostic factor and predictor of ICIs resistance. Mechanistically, Texterm cell infiltration strongly correlated with PD-L1 on tumor-derived extracellular vesicles (PD-L1+EVs). Most importantly, it is demonstrated that PD-L1+EVs drive Texterm cell differentiation by upregulating the basic leucine zipper transcription factor, ATF-like (BATF) in CD8⁺ T cells. Knocking out PD-L1 on EVs reduced Texterm cell infiltration and BATF expression. These findings elucidate an EV-mediated immune evasion axis and reveal actionable targets to overcome immunotherapy resistance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/42352676b8e9a00dc96bbc51d7f6504730603946" target='_blank'>
              PD-L1 on Tumor-Derived Extracellular Vesicles Induces CD8+ T Cell Terminal Exhaustion and Mediates Anti-PD-1 Resistance in Head and Neck Squamous Cell Carcinoma.
              </a>
            </td>
          <td>
            Ruihua Fang, B. Huang, Yun Li, Zhimou Cai, Yicheng Deng, Xiaoqing Cen, Wei Sun, Jinhong Zhang, Zhenglin Xu, Wenbin Guo, Yi Lyu, Shiyun Luo, Zhesheng Chen, Kexing Lyu, Weiping Wen, W. Lei
          </td>
          <td>2025-11-05</td>
          <td>Advanced science</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="
 Glioblastoma (GBM) is a highly treatment-resistant malignancy characterized by its poor prognosis and intrinsic resistance to therapy, driven largely by glioblastoma stem cells (GSCs) and an immunosuppressive tumor microenvironment (TME). This dual resistance plays a significant role in the failure of current treatment strategies. Consequently, there is an urgent need for novel therapeutic approaches that can effectively target GSCs while simultaneously reshaping the TME to promote anti-tumor immunity. In this study, we investigated the dual therapeutic potential of Xevinapant, a lead SMAC mimetic, through a combination of in vitro, in vivo, and single-cell transcriptomic analyses. We found that Xevinapant demonstrated potent anti-tumor activity through inducing dose-dependent apoptosis and significantly reduced cell viability in both human and mouse GSCs. In vivo administration of Xevinapant led to significant tumor suppression and extended overall survival in orthotopic models. Notably, our single-cell RNA sequencing result revealed that Xevinapant activated immune effector cell responses, contributing to the reprogramming of the immunosuppressive TME. Immune cell activation (both lymphoid and myeloid lineages) was further validated by flow cytometry using tumor-derived cells. To overcome potential therapeutic resistance, we derived Xevinapant-specific gene expression signatures and queried the LINCS database to identify small molecules with synergistic effects. Our analysis identified a promising compound ST-059620 that, when used in combination with Xevinapant, enhanced therapeutic efficacy and overcame resistance. Taken together, our findings highlight the dual mechanism of action of Xevinapant in targeting both tumor-intrinsic and microenvironmental resistance mechanisms. These results support the continued clinical development of Xevinapant and provide a strong rationale for combination strategies aimed at improving treatment efficacy in GBM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/14a501e3f81b4b4d8beaca0ed97f02367fa8f4c1" target='_blank'>
              TMIC-25. SMAC Mimetic Targets Glioblastoma Stem Cells and Reprograms the Associated Tumor Microenvironment
              </a>
            </td>
          <td>
            Qiong Wu, Jianan Chen, Anders E. Berglund, Dongliang Du, Robert Macaulay, Arnold B Etame
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Cryptococcal meningitis is a fungal infection in patients with compromised CD4 T cell function. CD4 T cells provide killing signals to macrophages, principally IFNγ, to limit intracellular fungal replication. However, CD4 T cells may also drive inflammatory tissue damage. Yet, it is not fully understood how fungal-specific CD4 T cells infiltrate the brain and how they influence functional phenotypes of CNS-resident myeloid cells. In the current work, we develop a mouse model to track fungal-specific CD4 T cells and determine their influence on microglia. We found IFNγ+ fungal-specific CD4 T cells have limited TCR signalling and characterise a population of inflammatory microglia that upregulate MHCII and IFNγ-regulated genes during infection. Inflammatory microglia have poor fungicidal capacity and significantly expand during infection, a process that depends on CD4 T cell infiltration. Taken together, these data identify the early inflammatory consequences of fungal-specific CD4 T cell infiltration and identify proliferating microglia as important drivers of brain inflammation during infection. Cryptococcal meningitis is a common infection in patients with compromised CD4 T cell function. Using a CD4 T cell activation tracking mouse the authors show the localisation and activation of CD4 T cells in the brain after cryptococcus infection and how these cells interact with MHCII expressing microglia which may increase pathologic brain inflammation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/37f4633c141c3226368499b170bc53f8df43b779" target='_blank'>
              Brain-infiltrating CD4 T cells drive inflammatory microglia proliferation during cryptococcal meningitis in mice
              </a>
            </td>
          <td>
            Sofia Hain, Man Shun Fu, Lucy Wigg, Lorna S. George, D. Lecky, Alexander J Whitehead, Erin Clipston, Ko Sato, Masahiro Ono, Marcel Wuthrich, Bruce Klein, Kazuyoshi Kawakami, J. Rayes, D. Bending, Rebecca A. Drummond
          </td>
          <td>2025-10-09</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="Immunotherapy remains ineffective in many solid tumors due to poor T-cell infiltration and a metabolically suppressive tumor microenvironment. A dual strategy combining low-level light (LLL) therapy with a nanoscale stimulator of interferon genes (STING) agonist formulation (nanoSTING@Mn) is presented to enhance immune activation and metabolic fitness for durable tumor immunity against T-cell lymphoma (EL4) model. NanoSTING@Mn, composed of ADU-S100 complexed with Mn2⁺ and encapsulated in biomimetic liposomes, potently activates the cGAS-STING pathway, induces a type I interferon response, and promotes lymphocyte infiltration. These monocytes polarize into M1 macrophages, suppressing regulatory T cells. Simultaneously, LLL photo-biomodulation reprograms mitochondrial metabolism in tumor-infiltrating CD8⁺ T and natural killer cells, restoring their durability and leading to complete local tumor eradication. This combination expands a distinct CD8⁺ T-cell subset with Tcf-1⁺ progenitor-exhausted features and elevated memory/effector gene expression, enhancing proliferation and cytotoxicity, as shown by single-cell RNA sequencing. Intranasal nanoSTING@Mn delivery mobilizes these LLL-revived T cells to the lung, where they differentiate into resident memory T cells and establish systemic antitumor immunity. Upon intravenous rechallenge, disseminated tumor cells are eliminated, preventing metastasis and ensuring long-term protection. This synergistic approach offers a scalable platform to boost immunotherapy efficacy and redefines immune-based metastasis prevention strategies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2e9ba5699caa736e818a9807d89458c43c8a2b62" target='_blank'>
              Light Metabolically Reprograms CD8+ T Cells to Potentiate STING-Driven Tumor Eradication and Prevent Metastasis.
              </a>
            </td>
          <td>
            Asmita Banstola, Shilin Gao, ZhengKun Zhang, Yan Dong, Prabhat Upadhyay, Quanwei Zhang, Yongli Li, Zuan-Tao Lin, Zhilong Wang, Mei X. Wu
          </td>
          <td>2025-10-23</td>
          <td>Advanced science</td>
          <td>0</td>
          <td>3</td>
        </tr>

    </tbody>
    <tfoot>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
      </tr>
    </tfoot>
    </table>
    </p>
  </div>

</body>

<script>

  function create_author_list(author_list) {
    let td_author_element = document.getElementById();
    for (let i = 0; i < author_list.length; i++) {
          // tdElements[i].innerHTML = greet(tdElements[i].innerHTML);
          alert (author_list[i]);
      }
  }

  var trace1 = {
    x: ['2025'],
    y: [15],
    name: 'Num of citations',
    yaxis: 'y1',
    type: 'scatter'
  };

  var data = [trace1];

  var layout = {
    yaxis: {
      title: 'Num of citations',
      }
  };
  Plotly.newPlot('myDiv1', data, layout);
</script>
<script>
var dataTableOptions = {
        initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;

                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);

                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';

                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    scrollX: true,
    scrollCollapse: true,
    paging: true,
    fixedColumns: true,
    columnDefs: [
        {"className": "dt-center", "targets": "_all"},
        // set width for both columns 0 and 1 as 25%
        { width: '7%', targets: 0 },
        { width: '30%', targets: 1 },
        { width: '25%', targets: 2 },
        { width: '15%', targets: 4 }

      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  }
  new DataTable('#table1', dataTableOptions);
  new DataTable('#table2', dataTableOptions);

  var table1 = $('#table1').DataTable();
  $('#table1 tbody').on('click', 'td:first-child', function () {
    var tr = $(this).closest('tr');
    var row = table1.row( tr );

    var rowId = tr.attr('id');
    // alert(rowId);

    if (row.child.isShown()) {
      // This row is already open - close it.
      row.child.hide();
      tr.removeClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility_off</i>');
    } else {
      // Open row.
      // row.child('foo').show();
      tr.find('td:first-child').html('<i class="material-icons">visibility</i>');
      var content = '<div class="child-row-content"><strong>Abstract:</strong> ' + rowId + '</div>';
      row.child(content).show();
      tr.addClass('shown');
    }
  });
  var table2 = $('#table2').DataTable();
  $('#table2 tbody').on('click', 'td:first-child', function () {
    var tr = $(this).closest('tr');
    var row = table2.row( tr );

    var rowId = tr.attr('id');
    // alert(rowId);

    if (row.child.isShown()) {
      // This row is already open - close it.
      row.child.hide();
      tr.removeClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility_off</i>');
    } else {
      // Open row.
      // row.child('foo').show();
      var content = '<div class="child-row-content"><strong>Abstract:</strong> ' + rowId + '</div>';
      row.child(content).show();
      tr.addClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility</i>');
    }
  });
</script>
<style>
  .child-row-content {
    text-align: justify;
    text-justify: inter-word;
    word-wrap: break-word; /* Ensure long words are broken */
    white-space: normal; /* Ensure text wraps to the next line */
    max-width: 100%; /* Ensure content does not exceed the table width */
    padding: 10px; /* Optional: add some padding for better readability */
    /* font size */
    font-size: small;
  }
</style>
</html>







  
  




  



                
              </article>
            </div>
          
          
<script>var target=document.getElementById(location.hash.slice(1));target&&target.name&&(target.checked=target.name.startsWith("__tabbed_"))</script>
        </div>
        
          <button type="button" class="md-top md-icon" data-md-component="top" hidden>
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M13 20h-2V8l-5.5 5.5-1.42-1.42L12 4.16l7.92 7.92-1.42 1.42L13 8v12Z"/></svg>
  Back to top
</button>
        
      </main>
      
        <footer class="md-footer">
  
  <div class="md-footer-meta md-typeset">
    <div class="md-footer-meta__inner md-grid">
      <div class="md-copyright">
  
  
    Made with
    <a href="https://squidfunk.github.io/mkdocs-material/" target="_blank" rel="noopener">
      Material for MkDocs
    </a>
  
</div>
      
    </div>
  </div>
</footer>
      
    </div>
    <div class="md-dialog" data-md-component="dialog">
      <div class="md-dialog__inner md-typeset"></div>
    </div>
    
    
    <script id="__config" type="application/json">{"base": "..", "features": ["navigation.top", "navigation.tabs"], "search": "../assets/javascripts/workers/search.b8dbb3d2.min.js", "translations": {"clipboard.copied": "Copied to clipboard", "clipboard.copy": "Copy to clipboard", "search.result.more.one": "1 more on this page", "search.result.more.other": "# more on this page", "search.result.none": "No matching documents", "search.result.one": "1 matching document", "search.result.other": "# matching documents", "search.result.placeholder": "Type to start searching", "search.result.term.missing": "Missing", "select.version": "Select version"}}</script>
    
    

      <script src="../assets/javascripts/bundle.c8d2eff1.min.js"></script>
      
    
<script>
  // Execute intro.js when a button with id 'intro' is clicked
  function startIntro(){
      introJs().setOptions({
          tooltipClass: 'customTooltip'
      }).start();
  }
</script>
<script>
  

  // new DataTable('#table1', {
  //   order: [[5, 'desc']],
  //   "columnDefs": [
  //       {"className": "dt-center", "targets": "_all"},
  //       { width: '30%', targets: 0 }
  //     ],
  //   pageLength: 10,
  //   layout: {
  //       topStart: {
  //           buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
  //       }
  //   }
  // });

  // new DataTable('#table2', {
  //   order: [[3, 'desc']],
  //   "columnDefs": [
  //       {"className": "dt-center", "targets": "_all"},
  //       { width: '30%', targets: 0 }
  //     ],
  //   pageLength: 10,
  //   layout: {
  //       topStart: {
  //           buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
  //       }
  //   }
  // });
  new DataTable('#table3', {
    initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;
 
                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);
 
                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';
 
                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    // order: [[3, 'desc']],
    "columnDefs": [
        {"className": "dt-center", "targets": "_all"},
        { width: '30%', targets: 0 }
      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  });
  new DataTable('#table4', {
    initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;
 
                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);
 
                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';
 
                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    // order: [[3, 'desc']],
    "columnDefs": [
        {"className": "dt-center", "targets": "_all"},
        { width: '30%', targets: 0 }
      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  });
</script>


  </body>
</html>